🧬 Gene fusions

Gene fusion calls from Isofox (part of the oncoanalyser RNA pipeline), one table per tumor sample. Tables are sortable — click a column header; by default they are sorted by Known, then by Total read support.

Interpreting support: Total counts the fragments supporting a call, but high support does not imply biological importance — in RNA-seq the strongest calls are usually artifacts: read-through between neighboring genes, antigen-receptor (TCR / immunoglobulin) recombination in infiltrating lymphocytes, and paralog or pseudogene mis-mapping. The Known column and Mitelman matches are usually the more meaningful signal. Linked fusion names open a detail page with a transcript diagram and read pileup.

Column guide

Fusion: The 5′ and 3′ partner genes (GeneUp::GeneDown). Linked names open a detail page (transcript diagram + read pileup).
Breakpoints: Genomic coordinate of each breakend (chromosome:position), 5′ → 3′, tagged with the rearrangement type: DEL (deletion — often a read-through of adjacent genes), DUP (duplication), INV (inversion), BND (translocation / breakend, e.g. between chromosomes).
Total: Total supporting fragments, broken down beneath as S split (read splits across the junction), R realigned (overlaps one breakend by ≥3 bases and matches the reference at the other), and D discordant (read pairs with one mate on each side). Total = S + R + D.
Known: Isofox's KnownFusionType, flagged against Hartwig's curated known-fusion knowledgebase (the list LINX uses). Values here: KNOWN_OTHER — at least one partner is a known or promiscuous fusion gene, but this specific pair is not itself a catalogued known pair; OTHER — neither partner is in the known-fusion list (the default; most read-through and artifact calls). Isofox/LINX also define KNOWN_PAIR, PROMISCUOUS_5/3, IG_KNOWN_PAIR and EXON_DEL_DUP (none appear here). See the Isofox docs.
Both: ✓ when the same gene pair is a passing call in both tumor samples; — when seen in this one only.
Mitelman: Whether this gene pair is recorded in the Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. Expand a cell to see each report's Abbreviation (citation), Journal, MorphName (disease / morphology) and tissue; each citation links to its PubMed article (or a PubMed search when the reference can't be uniquely resolved). The disease context helps separate a genuine oncogenic fusion — reported in the matching tumor type — from a recurrent artifact reported only as generic adenocarcinoma or a non-neoplastic lesion. A fusion can also be looked up in COSMIC Gene Fusions.

Left hand (primary)

678 passing fusions

Fusion	Breakpoints	Total	Known ▾	Both	Mitelman
EWSR1::KLF15 →	chr22:29,291,599 chr3:126,352,947 BND	35 2 S · 0 R · 33 D	KNOWN_OTHER	—	Mitelman Myoepithelioma/myoepithelial carcinoma/mixed tumor; Malignant epithelial tumor, special type ×4 Cyrta et al 2022, Cold Spring Harb Mol Case Stud — Myoepithelioma/myoepithelial carcinoma/mixed tumor · Soft tissue Suurmeijer et al 2020, Genes Chromosomes Cancer — Myoepithelioma/myoepithelial carcinoma/mixed tumor · Soft tissue Stevens et al 2018, Int J Surg Pathol — Myoepithelioma/myoepithelial carcinoma/mixed tumor · Salivary gland Cajaiba et al 2016, Am J Surg Pathol — Malignant epithelial tumor, special type · Kidney
EWSR1::KLF15 →	chr22:29,288,786 chr3:126,352,947 BND	34 2 S · 0 R · 32 D	KNOWN_OTHER	—	Mitelman Myoepithelioma/myoepithelial carcinoma/mixed tumor; Malignant epithelial tumor, special type ×4 Cyrta et al 2022, Cold Spring Harb Mol Case Stud — Myoepithelioma/myoepithelial carcinoma/mixed tumor · Soft tissue Suurmeijer et al 2020, Genes Chromosomes Cancer — Myoepithelioma/myoepithelial carcinoma/mixed tumor · Soft tissue Stevens et al 2018, Int J Surg Pathol — Myoepithelioma/myoepithelial carcinoma/mixed tumor · Salivary gland Cajaiba et al 2016, Am J Surg Pathol — Malignant epithelial tumor, special type · Kidney
::ROS1	chr6:117,442,434 chr6:117,418,506 DEL	17 13 S · 4 R · 0 D	KNOWN_OTHER	✓	—
EWSR1::KLF15 →	chr22:29,287,134 chr3:126,352,947 BND	17 5 S · 0 R · 12 D	KNOWN_OTHER	—	Mitelman Myoepithelioma/myoepithelial carcinoma/mixed tumor; Malignant epithelial tumor, special type ×4 Cyrta et al 2022, Cold Spring Harb Mol Case Stud — Myoepithelioma/myoepithelial carcinoma/mixed tumor · Soft tissue Suurmeijer et al 2020, Genes Chromosomes Cancer — Myoepithelioma/myoepithelial carcinoma/mixed tumor · Soft tissue Stevens et al 2018, Int J Surg Pathol — Myoepithelioma/myoepithelial carcinoma/mixed tumor · Salivary gland Cajaiba et al 2016, Am J Surg Pathol — Malignant epithelial tumor, special type · Kidney
NOS1AP::C1orf226 →	chr1:162,367,204 chr1:162,381,891 DEL	14 12 S · 0 R · 2 D	KNOWN_OTHER	✓	—
DCTN1::SLC4A5 →	chr2:74,361,413 chr2:74,342,534 DEL	7 1 S · 1 R · 5 D	KNOWN_OTHER	—	—
SLC45A3::ELK4 →	chr1:205,661,861 chr1:205,623,891 DEL	7 4 S · 0 R · 3 D	KNOWN_OTHER	—	Mitelman Acute myeloid leukemia, NOS; Adenocarcinoma … ×5 Ambayya et al 2026, J Mol Med (Berl) — Acute myeloid leukemia, NOS Zhao et al 2017, Oncotarget — Adenocarcinoma · Prostate Maher et al 2009, Nature — Adenocarcinoma · Prostate Rickman et al 2009, Cancer Res — Nonneoplastic epithelial disorder/lesion · Prostate Rickman et al 2009, Cancer Res — Adenocarcinoma · Prostate
ARL17B::KANSL1 →	chr17:46,352,820 chr17:46,094,701 DEL	5 3 S · 1 R · 1 D	KNOWN_OTHER	—	Mitelman Adenocarcinoma; Nonneoplastic epithelial disorder/lesion … ×9 Fu et al 2024, Biomark Res — Adenocarcinoma · Oesophagus Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Thyroid Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Gallbladder/Biliary system Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Bladder Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Adrenal Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Skin Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Oesophagus Wen et al 2012, PLoS One — Acute myeloid leukemia, NOS
COL3A1::ELP3 →	chr2:189,004,364 chr8:28,114,909 BND	5 1 S · 4 R · 0 D	KNOWN_OTHER	—	—
FGFR3::	chr4:1,806,934 chr4:1,815,712 DEL	5 4 S · 0 R · 1 D	KNOWN_OTHER	—	—
LMNA::SEMA4A →	chr1:156,137,743 chr1:156,156,414 DEL	5 5 S · 0 R · 0 D	KNOWN_OTHER	—	—
EIF3K::ACTN4 →	chr19:38,635,118 chr19:38,700,600 DEL	4 2 S · 0 R · 2 D	KNOWN_OTHER	—	Mitelman Adenocarcinoma; Transitional cell carcinoma ×2 Calabrese et al 2020, Nature — Adenocarcinoma · Ovary Hu et al 2018, Nucleic Acids Res — Transitional cell carcinoma · Bladder
KLC1::KLC1 →	chr14:103,587,364 chr14:103,654,564 DEL	4 4 S · 0 R · 0 D	KNOWN_OTHER	—	—
NPM1::FGF18 →	chr5:171,388,006 chr5:171,436,093 DEL	2 1 S · 0 R · 1 D	KNOWN_OTHER	—	—
AZGP1::GJC3 →	chr7:99,971,746 chr7:99,923,603 DEL	457 289 S · 7 R · 161 D	OTHER	✓	Mitelman Adenocarcinoma; Nonneoplastic epithelial disorder/lesion … ×10 Jung et al 2018, Cancer Lett — Adenocarcinoma · Breast Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Salivary gland Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Prostate Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Skin Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Kidney Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Liver Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Pancreas Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Testis Agnihotri et al 2016, Nat Genet — Schwannoma · Soft tissue Nacu et al 2011, BMC Med Genomics — Adenocarcinoma · Prostate
TRDJ1::TRDC →	chr14:22,450,139 chr14:22,462,932 DEL	386 275 S · 15 R · 96 D	OTHER	✓	—
KANSL1::ARL17B →	chr17:46,094,560 chr17:46,352,930 DUP	274 122 S · 63 R · 89 D	OTHER	✓	Mitelman Adenocarcinoma; Nonneoplastic epithelial disorder/lesion … ×9 Fu et al 2024, Biomark Res — Adenocarcinoma · Oesophagus Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Thyroid Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Gallbladder/Biliary system Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Bladder Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Adrenal Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Skin Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Oesophagus Wen et al 2012, PLoS One — Acute myeloid leukemia, NOS
AZGP1::GJC3 →	chr7:99,971,746 chr7:99,929,621 DEL	205 19 S · 5 R · 181 D	OTHER	✓	Mitelman Adenocarcinoma; Nonneoplastic epithelial disorder/lesion … ×10 Jung et al 2018, Cancer Lett — Adenocarcinoma · Breast Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Salivary gland Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Prostate Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Skin Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Kidney Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Liver Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Pancreas Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Testis Agnihotri et al 2016, Nat Genet — Schwannoma · Soft tissue Nacu et al 2011, BMC Med Genomics — Adenocarcinoma · Prostate
TRAJ39::TRAC →	chr14:22,501,663 chr14:22,547,506 DEL	113 82 S · 8 R · 23 D	OTHER	✓	—
MAG::CD22 →	chr19:35,312,017 chr19:35,329,189 DEL	95 62 S · 1 R · 32 D	OTHER	✓	—
RPL29P28::RPL29 →	chr13:36,926,530 chr3:51,993,865 BND	94 1 S · 93 R · 0 D	OTHER	—	—
POLR2A::	chr17:7,513,776 chr12:114,499,176 BND	92 4 S · 88 R · 0 D	OTHER	—	—
KANSL1::ARL17A →	chr17:46,094,560 chr17:46,570,869 DUP	84 3 S · 77 R · 4 D	OTHER	—	Mitelman Carcinoma, NOS; Chronic myeloid leukemia, t(9;22) … ×16 Guan et al 2026, J Biol Chem — Carcinoma, NOS · Lung Fontana et al 2024, Ann Hematol — Chronic myeloid leukemia, t(9;22) Fu et al 2024, Biomark Res — Adenocarcinoma · Oesophagus Dupain et al 2019, Mol Ther — Osteosarcoma, NOS · Skeleton Dupain et al 2019, Mol Ther — Embryonal rhabdomyosarcoma · Soft tissue Dupain et al 2019, Mol Ther — Wilms tumor · Kidney Dupain et al 2019, Mol Ther — Primitive neuroectodermal tumor/Medulloblastoma · Brain Dupain et al 2019, Mol Ther — Ependymoma · Brain Dupain et al 2019, Mol Ther — Astrocytoma, grade III-IV/Glioblastoma · Brain Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Thyroid Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Gallbladder/Biliary system Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Bladder Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Adrenal Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Oesophagus Atak et al 2013, PLoS Genet — Acute lymphoblastic leukemia/lymphoblastic lymphoma
TRAJ23::TRAC →	chr14:22,520,478 chr14:22,547,506 DEL	84 70 S · 4 R · 10 D	OTHER	—	—
H2BC12::	chr6:27,146,409 chr6:27,138,681 DEL	64 64 S · 0 R · 0 D	OTHER	—	—
SMURF2P1::LRRC37BP1 →	chr17:30,610,942 chr17:30,631,755 DEL	62 37 S · 0 R · 25 D	OTHER	✓	—
HACL1::COLQ →	chr3:15,563,358 chr3:15,489,637 DEL	59 27 S · 2 R · 30 D	OTHER	✓	Mitelman Nonneoplastic hematologic disorder/lesion; Nonneoplastic epithelial disorder/lesion ×8 Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Thyroid Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Gallbladder/Biliary system Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Testis Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Bladder Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Skin Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Uterus, corpus
LRRC37A::LRRC37A2 →	chr17:46,332,656 chr17:46,546,255 DEL	58 4 S · 1 R · 53 D	OTHER	—	—
::NAIPP2	chr5:70,139,127 chr5:70,128,434 DEL	56 56 S · 0 R · 0 D	OTHER	✓	—
NAIPP4::OCLNP1 →	chr5:71,104,744 chr5:71,093,192 DEL	54 30 S · 0 R · 24 D	OTHER	✓	—
POLR2J2::UPK3BL1 →	chr7:102,666,077 chr7:102,640,773 DEL	54 24 S · 0 R · 30 D	OTHER	—	—
IL3RA::	chrX:1,378,812 chrX:1,386,682 DEL	53 41 S · 3 R · 9 D	OTHER	—	—
::	chr2:242,119,057 chr2:242,122,287 DEL	52 52 S · 0 R · 0 D	OTHER	✓	—
PAOX::MTG1 →	chr10:133,391,428 chr10:133,395,713 DEL	52 30 S · 0 R · 22 D	OTHER	✓	—
LRRC37A::LRRC37A2 →	chr17:46,331,981 chr17:46,523,084 DEL	49 1 S · 0 R · 48 D	OTHER	—	—
ADGRL4::	chr1:79,079,816 chr21:34,097,414 BND	47 46 S · 1 R · 0 D	OTHER	—	—
RASA4::RASA4B →	chr7:102,605,959 chr7:102,506,795 DEL	46 46 S · 0 R · 0 D	OTHER	✓	—
PLEKHO2::ANKDD1A	chr15:64,861,575 chr15:64,921,921 DEL	45 19 S · 0 R · 26 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
AHSA2P::	chr2:61,186,497 chr2:61,187,909 DEL	42 20 S · 3 R · 19 D	OTHER	✓	—
PAOX::MTG1 →	chr10:133,391,491 chr10:133,395,713 DEL	41 17 S · 0 R · 24 D	OTHER	✓	—
SEPTIN7::SEPTIN7P3 →	chr7:35,898,353 chr7:35,966,498 DEL	41 1 S · 0 R · 40 D	OTHER	✓	—
KANSL1::ARL17B →	chr17:46,170,855 chr17:46,352,930 DUP	38 1 S · 1 R · 36 D	OTHER	✓	Mitelman Adenocarcinoma; Nonneoplastic epithelial disorder/lesion … ×9 Fu et al 2024, Biomark Res — Adenocarcinoma · Oesophagus Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Thyroid Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Gallbladder/Biliary system Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Bladder Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Adrenal Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Skin Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Oesophagus Wen et al 2012, PLoS One — Acute myeloid leukemia, NOS
NDUFB8::SEC31B	chr10:100,526,399 chr10:100,516,960 DEL	35 17 S · 0 R · 18 D	OTHER	—	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
PLEKHO2::ANKDD1A	chr15:64,861,575 chr15:64,917,386 DEL	35 1 S · 0 R · 34 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
KDM6B::ZDHHC14	chr17:7,846,896 chr6:157,467,329 BND	34 6 S · 28 R · 0 D	OTHER	—	—
MAG::CD22 →	chr19:35,313,429 chr19:35,329,189 DEL	33 3 S · 1 R · 29 D	OTHER	✓	—
RDM1P1::LRRC37A4P	chr17:45,558,407 chr17:45,545,944 DEL	33 28 S · 0 R · 5 D	OTHER	✓	—
SLC35E2A::SLC35E2B	chr1:1,734,690 chr1:1,676,846 DEL	33 1 S · 1 R · 31 D	OTHER	—	—
::SMG1P3	chr16:21,519,828 chr16:21,487,616 DEL	32 32 S · 0 R · 0 D	OTHER	—	—
::SON	chr1:157,710,371 chr21:33,576,392 BND	32 29 S · 3 R · 0 D	OTHER	✓	—
UBE2Q2P1::GOLGA6L5P	chr15:84,526,781 chr15:84,515,034 DEL	32 12 S · 0 R · 20 D	OTHER	✓	—
::HYDIN2	chr1:146,537,420 chr1:146,547,369 DEL	31 31 S · 0 R · 0 D	OTHER	✓	—
PLEKHO2::ANKDD1A	chr15:64,861,575 chr15:64,915,797 DEL	31 8 S · 1 R · 22 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
CDK11A::CDK11B	chr1:1,708,865 chr1:1,641,723 DEL	30 30 S · 0 R · 0 D	OTHER	—	—
SMG1P2::BOLA2-SMG1P6	chr16:29,548,538 chr16:29,447,026 DEL	30 2 S · 0 R · 28 D	OTHER	✓	—
LRRC37A::LRRC37A2 →	chr17:46,323,027 chr17:46,520,212 DEL	28 4 S · 3 R · 21 D	OTHER	—	—
MAG::CD22 →	chr19:35,312,325 chr19:35,329,189 DEL	28 1 S · 0 R · 27 D	OTHER	✓	—
SMURF2P1::LRRC37BP1 →	chr17:30,610,942 chr17:30,629,680 DEL	28 2 S · 0 R · 26 D	OTHER	✓	—
PLEKHO2::ANKDD1A	chr15:64,861,575 chr15:64,926,066 DEL	27 9 S · 5 R · 13 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
PLEKHO2::ANKDD1A	chr15:64,865,228 chr15:64,921,921 DEL	27 2 S · 2 R · 23 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
SMURF2P1::LRRC37BP1 →	chr17:30,610,942 chr17:30,631,737 DEL	27 1 S · 0 R · 26 D	OTHER	✓	—
NPEPPSP1::TBC1D3	chr17:38,195,880 chr17:38,191,030 DEL	26 3 S · 2 R · 21 D	OTHER	✓	—
LRRC37A::LRRC37A2 →	chr17:46,306,309 chr17:46,520,212 DEL	25 17 S · 0 R · 8 D	OTHER	—	—
RASA4CP::POLR2J4	chr7:44,030,781 chr7:44,016,523 DEL	25 21 S · 0 R · 4 D	OTHER	✓	—
::LRRC37A4P	chr17:45,584,572 chr17:45,545,676 DEL	24 24 S · 0 R · 0 D	OTHER	—	—
AGAP7P::AGAP14P	chr10:46,131,348 chr10:46,353,206 DEL	24 1 S · 0 R · 23 D	OTHER	—	—
GON4L::YY1AP1	chr1:155,771,067 chr1:155,675,096 DEL	24 3 S · 0 R · 21 D	OTHER	—	—
NAIPP4::NAIP	chr5:71,123,617 chr5:71,002,143 DEL	24 14 S · 3 R · 7 D	OTHER	—	—
::TRDC	chr14:22,449,967 chr14:22,462,932 DEL	23 23 S · 0 R · 0 D	OTHER	✓	—
BMS1P3::AGAP11	chr10:87,000,434 chr10:87,001,636 DEL	23 18 S · 0 R · 5 D	OTHER	✓	—
FAHD2CP::	chr2:96,021,465 chr2:96,022,674 DEL	23 17 S · 0 R · 6 D	OTHER	✓	—
GON4L::YY1AP1	chr1:155,765,000 chr1:155,660,913 DEL	23 7 S · 0 R · 16 D	OTHER	—	—
MAG::CD22 →	chr19:35,310,643 chr19:35,329,189 DEL	23 8 S · 1 R · 14 D	OTHER	✓	—
RRS1::ADHFE1	chr8:66,430,378 chr8:66,444,367 DEL	23 11 S · 0 R · 12 D	OTHER	—	—
STYXL1::TMEM120A	chr7:75,996,445 chr7:75,992,557 DEL	23 14 S · 3 R · 6 D	OTHER	✓	—
UPK3BL1::RASA4	chr7:102,638,714 chr7:102,611,142 DEL	23 5 S · 4 R · 14 D	OTHER	—	—
KRBOX1::GASK1A	chr3:42,942,071 chr3:43,032,267 DEL	22 17 S · 0 R · 5 D	OTHER	✓	—
NAIPP4::NAIP	chr5:71,108,661 chr5:70,985,886 DEL	22 1 S · 0 R · 21 D	OTHER	—	—
::SLC17A3	chr6:25,890,506 chr6:25,868,420 DEL	21 21 S · 0 R · 0 D	OTHER	✓	—
::SMG1P3	chr16:21,519,828 chr16:21,484,535 DEL	21 21 S · 0 R · 0 D	OTHER	—	—
LRRC37A::LRRC37A2 →	chr17:46,306,309 chr17:46,517,362 DEL	21 9 S · 2 R · 10 D	OTHER	—	—
NPEPPSP1::TBC1D3	chr17:38,195,880 chr17:38,190,795 DEL	21 5 S · 2 R · 14 D	OTHER	✓	—
PLEKHO2::ANKDD1A	chr15:64,855,037 chr15:64,921,921 DEL	21 4 S · 0 R · 17 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
NPIPB12::NPIPB11	chr16:29,491,467 chr16:29,394,076 DEL	20 1 S · 0 R · 19 D	OTHER	—	—
POLR2J2::UPK3BL1 →	chr7:102,668,915 chr7:102,640,773 DEL	20 2 S · 0 R · 18 D	OTHER	—	—
::USP32P1	chr17:16,788,135 chr17:16,796,043 DEL	19 13 S · 0 R · 6 D	OTHER	✓	—
GON4L::YY1AP1	chr1:155,773,066 chr1:155,679,512 DEL	19 1 S · 0 R · 18 D	OTHER	—	—
IFITM2::IFITM1	chr11:308,438 chr11:314,922 DEL	19 19 S · 0 R · 0 D	OTHER	✓	—
LSP1::TNNT3	chr11:1,887,576 chr11:1,922,857 DEL	19 10 S · 0 R · 9 D	OTHER	—	—
PFKFB3::LINC02649	chr10:6,226,365 chr10:6,326,546 DEL	19 10 S · 2 R · 7 D	OTHER	—	—
RASA4B::POLR2J	chr7:102,483,825 chr7:102,476,270 DEL	19 8 S · 2 R · 9 D	OTHER	—	—
UPK3BL1::POLR2J3	chr7:102,638,714 chr7:102,541,662 DEL	19 8 S · 0 R · 11 D	OTHER	—	—
DBT::LRRC39	chr1:100,196,214 chr1:100,178,231 DEL	18 9 S · 1 R · 8 D	OTHER	—	—
GON4L::YY1AP1	chr1:155,773,066 chr1:155,675,096 DEL	18 2 S · 0 R · 16 D	OTHER	—	—
GON4L::YY1AP1	chr1:155,765,000 chr1:155,661,423 DEL	18 1 S · 0 R · 17 D	OTHER	—	—
PCDHB18P::	chr5:141,236,045 chr5:141,241,408 DEL	18 18 S · 0 R · 0 D	OTHER	—	—
PLEKHO2::ANKDD1A	chr15:64,861,575 chr15:64,926,035 DEL	18 2 S · 0 R · 16 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
RASA4B::POLR2J	chr7:102,483,596 chr7:102,476,270 DEL	18 3 S · 1 R · 14 D	OTHER	—	—
ASIP::	chr20:34,235,030 chr20:34,281,027 DEL	17 9 S · 0 R · 8 D	OTHER	✓	—
EOLA1-DT::IDS	chrX:149,529,367 chrX:149,501,037 DEL	17 10 S · 0 R · 7 D	OTHER	✓	—
LRRC37A::LRRC37A2 →	chr17:46,323,027 chr17:46,540,176 DEL	17 9 S · 2 R · 6 D	OTHER	—	—
PLEKHO2::ANKDD1A	chr15:64,865,228 chr15:64,915,797 DEL	17 1 S · 1 R · 15 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
SERF1B::SMN2	chr5:70,041,631 chr5:70,063,415 DEL	17 3 S · 0 R · 14 D	OTHER	✓	—
SLC35E2A::CDK11A	chr1:1,734,690 chr1:1,722,831 DEL	17 9 S · 0 R · 8 D	OTHER	—	—
TRAJ49::TRAC	chr14:22,489,543 chr14:22,547,506 DEL	17 12 S · 0 R · 5 D	OTHER	—	—
TRDJ1::TRDC →	chr14:22,450,139 chr14:22,463,089 DEL	17 3 S · 0 R · 14 D	OTHER	✓	—
::CCDC146	chr7:77,043,778 chr7:77,167,658 DEL	16 10 S · 0 R · 6 D	OTHER	—	—
::OR2A7	chr7:144,272,445 chr7:144,259,632 DEL	16 16 S · 0 R · 0 D	OTHER	✓	—
AHSA2P::	chr2:61,186,754 chr2:61,187,909 DEL	16 1 S · 1 R · 14 D	OTHER	✓	—
MAG::CD22 →	chr19:35,310,643 chr19:35,329,182 DEL	16 1 S · 0 R · 15 D	OTHER	✓	—
NAIPP4::OCLNP1 →	chr5:71,108,661 chr5:71,093,192 DEL	16 6 S · 3 R · 7 D	OTHER	✓	—
PAOX::MTG1 →	chr10:133,389,747 chr10:133,395,713 DEL	16 8 S · 1 R · 7 D	OTHER	✓	—
PLEKHO2::ANKDD1A	chr15:64,859,998 chr15:64,926,066 DEL	16 1 S · 0 R · 15 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
PLEKHO2::ANKDD1A	chr15:64,855,037 chr15:64,926,066 DEL	16 5 S · 0 R · 11 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
SERF1B::SMN2	chr5:70,026,515 chr5:70,063,415 DEL	16 5 S · 2 R · 9 D	OTHER	✓	—
SLC7A5P2::SMG1P3	chr16:21,519,832 chr16:21,476,812 DEL	16 1 S · 0 R · 15 D	OTHER	—	—
RASA4::RASA4B →	chr7:102,599,860 chr7:102,501,227 DEL	15 5 S · 0 R · 10 D	OTHER	✓	—
RRS1::ADHFE1	chr8:66,430,378 chr8:66,442,798 DEL	15 3 S · 0 R · 12 D	OTHER	—	—
::	chr21:8,397,768 chr21:8,442,008 DEL	14 14 S · 0 R · 0 D	OTHER	✓	—
ASL::CRCP	chr7:66,092,663 chr7:66,127,704 DEL	14 6 S · 0 R · 8 D	OTHER	✓	Mitelman Astrocytoma, grade III-IV/Glioblastoma ×1 Frattini et al 2013, Nat Genet — Astrocytoma, grade III-IV/Glioblastoma · Brain
GON4L::YY1AP1	chr1:155,775,002 chr1:155,679,512 DEL	14 1 S · 0 R · 13 D	OTHER	—	—
LRRC37A::LRRC37A2 →	chr17:46,323,027 chr17:46,523,084 DEL	14 4 S · 1 R · 9 D	OTHER	—	—
MAPK12::HDAC10	chr22:50,255,197 chr22:50,250,905 DEL	14 14 S · 0 R · 0 D	OTHER	—	—
MIX23::	chr3:122,359,842 chr11:73,850,439 BND	14 3 S · 11 R · 0 D	OTHER	✓	—
POLR2J2::RASA4	chr7:102,666,077 chr7:102,611,142 DEL	14 4 S · 3 R · 7 D	OTHER	—	—
RRS1::ADHFE1	chr8:66,430,374 chr8:66,444,367 DEL	14 3 S · 0 R · 11 D	OTHER	—	—
UBE2Q2L::CSPG4P11	chr15:84,182,083 chr15:84,186,842 DEL	14 10 S · 0 R · 4 D	OTHER	—	—
COQ8B::NUMBL	chr19:40,691,592 chr19:40,686,995 DEL	13 2 S · 1 R · 10 D	OTHER	✓	Mitelman Squamous cell carcinoma; Astrocytoma, grade III-IV/Glioblastoma … ×3 Egashira et al 2019, J Invest Dermatol — Squamous cell carcinoma · Skin Frattini et al 2013, Nat Genet — Astrocytoma, grade III-IV/Glioblastoma · Brain Nacu et al 2011, BMC Med Genomics — Adenocarcinoma · Prostate
CYP2D7::CYP2D6	chr22:42,143,455 chr22:42,129,782 DEL	13 7 S · 0 R · 6 D	OTHER	—	—
PDXDC2P::	chr16:70,010,751 chr16:69,996,468 DEL	13 13 S · 0 R · 0 D	OTHER	✓	—
PLEKHO2::ANKDD1A	chr15:64,855,037 chr15:64,915,797 DEL	13 2 S · 0 R · 11 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
PTENP1-AS::TRBV26OR9-2	chr9:33,678,287 chr9:33,695,767 DEL	13 7 S · 0 R · 6 D	OTHER	—	—
TMEM141::CCDC183	chr9:136,792,358 chr9:136,799,102 DEL	13 9 S · 0 R · 4 D	OTHER	✓	—
ZNF207::PSMD11	chr17:32,373,453 chr17:32,446,945 DEL	13 7 S · 0 R · 6 D	OTHER	—	—
::NEMP2	chr2:190,648,220 chr2:190,525,378 DEL	12 12 S · 0 R · 0 D	OTHER	—	—
ANKRD20A11P::	chr21:13,979,702 chr13:18,872,751 BND	12 8 S · 4 R · 0 D	OTHER	—	—
CD81::TSSC4	chr11:2,396,964 chr11:2,402,294 DEL	12 5 S · 2 R · 5 D	OTHER	—	—
IL17RB::	chr3:53,865,019 chr3:53,868,674 DEL	12 8 S · 1 R · 3 D	OTHER	✓	—
MIX23::	chr3:122,359,843 chr11:73,850,439 BND	12 2 S · 10 R · 0 D	OTHER	✓	—
RRS1::ADHFE1	chr8:66,430,378 chr8:66,440,162 DEL	12 1 S · 0 R · 11 D	OTHER	—	—
ZNF587B::ZNF587	chr19:57,839,149 chr19:57,856,104 DEL	12 5 S · 0 R · 7 D	OTHER	✓	—
ZNF606::C19orf18	chr19:57,978,654 chr19:57,974,203 DEL	12 7 S · 0 R · 5 D	OTHER	✓	—
BACH1::	chr21:29,329,693 chr21:29,351,634 DEL	11 11 S · 0 R · 0 D	OTHER	✓	—
DHTKD1::SEC61A2	chr10:12,120,267 chr10:12,133,241 DEL	11 7 S · 2 R · 2 D	OTHER	✓	—
H2AC7::H3C4	chr6:26,198,859 chr6:26,197,266 DEL	11 8 S · 0 R · 3 D	OTHER	—	—
KIAA0753::PITPNM3	chr17:6,589,779 chr17:6,538,082 DEL	11 2 S · 3 R · 6 D	OTHER	—	—
NPIPA3::NPIPA2 →	chr16:14,723,299 chr16:14,755,192 DEL	11 3 S · 0 R · 8 D	OTHER	✓	—
RHBDD2::POR	chr7:75,883,848 chr7:75,953,989 DEL	11 9 S · 0 R · 2 D	OTHER	✓	Mitelman Adenocarcinoma ×1 Hu et al 2018, Nucleic Acids Res — Adenocarcinoma · Oesophagus
ZNF587B::ZNF587	chr19:57,840,927 chr19:57,856,107 DEL	11 2 S · 0 R · 9 D	OTHER	✓	—
::GTF2IP4	chr7:73,155,343 chr7:73,175,415 DEL	10 8 S · 0 R · 2 D	OTHER	—	—
CCDC163::TESK2	chr1:45,495,052 chr1:45,457,871 DEL	10 4 S · 0 R · 6 D	OTHER	—	—
DCLK1::	chr13:36,131,376 chr21:8,216,093 BND	10 10 S · 0 R · 0 D	OTHER	—	—
ELMOD3::	chr2:85,391,689 chr2:85,395,538 DEL	10 7 S · 0 R · 3 D	OTHER	—	—
EOLA1-DT::IDS	chrX:149,529,367 chrX:149,504,293 DEL	10 6 S · 2 R · 2 D	OTHER	✓	—
MRPS31P4::	chr13:52,637,446 chr13:52,642,406 DEL	10 10 S · 0 R · 0 D	OTHER	✓	—
MTG1::SCART1	chr10:133,402,773 chr10:133,456,237 DEL	10 4 S · 0 R · 6 D	OTHER	—	—
MUSK::	chr9:110,784,980 chr9:110,941,421 DEL	10 4 S · 1 R · 5 D	OTHER	—	—
NDUFB8::SEC31B	chr10:100,526,975 chr10:100,516,960 DEL	10 5 S · 0 R · 5 D	OTHER	—	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
POLR2J2::UPK3BL1 →	chr7:102,666,077 chr7:102,640,414 DEL	10 1 S · 2 R · 7 D	OTHER	—	—
PRKAA1::TTC33	chr5:40,764,514 chr5:40,747,019 DEL	10 4 S · 1 R · 5 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion; Nonneoplastic hematologic disorder/lesion ×7 Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Salivary gland Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Thyroid Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Gallbladder/Biliary system Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Bladder Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Testis Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node
RAB4B-EGLN2::	chr19:40,801,415 chr19:40,826,564 DEL	10 10 S · 0 R · 0 D	OTHER	✓	—
RPL14::CADPS	chr3:40,462,060 chr3:62,779,352 INV	10 10 S · 0 R · 0 D	OTHER	—	—
RRS1::ADHFE1	chr8:66,430,374 chr8:66,442,798 DEL	10 1 S · 0 R · 9 D	OTHER	—	—
ZNF208::ZNF100	chr19:21,974,729 chr19:21,745,067 DEL	10 7 S · 0 R · 3 D	OTHER	—	—
::CA5B	chrX:15,688,858 chrX:15,721,497 DEL	9 9 S · 0 R · 0 D	OTHER	✓	—
::SMG1P3	chr16:21,519,828 chr16:21,476,812 DEL	9 9 S · 0 R · 0 D	OTHER	—	—
BMS1P2::AGAP9	chr10:47,542,167 chr10:47,523,491 DEL	9 6 S · 0 R · 3 D	OTHER	✓	—
CDK11A::CDK11B	chr1:1,712,264 chr1:1,649,637 DEL	9 1 S · 0 R · 8 D	OTHER	—	—
EIF6::MMP24OS	chr20:35,279,566 chr20:35,272,145 DEL	9 9 S · 0 R · 0 D	OTHER	✓	—
GON4L::YY1AP1	chr1:155,771,067 chr1:155,670,464 DEL	9 3 S · 0 R · 6 D	OTHER	—	—
H2AC7::H3C4	chr6:26,198,859 chr6:26,197,269 DEL	9 6 S · 0 R · 3 D	OTHER	—	—
MED20::USP49	chr6:41,907,016 chr6:41,871,637 DEL	9 4 S · 0 R · 5 D	OTHER	—	Mitelman Adenocarcinoma ×1 Yoshihara et al 2015, Oncogene — Adenocarcinoma · Breast
MUSTN1::ITIH4	chr3:52,833,114 chr3:52,830,670 DEL	9 5 S · 0 R · 4 D	OTHER	—	—
NAIPP4::NAIP	chr5:71,123,617 chr5:71,003,857 DEL	9 1 S · 0 R · 8 D	OTHER	—	—
NDUFA11::FUT5	chr19:5,896,453 chr19:5,867,737 DEL	9 5 S · 0 R · 4 D	OTHER	—	—
PCDHB7::PCDHB9	chr5:141,174,155 chr5:141,188,639 DEL	9 9 S · 0 R · 0 D	OTHER	—	—
POLR2J3::RASA4B	chr7:102,566,997 chr7:102,511,981 DEL	9 1 S · 3 R · 5 D	OTHER	✓	—
UPK3BL1::POLR2J3	chr7:102,639,123 chr7:102,541,662 DEL	9 1 S · 0 R · 8 D	OTHER	—	—
ZNF587B::ZNF587	chr19:57,840,908 chr19:57,856,104 DEL	9 1 S · 0 R · 8 D	OTHER	✓	—
ZNF587B::ZNF587	chr19:57,840,908 chr19:57,856,107 DEL	9 1 S · 0 R · 8 D	OTHER	✓	—
ZNF812P::ZNF562	chr19:9,690,343 chr19:9,653,881 DEL	9 1 S · 0 R · 8 D	OTHER	—	—
::	chr21:14,027,597 chr21:14,083,950 DEL	8 8 S · 0 R · 0 D	OTHER	✓	—
::SEPTIN14P8	chr8:232,129 chr8:200,560 DEL	8 8 S · 0 R · 0 D	OTHER	—	—
AKR7A2::AKR7A3	chr1:19,306,018 chr1:19,286,372 DEL	8 5 S · 0 R · 3 D	OTHER	—	—
ANKRD18CP::CTSV	chr9:97,160,182 chr9:97,156,585 DEL	8 5 S · 0 R · 3 D	OTHER	—	—
BMP8A::	chr1:39,529,164 chr1:39,541,720 DEL	8 7 S · 0 R · 1 D	OTHER	✓	—
CLN8::ARHGEF10	chr8:1,771,597 chr8:1,843,353 DEL	8 3 S · 0 R · 5 D	OTHER	✓	—
EFCAB14::ATPAF1	chr1:46,678,469 chr1:46,665,364 DEL	8 3 S · 0 R · 5 D	OTHER	✓	—
GALT::IL11RA	chr9:34,649,564 chr9:34,655,218 DEL	8 6 S · 0 R · 2 D	OTHER	✓	—
LRRC37A::LRRC37A2 →	chr17:46,306,309 chr17:46,523,084 DEL	8 4 S · 3 R · 1 D	OTHER	—	—
NPIPA9::NPIPA8	chr16:18,360,117 chr16:18,321,063 DEL	8 8 S · 0 R · 0 D	OTHER	—	—
PEX1::	chr7:92,491,243 chr7:92,463,026 DEL	8 8 S · 0 R · 0 D	OTHER	✓	—
PIM3::	chr22:49,961,811 chr22:50,009,816 DEL	8 8 S · 0 R · 0 D	OTHER	—	—
PKD2L2-DT::KLHL3	chr5:137,858,428 chr5:137,720,584 DEL	8 6 S · 1 R · 1 D	OTHER	—	—
PRH1::PRR4	chr12:10,882,217 chr12:10,848,407 DEL	8 8 S · 0 R · 0 D	OTHER	✓	—
SDHAF2::PPP1R32	chr11:61,446,113 chr11:61,481,782 DEL	8 3 S · 0 R · 5 D	OTHER	✓	—
SDHD::TEX12	chr11:112,089,011 chr11:112,170,419 DEL	8 7 S · 0 R · 1 D	OTHER	✓	—
SLC35E2B::CDK11B	chr1:1,665,266 chr1:1,657,498 DEL	8 1 S · 0 R · 7 D	OTHER	—	—
UBA2::WTIP	chr19:34,467,014 chr19:34,490,376 DEL	8 4 S · 0 R · 4 D	OTHER	✓	Mitelman Adenocarcinoma; Acute monoblastic leukemia (FAB type M5) … ×10 Fu et al 2024, Biomark Res — Adenocarcinoma · Oesophagus Lu et al 2018, Exp Cell Res — Acute monoblastic leukemia (FAB type M5) Lu et al 2018, Exp Cell Res — Acute myeloid leukemia, NOS Lu et al 2018, Exp Cell Res — Acute myeloblastic leukemia with maturation (FAB type M2) Lu et al 2018, Exp Cell Res — Acute myelomonocytic leukemia (FAB type M4) Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Bladder Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Prostate Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Oesophagus Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Testis
UBE2Q2L::CSPG4P11	chr15:84,182,083 chr15:84,186,825 DEL	8 4 S · 0 R · 4 D	OTHER	—	—
UMAD1::GLCCI1	chr7:7,801,743 chr7:8,003,908 DEL	8 8 S · 0 R · 0 D	OTHER	✓	—
UPK3BL1::POLR2J3	chr7:102,640,204 chr7:102,541,662 DEL	8 2 S · 0 R · 6 D	OTHER	—	—
ZNF224::	chr19:44,108,337 chr19:44,112,822 DEL	8 8 S · 0 R · 0 D	OTHER	—	—
ZNF747::ZNF768	chr16:30,532,279 chr16:30,526,051 DEL	8 7 S · 0 R · 1 D	OTHER	—	—
ZNF8::ERVK3-1	chr19:58,295,581 chr19:58,306,088 DEL	8 5 S · 0 R · 3 D	OTHER	—	—
::	chr7:97,937,160 chr7:97,972,135 DEL	7 7 S · 0 R · 0 D	OTHER	✓	—
::RRS1	chr8:66,264,334 chr8:66,429,522 DEL	7 7 S · 0 R · 0 D	OTHER	—	—
::TMCO6	chr5:140,596,891 chr5:140,641,665 DEL	7 7 S · 0 R · 0 D	OTHER	—	—
AP5S1::MAVS	chr20:3,822,293 chr20:3,854,558 DEL	7 3 S · 1 R · 3 D	OTHER	—	—
ASNSD1::ANKAR	chr2:189,667,945 chr2:189,689,527 DEL	7 5 S · 1 R · 1 D	OTHER	—	Mitelman Adenocarcinoma ×1 Gao et al 2018, Cell Rep — Adenocarcinoma · Ovary
BLACAT1::LEMD1	chr1:205,455,917 chr1:205,420,574 DEL	7 7 S · 0 R · 0 D	OTHER	—	—
CFAP300::YAP1	chr11:102,081,281 chr11:102,114,144 DEL	7 3 S · 0 R · 4 D	OTHER	—	Mitelman Adenocarcinoma ×2 Gao et al 2018, Cell Rep — Adenocarcinoma · Lung Yoshihara et al 2015, Oncogene — Adenocarcinoma · Lung
CRYBB2P1::GRK3	chr22:25,520,733 chr22:25,604,377 DEL	7 3 S · 1 R · 3 D	OTHER	—	—
DDT::	chr22:23,974,307 chr22:23,926,520 DEL	7 7 S · 0 R · 0 D	OTHER	✓	—
FBXO25::	chr8:457,100 chr8:494,494 DEL	7 4 S · 0 R · 3 D	OTHER	✓	—
GANC::CAPN3	chr15:42,352,124 chr15:42,384,483 DEL	7 3 S · 0 R · 4 D	OTHER	—	—
GON4L::YY1AP1	chr1:155,777,622 chr1:155,679,512 DEL	7 7 S · 0 R · 0 D	OTHER	—	—
KLHL22::SCARF2	chr22:20,446,443 chr22:20,431,988 DEL	7 3 S · 0 R · 4 D	OTHER	—	—
MTG1::SCART1	chr10:133,419,592 chr10:133,456,237 DEL	7 1 S · 1 R · 5 D	OTHER	—	—
NFIX::NACC1	chr19:13,095,729 chr19:13,135,200 DEL	7 7 S · 0 R · 0 D	OTHER	—	—
NLRP3P1::VSIG1	chrX:107,984,708 chrX:108,058,038 DEL	7 3 S · 1 R · 3 D	OTHER	—	—
PCBP2::PCBP2P2	chr12:53,454,869 chr8:74,604,175 BND	7 7 S · 0 R · 0 D	OTHER	—	—
PLEKHO2::ANKDD1A	chr15:64,861,575 chr15:64,930,822 DEL	7 3 S · 0 R · 4 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
PMS2P3::POM121C	chr7:75,515,718 chr7:75,475,188 DEL	7 1 S · 0 R · 6 D	OTHER	—	—
POLR2J3::POLR2J	chr7:102,566,997 chr7:102,476,270 DEL	7 1 S · 0 R · 6 D	OTHER	—	—
POLR2J3::POLR2J	chr7:102,568,010 chr7:102,476,270 DEL	7 1 S · 0 R · 6 D	OTHER	—	—
PPP5D1P::	chr19:46,525,663 chr19:46,481,440 DEL	7 7 S · 0 R · 0 D	OTHER	✓	—
SLC17A3::SLC17A1	chr6:25,845,380 chr6:25,830,607 DEL	7 3 S · 1 R · 3 D	OTHER	✓	—
SLC35A3::MFSD14A	chr1:100,017,815 chr1:100,049,909 DEL	7 4 S · 0 R · 3 D	OTHER	✓	Mitelman Acute lymphoblastic leukemia/lymphoblastic lymphoma; Nonneoplastic epithelial disorder/lesion … ×9 López-Nieva et al 2019, Sci Rep — Acute lymphoblastic leukemia/lymphoblastic lymphoma Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Oesophagus Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Testis Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Thyroid Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Large intestine Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Gallbladder/Biliary system Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Bladder Wang et al 2015, Nat Genet — Mycosis fungoides/Sézary syndrome
SLC7A5P1::SMG1P2	chr16:29,613,103 chr16:29,566,249 DEL	7 4 S · 0 R · 3 D	OTHER	—	—
SUGT1P1::NOL6	chr9:33,503,827 chr9:33,472,412 DEL	7 4 S · 1 R · 2 D	OTHER	✓	—
TMSB4Y::	chrY:13,704,435 chrY:13,754,640 DEL	7 7 S · 0 R · 0 D	OTHER	✓	—
TMX2::CTNND1	chr11:57,737,668 chr11:57,789,037 DEL	7 4 S · 0 R · 3 D	OTHER	—	Mitelman Adenocarcinoma ×1 Yoshihara et al 2015, Oncogene — Adenocarcinoma · Kidney
UBE2D2::CXXC5	chr5:139,623,461 chr5:139,680,364 DEL	7 7 S · 0 R · 0 D	OTHER	—	—
::AAMDC	chr11:77,764,689 chr11:77,872,152 DEL	6 1 S · 2 R · 3 D	OTHER	—	—
::DNAH6	chr2:84,459,670 chr2:84,517,819 DEL	6 3 S · 0 R · 3 D	OTHER	—	—
::GOLGA7B	chr10:97,841,756 chr10:97,859,458 DEL	6 3 S · 0 R · 3 D	OTHER	—	—
::LRRC42	chr1:53,940,097 chr1:53,946,237 DEL	6 6 S · 0 R · 0 D	OTHER	✓	—
AGAP10P::	chr10:45,700,256 chr10:45,706,431 DEL	6 4 S · 0 R · 2 D	OTHER	—	—
CLDN11::	chr3:170,423,327 chr3:170,460,299 DEL	6 6 S · 0 R · 0 D	OTHER	—	—
CTBS::GNG5 →	chr1:84,563,257 chr1:84,501,970 DEL	6 6 S · 0 R · 0 D	OTHER	✓	Mitelman Adenocarcinoma; Malignant epithelial tumor, special type … ×17 Fu et al 2024, Biomark Res — Adenocarcinoma · Oesophagus Fu et al 2024, Biomark Res — Malignant epithelial tumor, special type · Oesophagus Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic mesenchymal disorder/lesion · Heart Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Bladder Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Thyroid Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Spleen Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Gallbladder/Biliary system Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Uterus, corpus Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Oesophagus Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Skin Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Adrenal Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Testis Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Lung Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion Agnihotri et al 2016, Nat Genet — Schwannoma · Soft tissue Lai et al 2015, BMC Genomics — Adenocarcinoma · Prostate
DNHD1::	chr11:6,498,939 chr11:6,603,404 DEL	6 2 S · 0 R · 4 D	OTHER	✓	—
EEF1AKMT2::FAM53B	chr10:124,760,386 chr10:124,706,887 DEL	6 3 S · 0 R · 3 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion; Nonneoplastic hematologic disorder/lesion ×6 Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Thyroid Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Lung Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Testis Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Oesophagus Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Adrenal Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node
GUSBP13::SERF1B	chr5:69,920,867 chr5:70,026,407 DEL	6 1 S · 0 R · 5 D	OTHER	—	—
LRRC37A::LRRC37A2 →	chr17:46,306,309 chr17:46,511,511 DEL	6 1 S · 0 R · 5 D	OTHER	—	—
ODR4::PDC-AS1	chr1:186,419,077 chr1:186,425,123 DEL	6 3 S · 1 R · 2 D	OTHER	—	—
RAB4B-EGLN2::	chr19:40,808,213 chr19:40,826,564 DEL	6 1 S · 0 R · 5 D	OTHER	✓	—
RASA4::RASA4B →	chr7:102,608,761 chr7:102,511,981 DEL	6 2 S · 0 R · 4 D	OTHER	✓	—
RPS19::CD79A	chr19:41,861,212 chr19:41,878,990 DEL	6 5 S · 0 R · 1 D	OTHER	—	—
SANBR::C2orf74	chr2:61,134,276 chr2:61,162,842 DEL	6 4 S · 0 R · 2 D	OTHER	✓	—
SIDT2::TAGLN	chr11:117,195,915 chr11:117,203,002 DEL	6 3 S · 0 R · 3 D	OTHER	✓	Mitelman Nonneoplastic hematologic disorder/lesion; Nonneoplastic epithelial disorder/lesion … ×13 Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Thyroid Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Lung Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Gallbladder/Biliary system Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Bladder Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Uterus, corpus Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Skin Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Oesophagus Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Pancreas Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Testis Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion Agnihotri et al 2016, Nat Genet — Schwannoma · Soft tissue Lai et al 2015, BMC Genomics — Adenocarcinoma · Prostate
SVIL-AS1::	chr10:29,415,412 chr10:29,458,274 DEL	6 6 S · 0 R · 0 D	OTHER	✓	—
TEX12::BCO2	chr11:112,170,674 chr11:112,179,278 DEL	6 1 S · 0 R · 5 D	OTHER	—	—
TMSB4Y::ANOS2P	chrY:13,704,435 chrY:13,790,919 DEL	6 2 S · 2 R · 2 D	OTHER	—	—
ZDHHC11::ZDHHC11B	chr5:837,365 chr5:741,628 DEL	6 4 S · 1 R · 1 D	OTHER	✓	—
ZNF782::ZNF510	chr9:96,827,080 chr9:96,776,245 DEL	6 3 S · 0 R · 3 D	OTHER	✓	—
ZW10::TMPRSS5	chr11:113,736,620 chr11:113,697,418 DEL	6 3 S · 0 R · 3 D	OTHER	—	—
::	chr7:92,461,410 chr7:92,491,243 DEL	5 5 S · 0 R · 0 D	OTHER	✓	—
::AFMID	chr17:78,186,830 chr17:78,190,970 DEL	5 4 S · 0 R · 1 D	OTHER	—	—
::ANK2	chr4:112,706,217 chr4:113,174,416 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
::CA5B	chrX:15,693,058 chrX:15,721,497 DEL	5 5 S · 0 R · 0 D	OTHER	✓	—
::DNAH6	chr2:84,459,675 chr2:84,517,819 DEL	5 2 S · 0 R · 3 D	OTHER	—	—
::NADSYN1	chr11:71,448,885 chr11:71,455,110 DEL	5 2 S · 0 R · 3 D	OTHER	—	—
::PPP5D1P	chr19:46,600,883 chr19:46,527,072 DEL	5 5 S · 0 R · 0 D	OTHER	✓	—
::SGCG	chr13:23,160,646 chr13:23,234,611 DEL	5 5 S · 0 R · 0 D	OTHER	✓	—
::SLF1	chr5:94,618,318 chr5:94,628,811 DEL	5 5 S · 0 R · 0 D	OTHER	✓	—
::TMEM170A	chr16:75,516,203 chr16:75,451,839 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
::TRAC	chr14:22,473,940 chr14:22,547,506 DEL	5 5 S · 0 R · 0 D	OTHER	✓	—
ABRAXAS1::HELQ	chr4:83,463,494 chr4:83,453,945 DEL	5 2 S · 0 R · 3 D	OTHER	✓	Mitelman Nonneoplastic hematologic disorder/lesion; Nonneoplastic epithelial disorder/lesion ×7 Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Thyroid Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Skin Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Oesophagus Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Ovary Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Gallbladder/Biliary system Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Bladder
ADAMTS13::CACFD1	chr9:133,456,719 chr9:133,463,483 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
ADHFE1::VXN	chr8:66,460,465 chr8:66,496,437 DEL	5 4 S · 0 R · 1 D	OTHER	—	—
ARL13A::	chrX:100,973,722 chrX:101,010,523 DEL	5 3 S · 0 R · 2 D	OTHER	—	—
ARL17A::ARL17B	chr17:46,552,858 chr17:46,335,735 DEL	5 1 S · 0 R · 4 D	OTHER	—	—
ATP1A2::ATP1A4	chr1:160,139,984 chr1:160,153,165 DEL	5 2 S · 1 R · 2 D	OTHER	—	—
CDK11A::CDK11B	chr1:1,721,596 chr1:1,657,498 DEL	5 1 S · 1 R · 3 D	OTHER	—	—
CDK11A::CDK11B	chr1:1,716,346 chr1:1,657,498 DEL	5 1 S · 0 R · 4 D	OTHER	—	—
CTNNBIP1::CLSTN1	chr1:9,871,187 chr1:9,773,394 DEL	5 4 S · 1 R · 0 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion ×4 Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Uterus, corpus Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Skin Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Adrenal Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Oesophagus
DCUN1D2::ADPRHL1	chr13:113,459,312 chr13:113,444,589 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
DET1::MRPL46	chr15:88,511,432 chr15:88,465,773 DEL	5 3 S · 0 R · 2 D	OTHER	✓	—
EEF1AKMT2::FAM53B	chr10:124,760,318 chr10:124,706,887 DEL	5 3 S · 0 R · 2 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion; Nonneoplastic hematologic disorder/lesion ×6 Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Thyroid Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Lung Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Testis Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Oesophagus Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Adrenal Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node
EFCAB14::ATPAF1	chr1:46,683,300 chr1:46,665,364 DEL	5 3 S · 0 R · 2 D	OTHER	✓	—
ENTPD1::CC2D2B	chr10:95,864,861 chr10:95,911,301 DEL	5 5 S · 0 R · 0 D	OTHER	—	Mitelman Adenocarcinoma ×1 Gao et al 2018, Cell Rep — Adenocarcinoma · Thyroid
GCSH::C16orf46	chr16:81,084,463 chr16:81,054,094 DEL	5 4 S · 0 R · 1 D	OTHER	✓	—
GCSH::C16orf46	chr16:81,084,463 chr16:81,063,993 DEL	5 1 S · 1 R · 3 D	OTHER	✓	—
GLYCTK::DNAH1	chr3:52,291,111 chr3:52,316,455 DEL	5 3 S · 0 R · 2 D	OTHER	✓	—
GUSBP9::NAIPP4	chr5:71,197,646 chr5:71,128,753 DEL	5 2 S · 0 R · 3 D	OTHER	—	—
IL17RB::	chr3:53,865,019 chr3:53,867,708 DEL	5 1 S · 0 R · 4 D	OTHER	✓	—
LZTFL1::SLC6A20	chr3:45,826,256 chr3:45,782,223 DEL	5 3 S · 0 R · 2 D	OTHER	—	—
MED20::USP49	chr6:41,907,096 chr6:41,871,637 DEL	5 1 S · 0 R · 4 D	OTHER	—	Mitelman Adenocarcinoma ×1 Yoshihara et al 2015, Oncogene — Adenocarcinoma · Breast
METTL13::DNM3	chr1:171,814,023 chr1:171,921,748 DEL	5 3 S · 0 R · 2 D	OTHER	—	Mitelman Meningioma ×1 Brastianos et al 2013, Nat Genet — Meningioma · Brain
NACA::NACA3P	chr12:56,713,062 chr4:164,943,800 BND	5 2 S · 0 R · 3 D	OTHER	—	—
NSFP1::LRRC37A2	chr17:46,487,140 chr17:46,511,511 DEL	5 2 S · 0 R · 3 D	OTHER	—	—
NUDT14::JAG2	chr14:105,176,534 chr14:105,157,763 DEL	5 2 S · 2 R · 1 D	OTHER	✓	—
ODR4::PDC-AS1	chr1:186,419,077 chr1:186,435,327 DEL	5 1 S · 2 R · 2 D	OTHER	—	—
PDCD7::UBAP1L	chr15:65,118,672 chr15:65,106,359 DEL	5 3 S · 1 R · 1 D	OTHER	—	—
PILRB::PILRA	chr7:100,359,537 chr7:100,373,581 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
PKD2L2-DT::KLHL3	chr5:137,814,333 chr5:137,720,584 DEL	5 3 S · 0 R · 2 D	OTHER	—	—
PLEKHA4::HSD17B14	chr19:48,835,805 chr19:48,834,358 DEL	5 1 S · 0 R · 4 D	OTHER	—	Mitelman Adenocarcinoma ×1 Zheng et al 2016, Cancer Cell — Adenocarcinoma · Adrenal
PLEKHO2::ANKDD1A	chr15:64,855,037 chr15:64,930,822 DEL	5 3 S · 0 R · 2 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
PPP1R21::STON1	chr2:48,511,468 chr2:48,529,880 DEL	5 2 S · 1 R · 2 D	OTHER	✓	—
PTENP1-AS::TRBV26OR9-2	chr9:33,677,509 chr9:33,695,767 DEL	5 4 S · 0 R · 1 D	OTHER	—	—
RASA4::RASA4B →	chr7:102,594,467 chr7:102,500,793 DEL	5 1 S · 0 R · 4 D	OTHER	✓	—
RGPD8::RGPD3	chr2:112,399,632 chr2:106,435,202 DEL	5 2 S · 3 R · 0 D	OTHER	—	—
RPL11::ELOA	chr1:23,695,908 chr1:23,749,021 DEL	5 1 S · 0 R · 4 D	OTHER	✓	Mitelman Adenocarcinoma; Mycosis fungoides/Sézary syndrome ×2 Linehan et al 2016, N Engl J Med — Adenocarcinoma · Kidney Wang et al 2015, Nat Genet — Mycosis fungoides/Sézary syndrome
SDHAF2::PPP1R32	chr11:61,430,182 chr11:61,484,688 DEL	5 4 S · 0 R · 1 D	OTHER	✓	—
SLC10A3::UBL4A	chrX:154,487,780 chrX:154,486,333 DEL	5 3 S · 1 R · 1 D	OTHER	—	—
SLC35E4::OSBP2	chr22:30,637,069 chr22:30,694,208 DEL	5 3 S · 1 R · 1 D	OTHER	—	—
STAG3L2::GTF2IRD2	chr7:74,883,349 chr7:74,836,383 DEL	5 2 S · 0 R · 3 D	OTHER	—	—
TRBJ2-3::TRBC2	chr7:142,796,895 chr7:142,801,041 DEL	5 3 S · 1 R · 1 D	OTHER	—	—
UBE2Q2P11::CSPG4P5	chr15:84,412,774 chr15:84,408,001 DEL	5 2 S · 1 R · 2 D	OTHER	—	—
UBE2Q2P6::CSPG4P10	chr15:82,454,694 chr15:82,459,472 DEL	5 1 S · 0 R · 4 D	OTHER	—	—
VPS45::PLEKHO1	chr1:150,110,627 chr1:150,150,912 DEL	5 2 S · 0 R · 3 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion ×3 Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Gallbladder/Biliary system Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Testis Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Thyroid
YEATS4::	chr12:69,370,975 chr12:69,407,160 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
ZMYM5::PSPC1	chr13:19,824,920 chr13:19,782,791 DEL	5 4 S · 0 R · 1 D	OTHER	✓	Mitelman Acute lymphoblastic leukemia/lymphoblastic lymphoma ×1 Lilljebjörn et al 2016, Nat Commun — Acute lymphoblastic leukemia/lymphoblastic lymphoma
ZNF343::SNRPB	chr20:2,492,699 chr20:2,467,758 DEL	5 3 S · 0 R · 2 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
ZNF662::KRBOX1	chr3:42,908,909 chr3:42,938,850 DEL	5 3 S · 0 R · 2 D	OTHER	✓	—
ZNF880::	chr19:52,385,324 chr19:52,392,659 DEL	5 4 S · 1 R · 0 D	OTHER	—	—
::ALG1L10P	chr12:8,226,390 chr12:8,227,735 DEL	4 3 S · 1 R · 0 D	OTHER	—	—
::CAPN3	chr15:42,354,453 chr15:42,384,483 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
::OR2L13	chr1:247,937,384 chr1:248,099,358 DEL	4 1 S · 0 R · 3 D	OTHER	—	—
::PRR4	chr12:10,973,655 chr12:10,848,407 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
::PSD2	chr5:139,721,967 chr5:139,809,391 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
::RPL13A	chr8:82,653,133 chr19:49,490,475 BND	4 2 S · 2 R · 0 D	OTHER	✓	—
::SLITRK2	chrX:145,759,451 chrX:145,822,399 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
::WDR82	chr3:52,293,027 chr3:52,284,591 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
ACAD10::ALDH2	chr12:111,755,745 chr12:111,775,605 DEL	4 2 S · 0 R · 2 D	OTHER	✓	—
AGAP7P::AGAP14P	chr10:46,125,899 chr10:46,340,188 DEL	4 3 S · 0 R · 1 D	OTHER	—	—
AKAP8L::AKAP8	chr19:15,397,150 chr19:15,377,014 DEL	4 1 S · 2 R · 1 D	OTHER	—	—
AKR7A3::AKR7L	chr1:19,283,996 chr1:19,270,935 DEL	4 1 S · 1 R · 2 D	OTHER	—	—
ANKDD1A::	chr15:64,957,269 chr15:64,963,531 DEL	4 2 S · 1 R · 1 D	OTHER	✓	—
ANKRD20A11P::	chr21:13,975,184 chr13:18,872,751 BND	4 2 S · 2 R · 0 D	OTHER	—	—
ANO7::	chr2:241,218,381 chr2:241,239,403 DEL	4 3 S · 1 R · 0 D	OTHER	—	—
ARL17A::ARL17B	chr17:46,517,094 chr17:46,299,665 DEL	4 1 S · 0 R · 3 D	OTHER	—	—
ARL17A::ARL17B	chr17:46,517,094 chr17:46,311,275 DEL	4 3 S · 0 R · 1 D	OTHER	—	—
BCKDHB::	chr6:80,273,221 chr6:80,418,296 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
BEND5::AGBL4	chr1:48,736,239 chr1:48,663,241 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
C1QA::C1QC	chr1:22,639,161 chr1:22,644,011 DEL	4 1 S · 0 R · 3 D	OTHER	✓	—
CFAP161::IL16	chr15:81,143,820 chr15:81,225,299 DEL	4 3 S · 0 R · 1 D	OTHER	—	—
CHCHD2::PHKG1	chr7:56,102,867 chr7:56,088,975 DEL	4 3 S · 0 R · 1 D	OTHER	—	—
CIRBP::FAM174C	chr19:1,274,440 chr19:1,277,183 DEL	4 1 S · 0 R · 3 D	OTHER	—	Mitelman Nonneoplastic hematologic disorder/lesion; Nonneoplastic epithelial disorder/lesion ×4 Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Skin Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Thyroid Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Uterus, corpus
DDT::	chr22:23,973,768 chr22:23,926,520 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
DNHD1::	chr11:6,592,823 chr11:6,600,486 DEL	4 3 S · 0 R · 1 D	OTHER	✓	—
EIF4E3::FOXP1	chr3:71,690,010 chr3:71,493,555 DEL	4 2 S · 0 R · 2 D	OTHER	—	Mitelman Adenocarcinoma ×1 Yoshihara et al 2015, Oncogene — Adenocarcinoma · Breast
ELAC1::SMAD4	chr18:50,974,561 chr18:51,046,920 DEL	4 2 S · 0 R · 2 D	OTHER	✓	Mitelman Adenocarcinoma ×1 Asmann et al 2012, Cancer Res — Adenocarcinoma · Breast
FAM205C::	chr9:34,889,579 chr9:34,703,038 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
FBXO25::	chr8:473,742 chr8:494,494 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
FXYD1::FXYD7	chr19:35,143,035 chr19:35,143,277 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
GCSH::C16orf46	chr16:81,084,463 chr16:81,062,138 DEL	4 2 S · 0 R · 2 D	OTHER	✓	—
GNPAT::	chr1:231,276,196 chr1:231,288,588 DEL	4 2 S · 2 R · 0 D	OTHER	—	—
GRAMD1A::SCN1B	chr19:35,026,215 chr19:35,032,528 DEL	4 1 S · 0 R · 3 D	OTHER	—	—
HEXA::CELF6	chr15:72,345,446 chr15:72,320,702 DEL	4 1 S · 3 R · 0 D	OTHER	—	—
HILPDA::METTL2B	chr7:128,456,023 chr7:128,479,158 DEL	4 3 S · 0 R · 1 D	OTHER	—	—
HSD17B11::HSD17B13	chr4:87,340,490 chr4:87,318,436 DEL	4 4 S · 0 R · 0 D	OTHER	—	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
HSP90B1::	chr12:103,938,417 chr12:104,021,978 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
IRGQ::XRCC1	chr19:43,592,868 chr19:43,561,020 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
KIAA1586::ZNF451	chr6:57,047,396 chr6:57,090,811 DEL	4 1 S · 0 R · 3 D	OTHER	—	—
KSR1::LGALS9	chr17:27,617,428 chr17:27,638,263 DEL	4 1 S · 0 R · 3 D	OTHER	✓	—
LILRB5::LILRB3	chr19:54,252,054 chr19:54,217,474 DEL	4 1 S · 0 R · 3 D	OTHER	—	—
LINC02908::	chr9:137,037,898 chr9:137,039,971 DEL	4 2 S · 1 R · 1 D	OTHER	✓	—
MED20::USP49	chr6:41,916,785 chr6:41,871,637 DEL	4 3 S · 0 R · 1 D	OTHER	—	Mitelman Adenocarcinoma ×1 Yoshihara et al 2015, Oncogene — Adenocarcinoma · Breast
MED22::SURF6	chr9:133,339,356 chr9:133,334,601 DEL	4 2 S · 1 R · 1 D	OTHER	—	Mitelman Nonneoplastic epithelial disorder/lesion; Mycosis fungoides/Sézary syndrome ×2 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung Wang et al 2015, Nat Genet — Mycosis fungoides/Sézary syndrome
METTL23::MFSD11	chr17:76,733,377 chr17:76,736,190 DEL	4 1 S · 2 R · 1 D	OTHER	✓	—
MGAM::MGAM2	chr7:142,103,439 chr7:142,116,874 DEL	4 3 S · 0 R · 1 D	OTHER	—	—
MLYCD::OSGIN1	chr16:83,912,367 chr16:83,957,640 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
MNAT1::SLC38A6	chr14:60,879,835 chr14:60,982,508 DEL	4 3 S · 0 R · 1 D	OTHER	—	—
MRAP2::	chr6:84,062,992 chr6:84,139,470 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
NIT2::	chr3:100,357,603 chr3:100,365,362 DEL	4 2 S · 0 R · 2 D	OTHER	✓	—
NOXRED1::TMED8	chr14:77,405,913 chr14:77,351,751 DEL	4 2 S · 0 R · 2 D	OTHER	—	—
NPTXR::DNAL4	chr22:38,823,083 chr22:38,781,009 DEL	4 1 S · 1 R · 2 D	OTHER	—	—
NUTF2::EDC4	chr16:67,868,599 chr16:67,875,945 DEL	4 3 S · 0 R · 1 D	OTHER	—	—
PARGP1::	chr10:45,888,165 chr10:45,863,114 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
PEX13::SANBR	chr2:61,048,573 chr2:61,068,849 DEL	4 1 S · 1 R · 2 D	OTHER	—	—
PPDPF::	chr20:63,521,589 chr20:63,530,786 DEL	4 3 S · 1 R · 0 D	OTHER	—	—
PRORSD1P::	chr2:55,282,434 chr2:55,308,832 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
PRR13::PCBP2	chr12:53,443,773 chr12:53,454,726 DEL	4 3 S · 0 R · 1 D	OTHER	✓	—
RAB11FIP3::CAPN15	chr16:520,925 chr16:533,946 DEL	4 2 S · 0 R · 2 D	OTHER	—	Mitelman Adenocarcinoma ×1 Gao et al 2018, Cell Rep — Adenocarcinoma · Ovary
RASA4::RASA4B →	chr7:102,595,305 chr7:102,496,964 DEL	4 1 S · 0 R · 3 D	OTHER	✓	—
RNASET2::RPS6KA2	chr6:166,938,895 chr6:166,858,259 DEL	4 1 S · 0 R · 3 D	OTHER	✓	—
SANBR::C2orf74	chr2:61,134,276 chr2:61,157,862 DEL	4 2 S · 0 R · 2 D	OTHER	✓	—
SDHAF2::PPP1R32	chr11:61,438,113 chr11:61,481,782 DEL	4 1 S · 0 R · 3 D	OTHER	✓	—
SDHAF2::PPP1R32	chr11:61,438,113 chr11:61,468,664 DEL	4 1 S · 0 R · 3 D	OTHER	✓	—
SLC17A3::SLC17A1	chr6:25,845,380 chr6:25,826,633 DEL	4 2 S · 1 R · 1 D	OTHER	✓	—
SLC25A16::DNA2	chr10:68,487,144 chr10:68,471,885 DEL	4 1 S · 1 R · 2 D	OTHER	—	—
SLC43A3::PRG2	chr11:57,409,175 chr11:57,389,956 DEL	4 2 S · 0 R · 2 D	OTHER	✓	—
SMURF2P1::LRRC37BP1 →	chr17:30,610,942 chr17:30,633,098 DEL	4 3 S · 0 R · 1 D	OTHER	✓	—
SNX12::	chrX:71,061,028 chrX:70,989,916 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
SPECC1::CCDC144CP	chr17:20,306,082 chr17:20,324,183 DEL	4 2 S · 1 R · 1 D	OTHER	—	—
SRSF6::L3MBTL1	chr20:43,460,598 chr20:43,513,476 DEL	4 3 S · 0 R · 1 D	OTHER	—	—
STAG3L2::GTF2IRD2	chr7:74,884,144 chr7:74,836,383 DEL	4 3 S · 0 R · 1 D	OTHER	—	—
TOPORS::DDX58	chr9:32,550,774 chr9:32,500,939 DEL	4 3 S · 0 R · 1 D	OTHER	✓	—
TRIM52::RACK1	chr5:181,260,001 chr5:181,242,345 DEL	4 4 S · 0 R · 0 D	OTHER	✓	Mitelman Squamous cell carcinoma ×1 Pan et al 2020, Mol Cell Probes — Squamous cell carcinoma · Oral cavity
TTC31::	chr2:74,492,747 chr2:74,497,960 DEL	4 2 S · 0 R · 2 D	OTHER	—	—
UBE2J1::GABRR2	chr6:89,329,783 chr6:89,299,865 DEL	4 2 S · 0 R · 2 D	OTHER	—	—
UBE2Q2P11::CSPG4P5	chr15:84,412,774 chr15:84,407,984 DEL	4 2 S · 0 R · 2 D	OTHER	—	—
UPK3BL1::POLR2J3	chr7:102,638,714 chr7:102,540,091 DEL	4 2 S · 0 R · 2 D	OTHER	—	—
WASH9P::WASH7P	chr1:187,376 chr1:17,319 DEL	4 1 S · 0 R · 3 D	OTHER	—	—
ZNF586::ZNF587	chr19:57,790,400 chr19:57,856,104 DEL	4 2 S · 0 R · 2 D	OTHER	—	—
ZNF655::TMEM225B	chr7:99,560,695 chr7:99,600,205 DEL	4 1 S · 0 R · 3 D	OTHER	✓	—
ZNRD2::EHBP1L1	chr11:65,573,766 chr11:65,579,082 DEL	4 3 S · 0 R · 1 D	OTHER	—	—
ZW10::TMPRSS5	chr11:113,736,620 chr11:113,699,027 DEL	4 1 S · 0 R · 3 D	OTHER	—	—
::AMDHD1	chr12:95,918,820 chr12:95,952,717 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
::ANK2	chr4:112,706,217 chr4:112,904,455 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
::ANKRD37	chr4:185,377,018 chr4:185,396,853 DEL	3 1 S · 0 R · 2 D	OTHER	✓	—
::ARFIP1	chr4:152,779,322 chr4:152,829,625 DEL	3 2 S · 0 R · 1 D	OTHER	—	—
::CCDC146	chr7:77,046,917 chr7:77,167,658 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
::COL1A2	chr3:47,633,084 chr7:94,424,336 BND	3 1 S · 2 R · 0 D	OTHER	✓	—
::MRPS18C	chr4:83,453,945 chr4:83,455,947 DEL	3 2 S · 0 R · 1 D	OTHER	✓	—
::NEFH	chr22:29,442,129 chr22:29,480,252 DEL	3 2 S · 0 R · 1 D	OTHER	—	—
::NME4	chr16:383,429 chr16:398,990 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
::OMA1	chr1:58,546,703 chr1:58,539,310 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
::PMS2P7	chr7:73,003,730 chr7:73,005,693 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
::PPP1R13B	chr14:103,848,272 chr14:103,797,518 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
::PRR11	chr17:59,107,591 chr17:59,169,748 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
::SEC22B4P	chr1:146,369,971 chr1:146,328,211 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
::SEPTIN14P3	chr3:198,225,969 chr3:198,228,194 DEL	3 1 S · 0 R · 2 D	OTHER	—	—
::SPDYE2B	chr7:102,640,773 chr7:102,659,694 DEL	3 1 S · 0 R · 2 D	OTHER	—	—
::TARBP2	chr12:53,487,428 chr12:53,503,421 DEL	3 1 S · 1 R · 1 D	OTHER	—	—
::TCAF1P1	chr7:143,560,364 chr7:143,598,039 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
::USP32P1	chr17:16,787,122 chr17:16,796,043 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
::ZNF91	chr19:23,490,701 chr19:23,362,725 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
ABCA6::ABCA9	chr17:69,078,960 chr17:69,051,139 DEL	3 2 S · 0 R · 1 D	OTHER	✓	—
ABRAXAS1::HELQ	chr4:83,467,454 chr4:83,453,945 DEL	3 1 S · 0 R · 2 D	OTHER	✓	Mitelman Nonneoplastic hematologic disorder/lesion; Nonneoplastic epithelial disorder/lesion ×7 Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Thyroid Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Skin Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Oesophagus Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Ovary Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Gallbladder/Biliary system Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Bladder
ACCS::EXT2	chr11:44,083,311 chr11:44,107,683 DEL	3 1 S · 0 R · 2 D	OTHER	—	Mitelman Chronic myeloid leukemia, t(9;22) ×1 Francis et al 2012, PLoS One — Chronic myeloid leukemia, t(9;22)
ARHGEF35-AS1::	chr7:144,251,610 chr7:144,355,338 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
ARSI::CAMK2A	chr5:150,297,421 chr5:150,273,159 DEL	3 1 S · 0 R · 2 D	OTHER	—	—
ASAP3::TCEA3	chr1:23,431,035 chr1:23,419,139 DEL	3 1 S · 0 R · 2 D	OTHER	—	Mitelman Squamous cell carcinoma ×2 Hu et al 2018, Nucleic Acids Res — Squamous cell carcinoma · Uterus, cervix Gao et al 2018, Cell Rep — Squamous cell carcinoma · Uterus, cervix
ASIC4::	chr2:219,537,736 chr2:219,540,903 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
C6orf163::SMIM8	chr6:87,356,503 chr6:87,375,462 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
CCDC126::FAM221A	chr7:23,611,553 chr7:23,684,499 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
CCDC65::	chr12:48,931,328 chr12:48,939,655 DEL	3 2 S · 1 R · 0 D	OTHER	—	—
CEP112::AXIN2	chr17:65,635,911 chr17:65,558,736 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
CFAP36::	chr2:55,543,825 chr2:55,558,775 DEL	3 2 S · 0 R · 1 D	OTHER	—	—
CIRBP::FAM174C	chr19:1,274,892 chr19:1,277,183 DEL	3 1 S · 0 R · 2 D	OTHER	—	Mitelman Nonneoplastic hematologic disorder/lesion; Nonneoplastic epithelial disorder/lesion ×4 Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Skin Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Thyroid Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Uterus, corpus
CLN3::NPIPB7	chr16:28,477,464 chr16:28,466,902 DEL	3 1 S · 0 R · 2 D	OTHER	✓	—
CNPY3::GNMT	chr6:42,938,207 chr6:42,962,212 DEL	3 2 S · 0 R · 1 D	OTHER	—	—
COX7C::	chr5:86,619,496 chr10:72,560,489 BND	3 1 S · 2 R · 0 D	OTHER	—	—
DAP3P1::DAP3	chr1:155,598,915 chr1:155,725,382 DEL	3 2 S · 1 R · 0 D	OTHER	—	—
DNAJC5::	chr20:63,935,981 chr20:63,940,150 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
DNHD1::	chr11:6,545,140 chr11:6,603,404 DEL	3 2 S · 0 R · 1 D	OTHER	✓	—
DNM1L::	chr12:32,726,636 chr12:76,053,205 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
DYNLT2B::PCYT1A	chr3:196,306,943 chr3:196,270,541 DEL	3 3 S · 0 R · 0 D	OTHER	—	Mitelman Transitional cell carcinoma ×1 Hu et al 2018, Nucleic Acids Res — Transitional cell carcinoma · Bladder
EIF4G3::HP1BP3	chr1:20,807,152 chr1:20,779,911 DEL	3 1 S · 1 R · 1 D	OTHER	—	Mitelman Adenocarcinoma ×1 Hu et al 2018, Nucleic Acids Res — Adenocarcinoma · Uterus, corpus
ERAL1::	chr17:28,859,283 chr17:28,874,095 DEL	3 1 S · 2 R · 0 D	OTHER	—	—
ERF::GSK3A	chr19:42,248,590 chr19:42,240,142 DEL	3 2 S · 0 R · 1 D	OTHER	—	Mitelman Astrocytoma, grade III-IV/Glioblastoma ×1 Frattini et al 2013, Nat Genet — Astrocytoma, grade III-IV/Glioblastoma · Brain
FBLN5::TC2N	chr14:91,877,487 chr14:91,813,825 DEL	3 3 S · 0 R · 0 D	OTHER	—	Mitelman Adenocarcinoma ×1 Yoshihara et al 2015, Oncogene — Adenocarcinoma · Breast
FKBP1A::SDCBP2	chr20:1,392,834 chr20:1,320,435 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
GALT::IL11RA	chr9:34,649,564 chr9:34,655,133 DEL	3 1 S · 0 R · 2 D	OTHER	✓	—
GCC2::RANBP2	chr2:108,499,754 chr2:108,753,825 DEL	3 1 S · 1 R · 1 D	OTHER	—	—
GNAQ::GNA14	chr9:77,728,514 chr9:77,529,253 DEL	3 1 S · 1 R · 1 D	OTHER	—	—
GPR155::CIR1	chr2:174,439,898 chr2:174,387,779 DEL	3 1 S · 0 R · 2 D	OTHER	✓	Mitelman Mycosis fungoides/Sézary syndrome ×1 Wang et al 2015, Nat Genet — Mycosis fungoides/Sézary syndrome
GTF2F1::PSPN	chr19:6,380,285 chr19:6,375,616 DEL	3 2 S · 1 R · 0 D	OTHER	—	—
H2BC21::H4C15	chr1:149,886,264 chr1:149,854,217 DEL	3 1 S · 0 R · 2 D	OTHER	—	—
HIF3A::PPP5C	chr19:46,334,986 chr19:46,353,748 DEL	3 2 S · 0 R · 1 D	OTHER	—	Mitelman Squamous cell carcinoma ×1 Gao et al 2018, Cell Rep — Squamous cell carcinoma · Uterus, cervix
HIF3A::PPP5C	chr19:46,342,159 chr19:46,353,748 DEL	3 1 S · 0 R · 2 D	OTHER	—	Mitelman Squamous cell carcinoma ×1 Gao et al 2018, Cell Rep — Squamous cell carcinoma · Uterus, cervix
HIGD1A::CCDC13	chr3:42,786,028 chr3:42,758,351 DEL	3 1 S · 0 R · 2 D	OTHER	—	—
HIGD1A::CCDC13	chr3:42,794,157 chr3:42,758,351 DEL	3 1 S · 0 R · 2 D	OTHER	—	—
HSF4::	chr16:67,169,101 chr16:67,170,240 DEL	3 2 S · 1 R · 0 D	OTHER	—	—
IFNAR2::IL10RB	chr21:33,252,830 chr21:33,268,394 DEL	3 2 S · 0 R · 1 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
KLRG1::	chr12:9,009,525 chr12:9,058,092 DEL	3 2 S · 0 R · 1 D	OTHER	—	—
LINC00271::PDE7B	chr6:135,809,976 chr6:135,947,464 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
LRRC8B::LRRC8C	chr1:89,584,789 chr1:89,686,470 DEL	3 2 S · 0 R · 1 D	OTHER	✓	—
LSM10::STK40	chr1:36,392,358 chr1:36,361,340 DEL	3 1 S · 0 R · 2 D	OTHER	—	—
MED22::SURF6	chr9:133,344,125 chr9:133,334,601 DEL	3 2 S · 0 R · 1 D	OTHER	—	Mitelman Nonneoplastic epithelial disorder/lesion; Mycosis fungoides/Sézary syndrome ×2 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung Wang et al 2015, Nat Genet — Mycosis fungoides/Sézary syndrome
MLEC::UNC119B	chr12:120,696,541 chr12:120,713,274 DEL	3 1 S · 0 R · 2 D	OTHER	—	—
MRPS6::	chr21:34,125,480 chr21:34,262,820 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
NAIPP4::GTF2H2	chr5:71,108,661 chr5:71,062,796 DEL	3 2 S · 0 R · 1 D	OTHER	✓	—
NANP::NINL	chr20:25,623,859 chr20:25,526,598 DEL	3 1 S · 1 R · 1 D	OTHER	—	—
NDUFA13::YJEFN3	chr19:19,527,770 chr19:19,532,632 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
NEDD8-MDP1::CHMP4A	chr14:24,213,994 chr14:24,211,829 DEL	3 1 S · 0 R · 2 D	OTHER	✓	—
NFU1::GFPT1	chr2:69,400,364 chr2:69,374,113 DEL	3 2 S · 0 R · 1 D	OTHER	—	Mitelman Malignant melanoma; Squamous cell carcinoma ×2 Calabrese et al 2020, Nature — Malignant melanoma · Skin Yoshihara et al 2015, Oncogene — Squamous cell carcinoma · Lung
NIPSNAP3A::NIPSNAP3B	chr9:104,759,171 chr9:104,766,325 DEL	3 1 S · 0 R · 2 D	OTHER	—	—
NOL11::	chr17:67,743,586 chr19:45,794,300 BND	3 1 S · 2 R · 0 D	OTHER	—	—
NPIPB7::NPIPB6	chr16:28,456,424 chr16:28,342,825 DEL	3 1 S · 0 R · 2 D	OTHER	—	—
NPIPP1::NPIPB2	chr16:15,114,443 chr16:11,937,668 DEL	3 1 S · 2 R · 0 D	OTHER	—	—
NSFP1::NSF	chr17:46,487,140 chr17:46,674,414 DEL	3 2 S · 0 R · 1 D	OTHER	—	—
NUCB1::DHDH	chr19:48,923,393 chr19:48,935,000 DEL	3 2 S · 0 R · 1 D	OTHER	—	—
NUDT14::JAG2	chr14:105,176,534 chr14:105,168,107 DEL	3 1 S · 0 R · 2 D	OTHER	✓	—
NUDT21::AMFR	chr16:56,432,671 chr16:56,414,344 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
PARL::MAP6D1	chr3:183,833,492 chr3:183,818,111 DEL	3 2 S · 0 R · 1 D	OTHER	—	—
PDCD7::UBAP1L	chr15:65,118,672 chr15:65,106,388 DEL	3 1 S · 0 R · 2 D	OTHER	—	—
PEX19::DCAF8	chr1:160,279,801 chr1:160,244,034 DEL	3 2 S · 0 R · 1 D	OTHER	—	—
PIK3C3::LINC00907	chr18:42,067,513 chr18:42,159,423 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
PMS2P3::POM121C	chr7:75,510,931 chr7:75,475,188 DEL	3 1 S · 1 R · 1 D	OTHER	—	—
POLR2J3::RASA4B	chr7:102,539,606 chr7:102,511,981 DEL	3 1 S · 1 R · 1 D	OTHER	✓	—
PSMD7::	chr16:74,305,571 chr16:74,332,567 DEL	3 2 S · 0 R · 1 D	OTHER	✓	—
RBPMS2::OAZ2	chr15:64,748,419 chr15:64,691,591 DEL	3 1 S · 1 R · 1 D	OTHER	—	Mitelman Astrocytoma, grade I-II ×1 Hu et al 2018, Nucleic Acids Res — Astrocytoma, grade I-II · Brain
RDH11::VTI1B	chr14:67,685,015 chr14:67,662,535 DEL	3 2 S · 0 R · 1 D	OTHER	—	Mitelman Acute myeloid leukemia, NOS; Acute monoblastic leukemia (FAB type M5) ×2 Gao et al 2018, Cell Rep — Acute myeloid leukemia, NOS The Cancer Genome 2013, N Engl J Med — Acute monoblastic leukemia (FAB type M5)
SDHAF2::PPP1R32	chr11:61,438,113 chr11:61,484,688 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
SEC24B-AS1::COL25A1	chr4:109,362,752 chr4:109,302,075 DEL	3 2 S · 0 R · 1 D	OTHER	—	—
SELENOH::CTNND1	chr11:57,742,984 chr11:57,789,037 DEL	3 1 S · 0 R · 2 D	OTHER	—	—
SF3A2::AMH	chr19:2,247,869 chr19:2,250,337 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
SFT2D2::TBX19	chr1:168,243,069 chr1:168,291,160 DEL	3 1 S · 0 R · 2 D	OTHER	—	—
SLC35A3::	chr1:100,017,815 chr1:100,043,073 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
SLC9C2::PRDX6-AS1	chr1:173,506,856 chr1:173,485,580 DEL	3 2 S · 0 R · 1 D	OTHER	—	—
SMDT1::NDUFA6-DT	chr22:42,082,065 chr22:42,091,297 DEL	3 1 S · 0 R · 2 D	OTHER	—	—
SSBP1::MGAM	chr7:141,750,384 chr7:142,005,529 DEL	3 1 S · 0 R · 2 D	OTHER	—	—
TEX15::PPP2CB	chr8:30,836,803 chr8:30,799,755 DEL	3 2 S · 0 R · 1 D	OTHER	—	—
TMC5::CCP110	chr16:19,497,163 chr16:19,527,867 DEL	3 2 S · 0 R · 1 D	OTHER	✓	—
TMED3::MINAR1	chr15:79,413,557 chr15:79,456,098 DEL	3 1 S · 0 R · 2 D	OTHER	—	—
TMED3::MINAR1	chr15:79,314,005 chr15:79,456,098 DEL	3 1 S · 0 R · 2 D	OTHER	—	—
TMEM184B::PLA2G6	chr22:38,224,785 chr22:38,214,617 DEL	3 1 S · 0 R · 2 D	OTHER	—	Mitelman Adenocarcinoma; Malignant melanoma ×3 Gao et al 2018, Cell Rep — Adenocarcinoma · Breast Gao et al 2018, Cell Rep — Malignant melanoma · Skin Yoshihara et al 2015, Oncogene — Adenocarcinoma · Breast
TOMM5::FBXO10	chr9:37,588,811 chr9:37,541,774 DEL	3 2 S · 0 R · 1 D	OTHER	—	—
TOMM5::FBXO10	chr9:37,588,753 chr9:37,541,774 DEL	3 2 S · 0 R · 1 D	OTHER	—	—
TRAJ38::TRAC	chr14:22,502,292 chr14:22,547,506 DEL	3 2 S · 0 R · 1 D	OTHER	—	—
TRAJ45::TRAC	chr14:22,493,990 chr14:22,547,506 DEL	3 2 S · 0 R · 1 D	OTHER	✓	—
TRIP10::	chr19:6,750,633 chr19:6,752,193 DEL	3 2 S · 1 R · 0 D	OTHER	—	—
TSC22D2::	chr3:150,452,438 chr3:150,545,703 DEL	3 2 S · 1 R · 0 D	OTHER	—	—
UBE2Q2L::CSPG4P11	chr15:84,174,157 chr15:84,186,825 DEL	3 1 S · 0 R · 2 D	OTHER	—	—
UQCR11::MBD3	chr19:1,599,412 chr19:1,585,214 DEL	3 2 S · 0 R · 1 D	OTHER	—	—
VAPB::APCDD1L-DT	chr20:58,418,363 chr20:58,547,812 DEL	3 1 S · 0 R · 2 D	OTHER	—	—
VAPB::APCDD1L-DT	chr20:58,418,363 chr20:58,523,169 DEL	3 1 S · 1 R · 1 D	OTHER	—	—
VWF::ANO2	chr12:5,949,786 chr12:5,946,228 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
WARS2::TBX15	chr1:119,034,095 chr1:118,931,832 DEL	3 1 S · 0 R · 2 D	OTHER	—	—
WBP2::UNC13D	chr17:75,846,738 chr17:75,844,371 DEL	3 2 S · 0 R · 1 D	OTHER	—	—
WDFY1::AP1S3	chr2:223,855,778 chr2:223,777,869 DEL	3 1 S · 0 R · 2 D	OTHER	—	—
WDR81::SERPINF2	chr17:1,737,691 chr17:1,744,992 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
YAF2::RYBP	chr12:42,238,155 chr3:72,446,621 BND	3 3 S · 0 R · 0 D	OTHER	—	—
YIPF4::BIRC6	chr2:32,307,190 chr2:32,377,588 DEL	3 2 S · 0 R · 1 D	OTHER	—	Mitelman Adenocarcinoma ×1 Yoshihara et al 2015, Oncogene — Adenocarcinoma · Lung
YY1AP1::GON4L	chr1:155,661,307 chr1:155,773,210 DUP	3 2 S · 0 R · 1 D	OTHER	—	—
ZFP41::GLI4	chr8:143,251,340 chr8:143,269,360 DEL	3 1 S · 1 R · 1 D	OTHER	—	—
ZMYM6::TMEM35B	chr1:34,992,234 chr1:34,983,947 DEL	3 2 S · 0 R · 1 D	OTHER	✓	—
ZNF221::ZNF155	chr19:43,967,326 chr19:43,988,459 DEL	3 1 S · 0 R · 2 D	OTHER	—	—
ZNF418::ZNF417	chr19:57,922,465 chr19:57,912,186 DEL	3 2 S · 0 R · 1 D	OTHER	—	—
ZNF551::ZNF776	chr19:57,682,244 chr19:57,746,852 DEL	3 1 S · 0 R · 2 D	OTHER	✓	Mitelman Adenocarcinoma ×1 Zhao et al 2017, Oncotarget — Adenocarcinoma · Prostate
ZNF551::ZNF776	chr19:57,682,244 chr19:57,750,785 DEL	3 1 S · 0 R · 2 D	OTHER	✓	Mitelman Adenocarcinoma ×1 Zhao et al 2017, Oncotarget — Adenocarcinoma · Prostate
ZNF551::ZNF776	chr19:57,685,385 chr19:57,746,852 DEL	3 1 S · 0 R · 2 D	OTHER	✓	Mitelman Adenocarcinoma ×1 Zhao et al 2017, Oncotarget — Adenocarcinoma · Prostate
ZNF587B::ZNF587	chr19:57,819,945 chr19:57,858,576 DEL	3 1 S · 0 R · 2 D	OTHER	✓	—
ZNF587B::ZNF587	chr19:57,820,549 chr19:57,856,104 DEL	3 1 S · 0 R · 2 D	OTHER	✓	—
ZNF587B::ZNF587	chr19:57,819,945 chr19:57,856,104 DEL	3 1 S · 0 R · 2 D	OTHER	✓	—
ZNF606::C19orf18	chr19:57,988,207 chr19:57,974,203 DEL	3 1 S · 0 R · 2 D	OTHER	✓	—
ZNF720::ZNF267	chr16:31,753,900 chr16:31,884,498 DEL	3 2 S · 0 R · 1 D	OTHER	—	Mitelman Carcinoma, NOS ×1 Ilnytskyy et al 2023, Cancer Genomics Proteomics — Carcinoma, NOS · Lung
ZNF720::ZNF267	chr16:31,723,353 chr16:31,884,498 DEL	3 2 S · 0 R · 1 D	OTHER	—	Mitelman Carcinoma, NOS ×1 Ilnytskyy et al 2023, Cancer Genomics Proteomics — Carcinoma, NOS · Lung
ZSCAN25::	chr7:99,624,180 chr7:99,669,095 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
::CDR2	chr16:22,426,213 chr16:22,365,014 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
::LMF1	chr16:980,127 chr16:954,666 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
ABCA10::ABCA6	chr17:69,149,033 chr17:69,140,748 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
ABCA6::ABCA9	chr17:69,079,210 chr17:69,051,139 DEL	2 1 S · 0 R · 1 D	OTHER	✓	—
ACAD10::ALDH2	chr12:111,755,745 chr12:111,781,918 DEL	2 1 S · 0 R · 1 D	OTHER	✓	—
ACAD11::NPHP3-ACAD11	chr3:132,659,603 chr3:132,644,891 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
AGAP7P::AGAP14P	chr10:46,129,246 chr10:46,340,188 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
AMDHD2::PDPK1	chr16:2,528,718 chr16:2,557,703 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
APEH::RNF123	chr3:49,683,146 chr3:49,691,130 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
APEH::RNF123	chr3:49,683,146 chr3:49,697,143 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
APOBEC3C::APOBEC3D	chr22:39,018,045 chr22:39,022,822 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
APOC1::APOC1P1	chr19:44,916,325 chr19:44,931,000 DEL	2 1 S · 0 R · 1 D	OTHER	✓	—
BACH1::	chr21:29,329,693 chr21:29,361,552 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
BRD9::ZDHHC11B	chr5:878,355 chr5:766,919 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
BRWD1::PSMG1	chr21:39,196,498 chr21:39,181,878 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
C17orf113::ZNF385C	chr17:42,042,834 chr17:42,037,885 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
C1RL-AS1::CLSTN3	chr12:7,120,625 chr12:7,130,580 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
C6orf163::SMIM8	chr6:87,356,503 chr6:87,371,593 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
CCDC163::TESK2	chr1:45,496,556 chr1:45,457,871 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
CD99P1::CD99	chrX:2,626,642 chrX:2,714,422 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
CFAP91::NR1I2	chr3:119,751,098 chr3:119,807,229 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
CHD4::NOP2	chr12:6,570,869 chr12:6,567,922 DEL	2 1 S · 0 R · 1 D	OTHER	✓	—
CLCF1::POLD4	chr11:67,373,524 chr11:67,353,077 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
CLEC4F::FIGLA	chr2:70,809,739 chr2:70,787,801 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
CLN6::CALML4	chr15:68,218,536 chr15:68,197,628 DEL	2 2 S · 0 R · 0 D	OTHER	✓	Mitelman Adenocarcinoma ×1 Kim et al 2014, Oncogene — Adenocarcinoma · Stomach
CNPY2::CS	chr12:56,310,958 chr12:56,300,220 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
CNRIP1::PPP3R1	chr2:68,317,157 chr2:68,217,131 DEL	2 1 S · 0 R · 1 D	OTHER	—	Mitelman Adenocarcinoma ×2 Gao et al 2018, Cell Rep — Adenocarcinoma · Lung Yoshihara et al 2015, Oncogene — Adenocarcinoma · Lung
COMMD1::B3GNT2	chr2:62,135,979 chr2:62,222,212 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
CPSF6::LYZ	chr12:69,262,562 chr12:69,350,108 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
CPSF6::PHF14	chr12:69,262,562 chr7:11,169,416 BND	2 1 S · 1 R · 0 D	OTHER	—	—
CSPG4P5::DNM1P51	chr15:84,402,649 chr15:84,399,684 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
CTSD::IFITM10	chr11:1,753,803 chr11:1,748,119 DEL	2 2 S · 0 R · 0 D	OTHER	—	Mitelman Nonneoplastic epithelial disorder/lesion; Adenocarcinoma ×2 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung Varley et al 2014, Breast Cancer Res Treat — Adenocarcinoma · Breast
CYP3A51P::CYP3A5	chr7:99,699,964 chr7:99,676,208 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
DLX5::DLX6-AS1	chr7:97,022,185 chr7:96,979,591 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
DMC1::DDX17	chr22:38,521,608 chr22:38,501,280 DEL	2 1 S · 0 R · 1 D	OTHER	—	Mitelman Adenocarcinoma ×1 Hu et al 2018, Nucleic Acids Res — Adenocarcinoma · Kidney
DNAJC25-GNG10::UGCG	chr9:111,666,946 chr9:111,914,605 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
DUS2::NFATC3	chr16:68,078,518 chr16:68,121,987 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
EEF1AKMT2::FAM53B	chr10:124,760,318 chr10:124,682,379 DEL	2 1 S · 0 R · 1 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion; Nonneoplastic hematologic disorder/lesion ×6 Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Thyroid Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Lung Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Testis Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Oesophagus Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Adrenal Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node
EEF1AKMT3::TSFM	chr12:57,773,128 chr12:57,783,110 DEL	2 2 S · 0 R · 0 D	OTHER	—	Mitelman Astrocytoma, grade III-IV/Glioblastoma ×1 Gao et al 2018, Cell Rep — Astrocytoma, grade III-IV/Glioblastoma · Brain
ELAVL1::TIMM44	chr19:7,973,725 chr19:7,941,197 DEL	2 2 S · 0 R · 0 D	OTHER	—	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
ERI2::DCUN1D3	chr16:20,896,308 chr16:20,862,643 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
FAM162B::ZUP1	chr6:116,761,977 chr6:116,667,207 DEL	2 1 S · 0 R · 1 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
FAM200B::BST1	chr4:15,687,148 chr4:15,705,515 DEL	2 1 S · 0 R · 1 D	OTHER	✓	—
FBXO16::ZNF395	chr8:28,447,171 chr8:28,361,142 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
FXYD6-FXYD2::DSCAML1	chr11:117,820,666 chr11:117,780,810 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
FZD4-DT::TMEM135	chr11:86,958,026 chr11:87,067,694 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
GCSH::C16orf46	chr16:81,096,131 chr16:81,063,993 DEL	2 1 S · 0 R · 1 D	OTHER	✓	—
GIGYF2::SNORC	chr2:232,850,409 chr2:232,869,047 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
HSPE1::HSPE1-MOB4	chr2:197,503,128 chr2:197,523,624 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
IL17RC::CRELD1	chr3:9,932,703 chr3:9,934,835 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
INTS4P2::CCT6P1	chr7:65,718,322 chr7:65,755,780 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
IRF1-AS1::RAD50	chr5:132,449,689 chr5:132,559,284 DEL	2 1 S · 0 R · 1 D	OTHER	✓	—
IRF1-AS1::RAD50	chr5:132,419,940 chr5:132,559,284 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
IRGQ::XRCC1	chr19:43,594,809 chr19:43,575,002 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
ITCH::DYNLRB1	chr20:34,507,908 chr20:34,526,268 DEL	2 2 S · 0 R · 0 D	OTHER	✓	Mitelman Adenocarcinoma ×1 Gao et al 2018, Cell Rep — Adenocarcinoma · Ovary
KANSL1::LRRC37A4P	chr17:46,170,855 chr17:45,545,676 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
KIF13A::SLC22A23	chr6:17,987,054 chr6:3,415,855 DEL	2 1 S · 1 R · 0 D	OTHER	—	—
L2HGDH::SOS2	chr14:50,265,358 chr14:50,204,409 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
LINC00271::PDE7B	chr6:135,810,770 chr6:135,947,464 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
LIPT1::MRPL30	chr2:99,155,051 chr2:99,186,177 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
LRG1::PLIN5	chr19:4,539,982 chr19:4,534,095 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
LRRC58::GPR156	chr3:120,334,862 chr3:120,244,478 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
MARCHF2::HNRNPM	chr19:8,430,867 chr19:8,455,405 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
MED8::ELOVL1	chr1:43,385,046 chr1:43,365,623 DEL	2 1 S · 1 R · 0 D	OTHER	✓	Mitelman Adenocarcinoma; Mature B-cell neoplasm, NOS ×3 Fu et al 2024, Biomark Res — Adenocarcinoma · Oesophagus Calabrese et al 2020, Nature — Mature B-cell neoplasm, NOS Calabrese et al 2020, Nature — Adenocarcinoma · Ovary
MIR34AHG::GPR157	chr1:9,182,007 chr1:9,111,489 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
MMP24OS::EDEM2	chr20:35,216,748 chr20:35,146,935 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
MMP24OS::EDEM2	chr20:35,217,812 chr20:35,142,478 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
MMP24OS::EDEM2	chr20:35,216,748 chr20:35,142,478 DEL	2 1 S · 1 R · 0 D	OTHER	—	—
MND1::TMEM131L	chr4:153,409,015 chr4:153,467,211 DEL	2 1 S · 0 R · 1 D	OTHER	—	Mitelman Mature B-cell neoplasm, NOS; Adenocarcinoma ×3 Calabrese et al 2020, Nature — Mature B-cell neoplasm, NOS Gao et al 2018, Cell Rep — Adenocarcinoma · Breast Yoshihara et al 2015, Oncogene — Adenocarcinoma · Breast
MOB3B::EQTN	chr9:27,359,034 chr9:27,296,738 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
MTMR8::ASB12	chrX:64,270,947 chrX:64,225,674 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
NAA40::COX8A	chr11:63,954,049 chr11:63,976,225 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
NAIPP4::NAIP	chr5:71,126,595 chr5:71,002,143 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
NBPF25P::NBPF20	chr1:145,590,886 chr1:145,420,756 DEL	2 1 S · 1 R · 0 D	OTHER	—	—
NDUFA7::CD320	chr19:8,311,412 chr19:8,302,980 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
NDUFB8::SEC31B	chr10:100,526,399 chr10:100,509,102 DEL	2 1 S · 0 R · 1 D	OTHER	—	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
NDUFV3::PKNOX1	chr21:42,904,276 chr21:43,004,326 DEL	2 1 S · 0 R · 1 D	OTHER	—	Mitelman Adenocarcinoma ×1 Gao et al 2018, Cell Rep — Adenocarcinoma · Oesophagus
NDUFV3::PKNOX1	chr21:42,897,047 chr21:43,004,326 DEL	2 1 S · 0 R · 1 D	OTHER	—	Mitelman Adenocarcinoma ×1 Gao et al 2018, Cell Rep — Adenocarcinoma · Oesophagus
NIPSNAP3B::NIPSNAP3A	chr9:104,772,908 chr9:104,750,956 DUP	2 2 S · 0 R · 0 D	OTHER	—	—
NXN::GLOD4	chr17:803,682 chr17:778,744 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
OAS3::OAS2	chr12:112,969,755 chr12:112,987,038 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
PCTP::ANKFN1	chr17:55,822,927 chr17:55,938,659 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
PHC2::A3GALT2	chr1:33,328,870 chr1:33,312,890 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
PIBF1::KLF5	chr13:72,998,995 chr13:73,061,861 DEL	2 1 S · 0 R · 1 D	OTHER	—	Mitelman Squamous cell carcinoma ×1 Hu et al 2018, Nucleic Acids Res — Squamous cell carcinoma · Uterus, cervix
PKD2L2-DT::KLHL3	chr5:137,858,428 chr5:137,698,408 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
PMS2P1::CASTOR3	chr7:100,328,836 chr7:100,233,674 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
PON3::PON1	chr7:95,362,362 chr7:95,318,393 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
PPP4R3B::CCDC88A	chr2:55,558,775 chr2:55,418,916 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
PRSS56::CHRND	chr2:232,524,844 chr2:232,526,529 DEL	2 1 S · 0 R · 1 D	OTHER	✓	—
PTBP3::SUSD1	chr9:112,227,411 chr9:112,157,613 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
RAB27A::PIGBOS1	chr15:55,318,931 chr15:55,317,867 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
RIPK3::ADCY4	chr14:24,336,885 chr14:24,332,988 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
RIPPLY2::CYB5R4	chr6:83,854,161 chr6:83,864,175 DEL	2 2 S · 0 R · 0 D	OTHER	—	Mitelman Benign epithelial tumor, special type; Miscellaneous hematopoietic/lymphoid neoplasm, special type ×2 Hu et al 2018, Nucleic Acids Res — Benign epithelial tumor, special type · Thyroid Gao et al 2018, Cell Rep — Miscellaneous hematopoietic/lymphoid neoplasm, special type
RPL38::TTYH2	chr17:74,204,190 chr17:74,222,485 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
SDHAF2::PPP1R32	chr11:61,430,182 chr11:61,481,782 DEL	2 1 S · 0 R · 1 D	OTHER	✓	—
SIRT2::RINL	chr19:38,879,434 chr19:38,876,781 DEL	2 1 S · 1 R · 0 D	OTHER	—	—
SLC23A3::NHEJ1	chr2:219,164,233 chr2:219,158,362 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
SLC25A51::EXOSC3	chr9:37,899,829 chr9:37,784,063 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
SLC7A6::PRMT7	chr16:68,297,476 chr16:68,315,897 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
SMG1P2::SMG1P6	chr16:29,533,045 chr16:29,437,322 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
SMIM8::C6orf163	chr6:87,322,632 chr6:87,356,301 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
SMIM8::C6orf163	chr6:87,322,632 chr6:87,364,961 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
SMOX::LINC01433	chr20:4,183,654 chr20:4,195,282 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
SORBS3::PDLIM2	chr8:22,571,821 chr8:22,580,603 DEL	2 1 S · 0 R · 1 D	OTHER	—	Mitelman Adenocarcinoma ×1 Gao et al 2018, Cell Rep — Adenocarcinoma · Oesophagus
SP140::SP140L	chr2:230,311,595 chr2:230,328,757 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
SRP9::EPHX1	chr1:225,778,012 chr1:225,828,725 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
STEAP1B::RAPGEF5	chr7:22,492,565 chr7:22,318,037 DEL	2 1 S · 0 R · 1 D	OTHER	—	Mitelman Adenocarcinoma ×1 Yoshihara et al 2015, Oncogene — Adenocarcinoma · Breast
STK33::LMO1	chr11:8,413,495 chr11:8,230,504 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
STX6::KIAA1614-AS1	chr1:180,984,677 chr1:180,950,918 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
SULT1A1::SULT1A2	chr16:28,606,761 chr16:28,592,481 DEL	2 1 S · 0 R · 1 D	OTHER	✓	—
TEAD2::SLC6A16	chr19:49,342,438 chr19:49,311,411 DEL	2 1 S · 1 R · 0 D	OTHER	—	—
TK2::BEAN1-AS1	chr16:66,513,731 chr16:66,475,678 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
TMCO3::TFDP1	chr13:113,539,507 chr13:113,585,774 DEL	2 1 S · 0 R · 1 D	OTHER	—	Mitelman Adenocarcinoma ×1 Yoshihara et al 2015, Oncogene — Adenocarcinoma · Breast
TMEM14C::TMEM14B	chr6:10,728,727 chr6:10,749,202 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
TMEM199::SARM1	chr17:28,360,847 chr17:28,381,203 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
TMEM233::PRKAB1	chr12:119,629,872 chr12:119,672,301 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
TMEM272::DHRS12	chr13:51,838,473 chr13:51,799,667 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
TMX2::CTNND1	chr11:57,737,668 chr11:57,791,385 DEL	2 1 S · 0 R · 1 D	OTHER	—	Mitelman Adenocarcinoma ×1 Yoshihara et al 2015, Oncogene — Adenocarcinoma · Kidney
TOMM5::FBXO10	chr9:37,588,813 chr9:37,541,774 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
TPCN2::SMIM38	chr11:69,085,930 chr11:69,159,446 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
TPTE2P5::MRPS31	chr13:40,826,506 chr13:40,767,033 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
TRAJ22::TRAC	chr14:22,522,102 chr14:22,547,506 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
TRAJ28::TRAC	chr14:22,515,688 chr14:22,547,506 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
TVP23C::TVP23C-CDRT4	chr17:15,516,419 chr17:15,440,285 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
TYW1B::CALN1	chr7:72,616,672 chr7:72,278,810 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
VAPB::APCDD1L-DT	chr20:58,418,363 chr20:58,519,504 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
VPS72::TMOD4	chr1:151,178,001 chr1:151,170,103 DEL	2 1 S · 0 R · 1 D	OTHER	✓	—
XPO7::NPM2	chr8:22,004,030 chr8:22,025,436 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
YBEY::PCNT	chr21:46,296,230 chr21:46,326,377 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
YY1AP1::GON4L	chr1:155,670,320 chr1:155,775,173 DUP	2 1 S · 0 R · 1 D	OTHER	—	—
ZBED3-AS1::PDE8B	chr5:77,118,521 chr5:77,311,994 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
ZBTB26::ZBTB6	chr9:122,931,437 chr9:122,912,081 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
ZFAND2A::C7orf50	chr7:1,155,453 chr7:1,127,386 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
ZNF253::ZNF93	chr19:19,880,146 chr19:19,915,280 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
ZNF320::ZNF468	chr19:52,890,241 chr19:52,849,213 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
ZNF320::ZNF83	chr19:52,888,127 chr19:52,635,153 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
ZNF419::ZNF773	chr19:57,491,597 chr19:57,504,657 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
ZNF430::ZNF714	chr19:21,034,184 chr19:21,098,185 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
ZNF468::ZNF28	chr19:52,857,572 chr19:52,818,031 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
ZNF544::ZNF8	chr19:58,246,794 chr19:58,285,717 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
ZNF587B::ZNF587	chr19:57,830,564 chr19:57,856,104 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
ZNF589::FBXW12	chr3:48,260,939 chr3:48,373,548 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
ZNF592::ALPK3	chr15:84,799,977 chr15:84,827,484 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
ZNF605::CHFR	chr12:132,933,035 chr12:132,877,654 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
ZNF605::CHFR	chr12:132,933,035 chr12:132,887,340 DEL	2 2 S · 0 R · 0 D	OTHER	—	—

Lung metastasis

769 passing fusions

Fusion	Breakpoints	Total	Known ▾	Both	Mitelman
ACTB::ACTBP8 →	chr7:5,529,162 chr6:88,276,645 BND	25 25 S · 0 R · 0 D	KNOWN_OTHER	—	—
NPM1::	chr5:171,400,168 chr8:21,559,991 BND	12 1 S · 11 R · 0 D	KNOWN_OTHER	—	—
::ASNS	chr7:97,928,082 chr7:97,872,449 DEL	10 8 S · 2 R · 0 D	KNOWN_OTHER	—	—
::ROS1	chr6:117,442,434 chr6:117,418,506 DEL	8 7 S · 1 R · 0 D	KNOWN_OTHER	✓	—
CAMTA1::CAMTA1 →	chr1:7,249,626 chr1:7,370,081 DEL	8 8 S · 0 R · 0 D	KNOWN_OTHER	—	—
SRGAP3::SRGAP3 →	chr3:9,362,840 chr3:9,350,066 DEL	5 5 S · 0 R · 0 D	KNOWN_OTHER	—	—
NOS1AP::C1orf226 →	chr1:162,367,204 chr1:162,381,891 DEL	4 4 S · 0 R · 0 D	KNOWN_OTHER	✓	—
CAMTA1::CAMTA1 →	chr1:7,091,371 chr1:7,370,081 DEL	2 2 S · 0 R · 0 D	KNOWN_OTHER	—	—
CCDC6::MRLN →	chr10:59,804,420 chr10:59,738,562 DEL	2 2 S · 0 R · 0 D	KNOWN_OTHER	—	—
AZGP1::GJC3 →	chr7:99,971,746 chr7:99,923,603 DEL	678 639 S · 14 R · 25 D	OTHER	✓	Mitelman Adenocarcinoma; Nonneoplastic epithelial disorder/lesion … ×10 Jung et al 2018, Cancer Lett — Adenocarcinoma · Breast Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Salivary gland Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Prostate Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Skin Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Kidney Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Liver Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Pancreas Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Testis Agnihotri et al 2016, Nat Genet — Schwannoma · Soft tissue Nacu et al 2011, BMC Med Genomics — Adenocarcinoma · Prostate
IGKJ2::IGKC →	chr2:88,861,525 chr2:88,857,683 DEL	301 1 S · 300 R · 0 D	OTHER	—	—
IGKJ1::IGKC →	chr2:88,861,886 chr2:88,857,683 DEL	282 1 S · 281 R · 0 D	OTHER	—	—
ASAH1::	chr8:18,067,137 chr6:145,370,350 BND	126 33 S · 93 R · 0 D	OTHER	—	—
HMGB1::	chr13:30,460,955 chr2:9,017,880 BND	124 2 S · 122 R · 0 D	OTHER	—	—
SEPTIN7::SEPTIN7P3 →	chr7:35,903,119 chr7:35,966,401 DEL	115 1 S · 0 R · 114 D	OTHER	✓	—
::COL1A2	chr7:14,332,310 chr7:94,431,048 DEL	114 16 S · 98 R · 0 D	OTHER	✓	—
DHRS1::RABGGTA →	chr14:24,298,614 chr14:24,271,310 DEL	107 107 S · 0 R · 0 D	OTHER	—	Mitelman Adenocarcinoma ×1 Lai et al 2015, BMC Genomics — Adenocarcinoma · Prostate
KLF10::	chr8:102,649,138 chr4:187,219,715 BND	97 75 S · 22 R · 0 D	OTHER	—	—
::	chrY:11,163,137 chrY:11,212,744 DEL	94 94 S · 0 R · 0 D	OTHER	✓	—
KLF10::	chr8:102,649,138 chr9:115,335,727 BND	77 55 S · 22 R · 0 D	OTHER	—	—
PAIP2::	chr5:139,369,501 chr12:48,557,802 BND	76 3 S · 73 R · 0 D	OTHER	—	—
LINC01378::	chr4:117,574,873 chr7:33,014,506 BND	71 9 S · 62 R · 0 D	OTHER	—	—
CAP1P1::CAP1 →	chr3:76,434,752 chr1:40,067,662 BND	70 70 S · 0 R · 0 D	OTHER	—	—
::GAPVD1	chr12:93,083,445 chr9:125,273,661 BND	67 1 S · 66 R · 0 D	OTHER	—	—
::SFTPA2	chr10:79,594,837 chr10:79,556,745 DEL	64 64 S · 0 R · 0 D	OTHER	—	—
::PTCSC3	chr14:36,235,324 chr14:36,215,515 DEL	62 62 S · 0 R · 0 D	OTHER	—	—
LYZ::	chr12:69,353,508 chr19:11,144,472 BND	61 14 S · 47 R · 0 D	OTHER	—	—
SMURF2P1::LRRC37BP1 →	chr17:30,610,942 chr17:30,631,755 DEL	61 58 S · 0 R · 3 D	OTHER	✓	—
SEPTIN7::SEPTIN7P3 →	chr7:35,898,383 chr7:35,972,447 DEL	59 30 S · 0 R · 29 D	OTHER	✓	—
NPIPA3::NPIPA2 →	chr16:14,726,162 chr16:14,765,157 DEL	58 49 S · 0 R · 9 D	OTHER	✓	—
EEF1A1P19::EEF1A1P8 →	chr5:43,495,230 chr3:184,026,528 BND	57 1 S · 56 R · 0 D	OTHER	—	—
ZNF443::ZNF799 →	chr19:12,430,320 chr19:12,393,423 DEL	55 1 S · 0 R · 54 D	OTHER	—	—
SEPTIN7::SEPTIN7P3 →	chr7:35,903,092 chr7:35,966,403 DEL	53 1 S · 0 R · 52 D	OTHER	✓	—
MRPS31P4::	chr13:52,637,446 chr13:52,642,406 DEL	52 52 S · 0 R · 0 D	OTHER	✓	—
::LRRC42	chr1:53,940,097 chr1:53,946,237 DEL	49 48 S · 1 R · 0 D	OTHER	✓	—
CTBS::GNG5 →	chr1:84,563,257 chr1:84,501,970 DEL	48 48 S · 0 R · 0 D	OTHER	✓	Mitelman Adenocarcinoma; Malignant epithelial tumor, special type … ×17 Fu et al 2024, Biomark Res — Adenocarcinoma · Oesophagus Fu et al 2024, Biomark Res — Malignant epithelial tumor, special type · Oesophagus Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic mesenchymal disorder/lesion · Heart Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Bladder Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Thyroid Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Spleen Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Gallbladder/Biliary system Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Uterus, corpus Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Oesophagus Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Skin Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Adrenal Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Testis Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Lung Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion Agnihotri et al 2016, Nat Genet — Schwannoma · Soft tissue Lai et al 2015, BMC Genomics — Adenocarcinoma · Prostate
LINC02210-CRHR1::	chr17:45,630,158 chr17:45,636,283 DEL	48 48 S · 0 R · 0 D	OTHER	—	—
RRBP1::	chr20:17,659,144 chr3:65,327,497 BND	48 1 S · 47 R · 0 D	OTHER	—	—
RPL6::BET1 →	chr12:112,408,240 chr7:93,965,855 BND	47 1 S · 46 R · 0 D	OTHER	—	—
ZNF224::ZNF225 →	chr19:44,108,337 chr19:44,112,822 DEL	47 45 S · 0 R · 2 D	OTHER	—	—
::	chr2:71,083,611 chr2:71,182,093 DEL	46 46 S · 0 R · 0 D	OTHER	✓	—
ACTR2::	chr2:65,270,205 chr22:24,689,560 BND	46 41 S · 5 R · 0 D	OTHER	—	—
UPK3B::PMS2P7 →	chr7:76,515,456 chr7:73,016,229 DUP	46 36 S · 8 R · 2 D	OTHER	—	—
::NBEAP5	chr14:19,093,006 chr14:19,130,636 DEL	45 45 S · 0 R · 0 D	OTHER	—	—
BMP8A::	chr1:39,529,164 chr1:39,541,720 DEL	44 44 S · 0 R · 0 D	OTHER	✓	—
RPL14::AFG1L	chr3:40,462,061 chr6:108,465,668 BND	42 2 S · 40 R · 0 D	OTHER	—	—
SFTPC::SFTPA1 →	chr8:22,164,466 chr10:79,614,254 BND	42 1 S · 0 R · 41 D	OTHER	—	—
NPIPA5::NPIPP1	chr16:15,363,790 chr16:15,104,604 DEL	41 36 S · 0 R · 5 D	OTHER	—	—
::KCTD12	chrX:128,707,537 chr13:76,881,665 BND	38 38 S · 0 R · 0 D	OTHER	—	—
::	chrY:11,155,884 chrY:11,212,744 DEL	36 36 S · 0 R · 0 D	OTHER	✓	—
::CUL1	chr1:64,833,874 chr7:148,709,758 BND	34 1 S · 33 R · 0 D	OTHER	—	—
::SLC17A3	chr6:25,890,506 chr6:25,868,420 DEL	34 33 S · 1 R · 0 D	OTHER	✓	—
SOGA3::KIAA0408	chr6:127,473,080 chr6:127,454,101 DEL	34 32 S · 0 R · 2 D	OTHER	—	—
::	chr19:50,799,357 chr19:50,802,217 DEL	33 33 S · 0 R · 0 D	OTHER	✓	—
::SFTPA2	chr10:79,595,098 chr10:79,557,047 DEL	33 33 S · 0 R · 0 D	OTHER	—	—
EMP2::LSAMP	chr16:10,529,932 chr3:117,026,144 BND	32 3 S · 29 R · 0 D	OTHER	—	—
LEMD1::LEMD1	chr1:205,455,917 chr1:205,420,574 DEL	32 32 S · 0 R · 0 D	OTHER	—	—
NKX2-1::SFTA3	chr14:36,519,468 chr14:36,491,291 DEL	32 32 S · 0 R · 0 D	OTHER	—	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
SVIL-AS1::	chr10:29,415,412 chr10:29,482,833 DEL	32 32 S · 0 R · 0 D	OTHER	✓	—
::SFTPA2	chr10:79,594,627 chr10:79,556,535 DEL	31 31 S · 0 R · 0 D	OTHER	—	—
FAHD2CP::	chr2:96,021,465 chr2:96,022,674 DEL	31 31 S · 0 R · 0 D	OTHER	✓	—
RDM1P1::LRRC37A4P	chr17:45,558,407 chr17:45,545,944 DEL	31 31 S · 0 R · 0 D	OTHER	✓	—
::GOLGA2P7	chr15:84,229,852 chr15:84,205,319 DEL	30 30 S · 0 R · 0 D	OTHER	—	—
::SON	chr1:157,710,375 chr21:33,576,396 BND	30 30 S · 0 R · 0 D	OTHER	✓	—
EEF1A1P4::EEF1A1P12	chr12:19,457,112 chr2:106,698,152 BND	30 1 S · 29 R · 0 D	OTHER	—	—
LAMC2::	chr1:183,240,391 chr1:183,258,109 DEL	30 28 S · 2 R · 0 D	OTHER	—	—
MUSK::ZNF195	chr9:110,711,524 chr11:3,358,770 BND	29 29 S · 0 R · 0 D	OTHER	—	—
PPP5D1P::	chr19:46,525,663 chr19:46,481,440 DEL	29 29 S · 0 R · 0 D	OTHER	✓	—
::RPL27	chr1:191,567,394 chr17:42,998,452 BND	28 28 S · 0 R · 0 D	OTHER	—	—
EMP2::CCNY-AS1	chr16:10,529,933 chr10:35,315,081 BND	28 2 S · 26 R · 0 D	OTHER	—	—
TNFSF10::	chr3:172,505,838 chr9:93,047,757 BND	28 26 S · 2 R · 0 D	OTHER	—	—
IFITM2::IFITM1	chr11:308,438 chr11:314,922 DEL	27 27 S · 0 R · 0 D	OTHER	✓	—
RPL10A::	chr6:35,470,609 chr8:18,383,477 BND	27 27 S · 0 R · 0 D	OTHER	—	—
::USP32P1	chr17:16,788,135 chr17:16,796,043 DEL	26 22 S · 0 R · 4 D	OTHER	✓	—
MIX23::	chr3:122,359,842 chr11:73,850,439 BND	26 6 S · 20 R · 0 D	OTHER	✓	—
NPIPA3::NPIPA2 →	chr16:14,726,231 chr16:14,765,157 DEL	25 5 S · 0 R · 20 D	OTHER	✓	—
KRT8::CTNNA3	chr12:52,897,225 chr10:67,663,382 BND	24 2 S · 22 R · 0 D	OTHER	—	—
MAP3K12::	chr12:53,479,669 chr5:73,141,610 BND	24 1 S · 23 R · 0 D	OTHER	—	—
PDPK1::	chr16:2,601,639 chr16:2,680,061 DEL	24 17 S · 2 R · 5 D	OTHER	—	—
RPL5::RPL5P17	chr1:92,837,633 chr5:85,465,129 BND	24 1 S · 23 R · 0 D	OTHER	—	—
NKX2-1::SFTA3	chr14:36,518,985 chr14:36,491,291 DEL	23 22 S · 0 R · 1 D	OTHER	—	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
SFTPC::SFTPA1 →	chr8:22,163,511 chr10:79,614,145 BND	23 1 S · 0 R · 22 D	OTHER	—	—
::SFTPB	chr6:14,163,453 chr2:85,660,117 BND	22 22 S · 0 R · 0 D	OTHER	—	—
CAP1::CAP1P2	chr1:40,067,642 chr10:43,605,520 BND	22 22 S · 0 R · 0 D	OTHER	—	—
::	chr2:242,119,057 chr2:242,122,287 DEL	21 21 S · 0 R · 0 D	OTHER	✓	—
::PRR4	chr12:10,973,655 chr12:10,848,407 DEL	21 21 S · 0 R · 0 D	OTHER	✓	—
::STARD4-AS1	chr4:37,805,545 chr5:111,729,914 BND	21 21 S · 0 R · 0 D	OTHER	—	—
::TRDC	chr14:22,449,967 chr14:22,462,932 DEL	21 21 S · 0 R · 0 D	OTHER	✓	—
NIPA2::POLA1	chr15:22,867,855 chrX:24,703,269 BND	21 14 S · 7 R · 0 D	OTHER	—	—
RPS9::	chr19:54,207,647 chrX:102,915,262 BND	21 1 S · 20 R · 0 D	OTHER	—	—
SEPTIN7::	chr7:35,904,434 chr7:35,973,805 DEL	21 2 S · 19 R · 0 D	OTHER	—	—
::LANCL1-AS1	chr2:210,253,468 chr2:210,427,749 DEL	20 20 S · 0 R · 0 D	OTHER	—	—
CTSC::RAB38	chr11:88,300,530 chr11:88,149,955 DEL	20 20 S · 0 R · 0 D	OTHER	—	Mitelman Adenocarcinoma; Nonneoplastic epithelial disorder/lesion … ×7 Zheng et al 2016, Cancer Cell — Adenocarcinoma · Adrenal Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Thyroid Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung Wang et al 2015, Nat Genet — Mycosis fungoides/Sézary syndrome Frattini et al 2013, Nat Genet — Astrocytoma, grade III-IV/Glioblastoma · Brain Atak et al 2013, PLoS Genet — Acute lymphoblastic leukemia/lymphoblastic lymphoma
CYP4B1::	chr1:46,815,264 chr1:46,868,830 DEL	20 16 S · 2 R · 2 D	OTHER	—	—
TRAJ39::TRAC →	chr14:22,501,663 chr14:22,547,506 DEL	20 20 S · 0 R · 0 D	OTHER	✓	—
::CRYBB2P1	chr22:25,448,284 chr22:25,455,712 DEL	19 19 S · 0 R · 0 D	OTHER	—	—
::SFTPA2	chr10:79,594,922 chr10:79,556,841 DEL	19 19 S · 0 R · 0 D	OTHER	—	—
LINC01291::POLE4	chr2:74,931,043 chr2:74,958,732 DEL	19 18 S · 1 R · 0 D	OTHER	—	—
TRBJ2-5::TRBC2	chr7:142,797,166 chr7:142,801,041 DEL	19 19 S · 0 R · 0 D	OTHER	—	—
::AATF	chr3:98,796,319 chr17:37,041,224 BND	18 4 S · 14 R · 0 D	OTHER	—	—
::C19orf48	chr19:50,799,294 chr19:50,798,958 DEL	18 18 S · 0 R · 0 D	OTHER	—	—
ADH1C::ADH1B	chr4:99,347,006 chr4:99,318,820 DEL	18 1 S · 0 R · 17 D	OTHER	—	—
CAP1::CAP1P1	chr1:40,067,614 chr3:76,434,706 BND	18 16 S · 2 R · 0 D	OTHER	—	—
HSD17B1-AS1::	chr17:42,552,568 chr17:42,546,397 DEL	18 18 S · 0 R · 0 D	OTHER	—	—
MCEMP1::TRAPPC5	chr19:7,678,983 chr19:7,682,242 DEL	18 14 S · 0 R · 4 D	OTHER	—	—
RNY3P8::ABCC4	chr13:95,310,835 chr13:95,301,263 DEL	18 16 S · 2 R · 0 D	OTHER	—	—
SNORD3B-1::SNORD3A	chr17:19,061,945 chr17:19,188,032 DEL	18 18 S · 0 R · 0 D	OTHER	—	—
::	chr21:14,027,597 chr21:14,083,950 DEL	17 17 S · 0 R · 0 D	OTHER	✓	—
DHRS1::RABGGTA →	chr14:24,292,198 chr14:24,271,310 DEL	17 17 S · 0 R · 0 D	OTHER	—	Mitelman Adenocarcinoma ×1 Lai et al 2015, BMC Genomics — Adenocarcinoma · Prostate
FTH1P12::FTH1P4	chr9:15,527,606 chr3:128,764,939 BND	17 17 S · 0 R · 0 D	OTHER	—	—
LINC00598::UBLCP1	chr13:40,430,737 chr5:159,285,255 BND	17 17 S · 0 R · 0 D	OTHER	—	—
LINC00680::GUSBP4	chr6:57,959,028 chr6:57,930,291 DEL	17 17 S · 0 R · 0 D	OTHER	—	—
RBPMS-AS1::	chr8:30,385,144 chr8:30,351,931 DEL	17 17 S · 0 R · 0 D	OTHER	—	—
SEPTIN7::SEPTIN7P3 →	chr7:35,898,345 chr7:35,966,443 DEL	17 1 S · 0 R · 16 D	OTHER	✓	—
SEPTIN7::SEPTIN7P3 →	chr7:35,898,341 chr7:35,966,461 DEL	17 1 S · 1 R · 15 D	OTHER	✓	—
::DLG2	chr11:43,855,897 chr11:84,506,381 DUP	16 8 S · 8 R · 0 D	OTHER	—	—
::JCHAIN	chr8:84,979,756 chr4:70,656,003 BND	16 1 S · 15 R · 0 D	OTHER	—	—
::OR2I1P	chr15:55,143,191 chr6:29,552,585 BND	16 13 S · 3 R · 0 D	OTHER	—	—
::SFTPB	chr19:46,109,255 chr2:85,657,810 BND	16 1 S · 15 R · 0 D	OTHER	—	—
ARPP19::LRRIQ3	chr15:52,548,485 chr1:74,173,295 BND	16 5 S · 11 R · 0 D	OTHER	—	—
EEF1A1::SFTPB	chr6:73,518,714 chr2:85,659,524 BND	16 1 S · 0 R · 15 D	OTHER	—	—
FRG1BP::	chr20:30,398,044 chr20:30,404,250 DEL	16 14 S · 2 R · 0 D	OTHER	—	—
HEPHL1::PANX1	chr11:94,067,743 chr11:94,129,328 DEL	16 15 S · 0 R · 1 D	OTHER	—	Mitelman Squamous cell carcinoma ×2 Gao et al 2018, Cell Rep — Squamous cell carcinoma · Nasopharynx Yoshihara et al 2015, Oncogene — Squamous cell carcinoma · Oral cavity
NBPF20::	chr1:145,290,685 chr1:119,834,404 DEL	16 2 S · 14 R · 0 D	OTHER	—	—
SERPINB9::HIBCH	chr6:2,887,627 chr2:190,206,905 BND	16 2 S · 14 R · 0 D	OTHER	—	—
SFTPC::SFTPA1 →	chr8:22,163,154 chr10:79,614,090 BND	16 1 S · 0 R · 15 D	OTHER	—	—
ZNF585B::ZNF585A	chr19:37,185,659 chr19:37,152,188 DEL	16 11 S · 0 R · 5 D	OTHER	—	—
::SNX18P12	chr20:30,651,400 chr21:9,364,893 BND	15 15 S · 0 R · 0 D	OTHER	—	—
ARCN1::	chr11:118,601,077 chr13:72,464,582 BND	15 2 S · 13 R · 0 D	OTHER	—	—
IL32::	chr16:3,081,086 chr16:3,086,891 DEL	15 14 S · 1 R · 0 D	OTHER	—	—
IMMTP1::IMMT	chr21:44,677,776 chr2:86,173,760 BND	15 2 S · 13 R · 0 D	OTHER	—	—
LILRB2::LILRB3	chr19:54,276,264 chr19:54,218,413 DEL	15 15 S · 0 R · 0 D	OTHER	—	—
LINC01291::POLE4	chr2:74,933,609 chr2:74,958,732 DEL	15 14 S · 0 R · 1 D	OTHER	—	—
NAIPP4::OCLNP1 →	chr5:71,104,744 chr5:71,093,192 DEL	15 12 S · 2 R · 1 D	OTHER	✓	—
PSME2::PSME2P2	chr14:24,145,243 chr13:48,771,372 BND	15 15 S · 0 R · 0 D	OTHER	—	—
SEPTIN7::SEPTIN7P3 →	chr7:35,898,335 chr7:35,966,403 DEL	15 2 S · 0 R · 13 D	OTHER	✓	—
SIDT2::TAGLN	chr11:117,195,915 chr11:117,203,002 DEL	15 14 S · 0 R · 1 D	OTHER	✓	Mitelman Nonneoplastic hematologic disorder/lesion; Nonneoplastic epithelial disorder/lesion … ×13 Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Thyroid Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Lung Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Gallbladder/Biliary system Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Bladder Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Uterus, corpus Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Skin Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Oesophagus Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Pancreas Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Testis Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion Agnihotri et al 2016, Nat Genet — Schwannoma · Soft tissue Lai et al 2015, BMC Genomics — Adenocarcinoma · Prostate
SVIL-AS1::	chr10:29,415,412 chr10:29,467,240 DEL	15 15 S · 0 R · 0 D	OTHER	✓	—
TPT1::SFTPA2	chr13:45,339,543 chr10:79,557,233 BND	15 1 S · 0 R · 14 D	OTHER	—	—
TRGJP2::TRGC2	chr7:38,256,337 chr7:38,249,572 DEL	15 15 S · 0 R · 0 D	OTHER	—	—
TSPAN1::	chr1:46,185,308 chr1:46,196,202 DEL	15 12 S · 2 R · 1 D	OTHER	—	—
::	chr2:174,547,477 chr2:174,729,721 DEL	14 14 S · 0 R · 0 D	OTHER	✓	—
B2M::FTL	chr15:44,717,970 chr19:48,965,315 BND	14 1 S · 0 R · 13 D	OTHER	—	—
CCDC30::CCSER1	chr1:42,499,860 chr4:90,838,560 BND	14 1 S · 13 R · 0 D	OTHER	—	—
LINC01378::	chr4:117,574,873 chr7:33,014,507 BND	14 2 S · 12 R · 0 D	OTHER	—	—
LSG1::TMEM44	chr3:194,644,675 chr3:194,633,167 DEL	14 14 S · 0 R · 0 D	OTHER	—	—
NDUFA13::YJEFN3	chr19:19,527,770 chr19:19,535,034 DEL	14 14 S · 0 R · 0 D	OTHER	✓	—
RPL31::SFTPC	chr2:101,006,002 chr8:22,163,156 BND	14 1 S · 0 R · 13 D	OTHER	—	—
SFTPA1::B2M	chr10:79,615,207 chr15:44,711,564 BND	14 1 S · 0 R · 13 D	OTHER	—	—
STT3B::XPO7	chr3:31,636,311 chr8:21,972,188 BND	14 1 S · 13 R · 0 D	OTHER	—	—
::	chr8:32,928,093 chr8:33,041,635 DEL	13 13 S · 0 R · 0 D	OTHER	✓	—
::KMT2C	chr7:55,773,180 chr7:152,367,263 DUP	13 12 S · 0 R · 1 D	OTHER	—	—
::SFTPA2	chr10:79,595,045 chr10:79,557,006 DEL	13 13 S · 0 R · 0 D	OTHER	—	—
ADIRF::	chr10:86,983,941 chr10:86,992,247 DEL	13 13 S · 0 R · 0 D	OTHER	—	—
CEMIP2::	chr9:71,683,550 chr2:217,763,940 BND	13 6 S · 7 R · 0 D	OTHER	—	—
DNAJC25-GNG10::UGCG	chr9:111,666,946 chr9:111,914,605 DEL	13 13 S · 0 R · 0 D	OTHER	✓	—
EMP2::	chr16:10,531,561 chr11:95,036,776 BND	13 1 S · 12 R · 0 D	OTHER	—	—
EYA1::	chr8:71,198,804 chr2:236,737,380 BND	13 13 S · 0 R · 0 D	OTHER	—	—
MRAP2::	chr6:84,062,992 chr6:84,139,470 DEL	13 13 S · 0 R · 0 D	OTHER	✓	—
SVIL-AS1::	chr10:29,415,412 chr10:29,457,651 DEL	13 13 S · 0 R · 0 D	OTHER	✓	—
UBE2Q2P1::GOLGA6L5P	chr15:84,526,781 chr15:84,515,034 DEL	13 12 S · 0 R · 1 D	OTHER	✓	—
VAMP8::VAMP5	chr2:85,581,876 chr2:85,591,725 DEL	13 10 S · 1 R · 2 D	OTHER	—	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
YBEY::	chr21:46,296,230 chr21:46,313,004 DEL	13 13 S · 0 R · 0 D	OTHER	—	—
::	chr7:97,937,160 chr7:97,972,135 DEL	12 12 S · 0 R · 0 D	OTHER	✓	—
::CLUHP10	chr3:75,625,153 chr3:75,630,080 DEL	12 12 S · 0 R · 0 D	OTHER	—	—
::RCBTB1	chr15:100,821,075 chr13:49,533,074 BND	12 12 S · 0 R · 0 D	OTHER	—	—
::SUMF1	chr16:26,728,491 chr3:4,362,132 BND	12 6 S · 6 R · 0 D	OTHER	—	—
ADH6::	chr4:99,204,357 chr4:99,159,622 DEL	12 12 S · 0 R · 0 D	OTHER	—	—
ANKDD1A::	chr15:64,957,269 chr15:64,963,531 DEL	12 11 S · 1 R · 0 D	OTHER	✓	—
COQ10B::SFTPB	chr2:197,468,467 chr2:85,660,117 INV	12 12 S · 0 R · 0 D	OTHER	—	—
EEF1A1P13::UNC5C	chr5:14,651,977 chr4:95,260,458 BND	12 12 S · 0 R · 0 D	OTHER	—	—
IL17RB::	chr3:53,865,019 chr3:53,868,674 DEL	12 11 S · 0 R · 1 D	OTHER	✓	—
KRT8::SGK1	chr12:52,897,224 chr6:134,296,777 BND	12 3 S · 9 R · 0 D	OTHER	—	—
MED1::FBXL20	chr17:39,405,480 chr17:39,401,898 DEL	12 12 S · 0 R · 0 D	OTHER	—	—
NCBP1::	chr9:97,654,724 chr9:97,675,489 DEL	12 10 S · 1 R · 1 D	OTHER	—	—
RDX::	chr11:110,230,586 chr2:31,861,947 BND	12 2 S · 10 R · 0 D	OTHER	—	—
SFTPA2::RPL12	chr10:79,555,999 chr9:127,451,338 BND	12 1 S · 0 R · 11 D	OTHER	—	—
SFTPA2::RPS6	chr10:79,556,064 chr9:19,379,547 BND	12 1 S · 0 R · 11 D	OTHER	—	—
SULT1A1::SULT1A2	chr16:28,609,931 chr16:28,592,481 DEL	12 12 S · 0 R · 0 D	OTHER	✓	—
SYNPO::	chr5:150,657,433 chr2:82,538,063 BND	12 4 S · 8 R · 0 D	OTHER	—	—
TCERG1L::	chr10:131,107,869 chr13:112,885,605 BND	12 1 S · 11 R · 0 D	OTHER	—	—
::	chr21:8,384,098 chr21:8,405,960 DEL	11 11 S · 0 R · 0 D	OTHER	✓	—
::	chr6:120,462,591 chr6:120,706,390 DEL	11 11 S · 0 R · 0 D	OTHER	✓	—
::PMS2P7	chr7:73,003,730 chr7:73,005,693 DEL	11 10 S · 0 R · 1 D	OTHER	✓	—
::SGCG	chr13:23,160,646 chr13:23,203,695 DEL	11 11 S · 0 R · 0 D	OTHER	✓	—
ACTR2::	chr2:65,270,205 chr19:20,261,841 BND	11 6 S · 5 R · 0 D	OTHER	—	—
BEX2::BEX1	chrX:103,309,704 chrX:103,063,010 DEL	11 11 S · 0 R · 0 D	OTHER	—	—
BMS1P2::AGAP9	chr10:47,542,167 chr10:47,523,491 DEL	11 9 S · 0 R · 2 D	OTHER	✓	—
C2orf49::	chr2:105,345,389 chr2:105,359,745 DEL	11 10 S · 1 R · 0 D	OTHER	—	—
CTSL::CTSLP8	chr9:87,728,067 chr9:87,844,579 DEL	11 11 S · 0 R · 0 D	OTHER	—	—
DCAF10::	chr9:37,860,490 chr9:37,899,829 DEL	11 7 S · 3 R · 1 D	OTHER	—	—
DET1::MRPL46	chr15:88,511,432 chr15:88,465,773 DEL	11 9 S · 0 R · 2 D	OTHER	✓	—
EEF1A1P5::SFTPA1	chr9:133,020,238 chr10:79,611,929 BND	11 1 S · 0 R · 10 D	OTHER	—	—
G0S2::	chr1:209,676,054 chr6:11,351,191 BND	11 2 S · 9 R · 0 D	OTHER	—	—
GBP4::GBP7	chr1:89,186,444 chr1:89,133,368 DEL	11 10 S · 0 R · 1 D	OTHER	—	—
MYL6::MYL6P5	chr12:56,160,280 chr17:71,621,333 BND	11 11 S · 0 R · 0 D	OTHER	—	—
NEDD8-MDP1::CHMP4A	chr14:24,213,994 chr14:24,211,829 DEL	11 10 S · 0 R · 1 D	OTHER	✓	—
PRKAA1::TTC33	chr5:40,764,514 chr5:40,747,019 DEL	11 11 S · 0 R · 0 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion; Nonneoplastic hematologic disorder/lesion ×7 Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Salivary gland Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Thyroid Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Gallbladder/Biliary system Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Bladder Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Testis Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node
PTMA::	chr2:231,713,109 chr14:92,027,084 BND	11 5 S · 6 R · 0 D	OTHER	—	—
RASA4::RASA4B →	chr7:102,605,959 chr7:102,506,795 DEL	11 11 S · 0 R · 0 D	OTHER	✓	—
RBMX::RBMXL1	chrX:136,879,429 chr1:88,983,828 BND	11 10 S · 1 R · 0 D	OTHER	—	—
RPL36AP13::FAM241A	chr2:24,334,756 chr4:112,171,456 BND	11 11 S · 0 R · 0 D	OTHER	—	—
RPL8::PCOLCE2	chr8:144,791,299 chr3:142,827,454 BND	11 1 S · 10 R · 0 D	OTHER	—	Mitelman Multiple myeloma ×1 Cleynen et al 2017, Nat Commun — Multiple myeloma
SEPTIN7::	chr7:35,904,436 chr7:35,973,805 DEL	11 4 S · 7 R · 0 D	OTHER	—	—
SEPTIN7::SEPTIN7P3 →	chr7:35,898,326 chr7:35,966,470 DEL	11 1 S · 0 R · 10 D	OTHER	✓	—
ZNF318::	chr6:43,356,856 chr11:3,358,773 BND	11 11 S · 0 R · 0 D	OTHER	—	—
::	chr4:49,244,357 chr4:49,488,466 DEL	10 10 S · 0 R · 0 D	OTHER	✓	—
::	chr1:143,594,416 chr1:145,573,167 DEL	10 10 S · 0 R · 0 D	OTHER	✓	—
::ARHGAP27P1-BPTFP1-KPNA2P3	chr17:64,785,222 chr17:64,781,680 DEL	10 10 S · 0 R · 0 D	OTHER	—	—
::LRRC37A11P	chr17:39,013,029 chr17:39,027,550 DEL	10 10 S · 0 R · 0 D	OTHER	—	—
::STAG3L1	chr7:75,359,409 chr7:75,361,374 DEL	10 7 S · 0 R · 3 D	OTHER	—	—
::TRBC2	chr7:142,786,039 chr7:142,801,041 DEL	10 10 S · 0 R · 0 D	OTHER	—	—
ABRAXAS1::HELQ	chr4:83,463,494 chr4:83,453,945 DEL	10 9 S · 1 R · 0 D	OTHER	✓	Mitelman Nonneoplastic hematologic disorder/lesion; Nonneoplastic epithelial disorder/lesion ×7 Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Thyroid Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Skin Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Oesophagus Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Ovary Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Gallbladder/Biliary system Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Bladder
BMS1P10::	chr9:63,372,803 chr9:63,309,312 DEL	10 10 S · 0 R · 0 D	OTHER	—	—
CACNA1E::	chr1:181,806,086 chr1:181,998,699 DEL	10 9 S · 1 R · 0 D	OTHER	—	—
DNAAF4::LIN7C	chr15:55,484,256 chr11:27,495,239 BND	10 7 S · 3 R · 0 D	OTHER	—	—
FTH1::FTH1P4	chr11:61,967,353 chr3:128,764,983 BND	10 10 S · 0 R · 0 D	OTHER	—	—
KANSL1::ARL17B →	chr17:46,094,560 chr17:46,352,930 DUP	10 6 S · 3 R · 1 D	OTHER	✓	Mitelman Adenocarcinoma; Nonneoplastic epithelial disorder/lesion … ×9 Fu et al 2024, Biomark Res — Adenocarcinoma · Oesophagus Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Thyroid Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Gallbladder/Biliary system Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Bladder Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Adrenal Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Skin Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Oesophagus Wen et al 2012, PLoS One — Acute myeloid leukemia, NOS
MOV10::	chr1:112,700,230 chr1:112,701,582 DEL	10 10 S · 0 R · 0 D	OTHER	—	—
NUPR2::PSPH	chr7:56,116,015 chr7:56,021,231 DEL	10 5 S · 5 R · 0 D	OTHER	—	—
PIK3R1::	chr5:68,301,393 chr4:171,395,484 BND	10 1 S · 9 R · 0 D	OTHER	—	—
RPL7L1::	chr6:42,888,349 chr6:42,976,555 DEL	10 10 S · 0 R · 0 D	OTHER	—	—
RPS18::SFTPA1	chr6:33,276,418 chr10:79,613,846 BND	10 1 S · 0 R · 9 D	OTHER	—	—
SCN5A::	chr3:38,548,176 chr2:4,608,548 BND	10 8 S · 2 R · 0 D	OTHER	—	—
SLC35A1::	chr6:87,507,828 chr20:53,405,105 BND	10 10 S · 0 R · 0 D	OTHER	—	—
TRDJ2::TRDC	chr14:22,456,742 chr14:22,462,932 DEL	10 10 S · 0 R · 0 D	OTHER	—	—
UPK3B::DTX2P1-UPK3BP1-PMS2P11	chr7:76,515,456 chr7:77,018,809 DEL	10 4 S · 6 R · 0 D	OTHER	—	—
::APLP1	chr14:77,507,609 chr19:35,873,525 BND	9 4 S · 5 R · 0 D	OTHER	—	—
::EMP2	chr22:19,609,066 chr16:10,529,699 BND	9 2 S · 7 R · 0 D	OTHER	—	—
::HULC	chr6:8,307,560 chr6:8,437,963 DEL	9 9 S · 0 R · 0 D	OTHER	—	—
::MPEG1	chr11:59,285,822 chr11:59,209,227 DEL	9 9 S · 0 R · 0 D	OTHER	—	—
::PPP5D1P	chr19:46,600,883 chr19:46,527,072 DEL	9 9 S · 0 R · 0 D	OTHER	✓	—
::SMPD4BP	chr2:131,492,024 chr2:131,492,992 DEL	9 8 S · 1 R · 0 D	OTHER	—	—
::TRIM46	chr1:155,173,474 chr1:155,178,772 DEL	9 9 S · 0 R · 0 D	OTHER	—	—
::ZRANB2	chr1:71,083,777 chr1:71,078,708 DEL	9 8 S · 1 R · 0 D	OTHER	—	—
ARL6IP1::RPS15A	chr16:18,794,599 chr16:18,789,118 DEL	9 9 S · 0 R · 0 D	OTHER	—	Mitelman Adenocarcinoma ×1 Kim et al 2014, Oncogene — Adenocarcinoma · Stomach
C1QA::C1QC	chr1:22,639,161 chr1:22,644,011 DEL	9 8 S · 0 R · 1 D	OTHER	✓	—
CYTOR::ANAPC1P4	chr2:87,606,769 chr2:87,700,984 DEL	9 8 S · 1 R · 0 D	OTHER	—	—
EEF1A1P19::	chr5:43,495,120 chr13:95,619,349 BND	9 9 S · 0 R · 0 D	OTHER	—	—
EEF1A1P19::	chr5:43,495,120 chr12:8,081,408 BND	9 9 S · 0 R · 0 D	OTHER	—	—
GATAD1::	chr7:92,461,410 chr7:92,491,243 DEL	9 9 S · 0 R · 0 D	OTHER	—	—
LINC02908::	chr9:137,037,910 chr9:137,039,971 DEL	9 8 S · 0 R · 1 D	OTHER	✓	—
RPL6::	chr12:112,408,579 chr7:64,142,394 BND	9 9 S · 0 R · 0 D	OTHER	—	—
RPS12P3::	chr2:60,938,370 chr17:4,704,990 BND	9 9 S · 0 R · 0 D	OTHER	—	—
SPIN2A::SPIN2B	chrX:57,135,983 chrX:57,120,186 DEL	9 1 S · 0 R · 8 D	OTHER	—	—
USP34::	chr2:61,189,508 chr19:4,243,224 BND	9 9 S · 0 R · 0 D	OTHER	—	—
YY1::	chr14:100,280,065 chr14:100,291,358 DEL	9 9 S · 0 R · 0 D	OTHER	—	—
::	chr8:32,996,316 chr8:33,041,635 DEL	8 8 S · 0 R · 0 D	OTHER	✓	—
::HYDIN2	chr1:146,537,420 chr1:146,547,369 DEL	8 8 S · 0 R · 0 D	OTHER	✓	—
::IFNL1	chr19:39,203,048 chr19:39,296,805 DEL	8 8 S · 0 R · 0 D	OTHER	—	—
::RPL23AP49	chr3:75,641,072 chr3:75,625,153 DEL	8 8 S · 0 R · 0 D	OTHER	—	—
::SFTPA2	chr10:79,595,086 chr10:79,557,047 DEL	8 8 S · 0 R · 0 D	OTHER	—	—
::SFTPA2	chr10:79,594,637 chr10:79,556,544 DEL	8 8 S · 0 R · 0 D	OTHER	—	—
ARHGEF35-AS1::	chr7:144,251,610 chr7:144,355,338 DEL	8 8 S · 0 R · 0 D	OTHER	✓	—
COX14::	chr12:50,112,301 chr12:50,165,026 DEL	8 8 S · 0 R · 0 D	OTHER	—	—
MCEMP1::TRAPPC5	chr19:7,679,254 chr19:7,682,242 DEL	8 2 S · 1 R · 5 D	OTHER	—	—
MED8::ELOVL1	chr1:43,385,046 chr1:43,365,623 DEL	8 8 S · 0 R · 0 D	OTHER	✓	Mitelman Adenocarcinoma; Mature B-cell neoplasm, NOS ×3 Fu et al 2024, Biomark Res — Adenocarcinoma · Oesophagus Calabrese et al 2020, Nature — Mature B-cell neoplasm, NOS Calabrese et al 2020, Nature — Adenocarcinoma · Ovary
NTM::OPCML	chr11:131,370,888 chr11:132,943,010 INV	8 8 S · 0 R · 0 D	OTHER	—	—
PAPSS2::	chr10:87,683,346 chr16:10,531,566 BND	8 8 S · 0 R · 0 D	OTHER	—	—
PEX1::	chr7:92,491,243 chr7:92,463,026 DEL	8 8 S · 0 R · 0 D	OTHER	✓	—
PRELID3B::ATP5F1E	chr20:59,034,972 chr20:59,030,429 DEL	8 7 S · 0 R · 1 D	OTHER	—	—
RNF2P1::	chr9:6,669,544 chr9:6,646,085 DEL	8 8 S · 0 R · 0 D	OTHER	—	—
SBNO1::	chr12:123,290,881 chr12:123,277,124 DEL	8 8 S · 0 R · 0 D	OTHER	—	—
SPINT2::C19orf33	chr19:38,290,575 chr19:38,304,375 DEL	8 7 S · 0 R · 1 D	OTHER	—	—
SVIL-AS1::	chr10:29,415,412 chr10:29,468,920 DEL	8 8 S · 0 R · 0 D	OTHER	✓	—
TRBJ2-7::	chr7:142,797,502 chr7:142,801,041 DEL	8 8 S · 0 R · 0 D	OTHER	—	—
TRGC1::TRGC2	chr7:38,262,171 chr7:38,249,572 DEL	8 1 S · 0 R · 7 D	OTHER	—	—
ZMYM6::TMEM35B	chr1:34,992,234 chr1:34,983,947 DEL	8 8 S · 0 R · 0 D	OTHER	✓	—
ZNF138::ZNF273	chr7:64,831,609 chr7:64,927,813 DEL	8 8 S · 0 R · 0 D	OTHER	—	—
ZSCAN25::	chr7:99,624,180 chr7:99,669,095 DEL	8 4 S · 3 R · 1 D	OTHER	✓	—
::	chr17:38,686,901 chr17:38,706,054 DEL	7 7 S · 0 R · 0 D	OTHER	✓	—
::	chr1:223,863,192 chr22:41,073,622 BND	7 7 S · 0 R · 0 D	OTHER	✓	—
::CRYBB2P1	chr22:25,453,434 chr22:25,455,712 DEL	7 7 S · 0 R · 0 D	OTHER	—	—
::CYB5A	chr18:74,333,451 chr18:74,263,477 DEL	7 7 S · 0 R · 0 D	OTHER	—	—
::EMP2	chr13:20,926,809 chr16:10,529,699 BND	7 1 S · 6 R · 0 D	OTHER	—	—
::IL10RB	chr21:33,266,175 chr21:33,268,394 DEL	7 7 S · 0 R · 0 D	OTHER	—	—
::MBIP	chr11:39,928,812 chr14:36,320,583 BND	7 7 S · 0 R · 0 D	OTHER	—	—
::MRPS18C	chr4:83,453,945 chr4:83,455,947 DEL	7 6 S · 0 R · 1 D	OTHER	✓	—
::OR2A7	chr7:144,272,445 chr7:144,259,632 DEL	7 7 S · 0 R · 0 D	OTHER	✓	—
::SP4	chr7:21,294,502 chr7:21,429,792 DEL	7 7 S · 0 R · 0 D	OTHER	—	—
::TRGC1	chr7:38,276,259 chr7:38,265,678 DEL	7 7 S · 0 R · 0 D	OTHER	—	—
AHSA2P::	chr2:61,186,497 chr2:61,187,909 DEL	7 7 S · 0 R · 0 D	OTHER	✓	—
APOC1::APOC1P1	chr19:44,927,033 chr19:44,931,000 DEL	7 3 S · 0 R · 4 D	OTHER	✓	—
ASIP::	chr20:34,235,030 chr20:34,281,027 DEL	7 6 S · 0 R · 1 D	OTHER	✓	—
CPLANE1::	chr5:37,108,293 chr5:37,079,821 DEL	7 7 S · 0 R · 0 D	OTHER	—	—
FCGR3B::FCGR3A	chr1:161,626,145 chr1:161,543,199 DEL	7 7 S · 0 R · 0 D	OTHER	—	—
MT1M::MT1F	chr16:56,633,405 chr16:56,659,073 DEL	7 7 S · 0 R · 0 D	OTHER	—	—
RHBDD1::	chr2:226,982,270 chr2:227,022,048 DEL	7 6 S · 1 R · 0 D	OTHER	—	—
RPGRIP1::	chr14:21,299,250 chr14:21,460,862 DEL	7 7 S · 0 R · 0 D	OTHER	—	—
SCNN1A::TNFRSF1A	chr12:6,348,071 chr12:6,334,244 DEL	7 7 S · 0 R · 0 D	OTHER	—	Mitelman Nonneoplastic epithelial disorder/lesion; Adenocarcinoma … ×6 Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Bladder Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Lung Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Stomach Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung Varley et al 2014, Breast Cancer Res Treat — Adenocarcinoma · Breast Frattini et al 2013, Nat Genet — Astrocytoma, grade III-IV/Glioblastoma · Brain
SLC25A15::	chr13:40,799,287 chr13:40,826,506 DEL	7 7 S · 0 R · 0 D	OTHER	—	—
SPICE1::CFAP44	chr3:113,444,741 chr3:113,441,654 DEL	7 6 S · 0 R · 1 D	OTHER	—	—
SUGT1P3::TPTE2P5	chr13:40,908,159 chr13:40,855,815 DEL	7 7 S · 0 R · 0 D	OTHER	—	—
TMC5::CCP110	chr16:19,497,163 chr16:19,527,867 DEL	7 7 S · 0 R · 0 D	OTHER	✓	—
TRAJ22::TRAC	chr14:22,522,102 chr14:22,547,506 DEL	7 7 S · 0 R · 0 D	OTHER	✓	—
TRBJ2-1::	chr7:142,796,414 chr7:142,801,041 DEL	7 7 S · 0 R · 0 D	OTHER	—	—
VPS72::TMOD4	chr1:151,178,001 chr1:151,170,103 DEL	7 7 S · 0 R · 0 D	OTHER	✓	—
ZDHHC11::ZDHHC11B	chr5:840,219 chr5:745,298 DEL	7 6 S · 1 R · 0 D	OTHER	✓	—
ZNF302::ZNF181	chr19:34,684,340 chr19:34,739,577 DEL	7 1 S · 0 R · 6 D	OTHER	—	—
ZNF606::C19orf18	chr19:57,978,654 chr19:57,974,203 DEL	7 6 S · 1 R · 0 D	OTHER	✓	—
ZNF626::ZNF737	chr19:20,645,684 chr19:20,553,835 DEL	7 1 S · 0 R · 6 D	OTHER	—	—
ZNF782::ZNF510	chr9:96,827,080 chr9:96,776,245 DEL	7 6 S · 1 R · 0 D	OTHER	✓	—
ZSCAN32::	chr16:3,397,203 chr16:3,365,182 DEL	7 7 S · 0 R · 0 D	OTHER	—	—
::	chr22:23,652,861 chr22:23,652,576 DEL	6 6 S · 0 R · 0 D	OTHER	✓	—
::	chr5:43,015,150 chr5:43,067,087 DEL	6 6 S · 0 R · 0 D	OTHER	✓	—
::HMGB1	chr13:30,618,218 chr13:30,463,694 DEL	6 6 S · 0 R · 0 D	OTHER	—	—
::OR7E14P	chr11:17,014,367 chr11:17,052,032 DEL	6 6 S · 0 R · 0 D	OTHER	—	—
::PTCSC3	chr14:36,235,320 chr14:36,215,515 DEL	6 6 S · 0 R · 0 D	OTHER	—	—
::RPL32P3	chr3:129,399,008 chr3:129,397,140 DEL	6 6 S · 0 R · 0 D	OTHER	—	—
ADRB2::	chr5:148,828,005 chr5:148,960,917 DEL	6 6 S · 0 R · 0 D	OTHER	—	—
AOC3::AOC4P	chr17:42,854,733 chr17:42,867,416 DEL	6 1 S · 0 R · 5 D	OTHER	—	—
BMS1P1::	chr10:46,798,168 chr10:46,808,996 DEL	6 6 S · 0 R · 0 D	OTHER	—	—
CELF5::	chr19:3,297,010 chr19:3,360,582 DEL	6 5 S · 1 R · 0 D	OTHER	—	—
CTSLP3::	chr10:46,768,292 chr10:46,770,739 DEL	6 6 S · 0 R · 0 D	OTHER	—	—
DNHD1::	chr11:6,592,823 chr11:6,603,404 DEL	6 5 S · 0 R · 1 D	OTHER	✓	—
FAAHP1::	chr1:46,443,037 chr1:46,482,210 DEL	6 6 S · 0 R · 0 D	OTHER	—	—
FRG1BP::	chr20:30,398,045 chr20:30,404,268 DEL	6 6 S · 0 R · 0 D	OTHER	—	—
GJA9::	chr1:38,875,941 chr1:38,860,239 DEL	6 6 S · 0 R · 0 D	OTHER	—	—
H2BC5::H2BC6	chr6:26,158,559 chr6:26,183,781 DEL	6 1 S · 0 R · 5 D	OTHER	—	—
HSP90B1::	chr12:103,938,417 chr12:104,021,978 DEL	6 6 S · 0 R · 0 D	OTHER	✓	—
LINC00680::GUSBP4	chr6:57,959,028 chr6:57,926,510 DEL	6 6 S · 0 R · 0 D	OTHER	—	—
LINC01004::LHFPL3-AS2	chr7:104,953,700 chr7:104,926,537 DEL	6 4 S · 2 R · 0 D	OTHER	—	—
LUC7L2::FMC1-LUC7L2	chr7:139,340,517 chr7:139,345,501 DEL	6 6 S · 0 R · 0 D	OTHER	—	—
MZT2B::	chr2:130,182,775 chr2:130,202,325 DEL	6 6 S · 0 R · 0 D	OTHER	—	—
NIT2::	chr3:100,358,344 chr3:100,365,362 DEL	6 6 S · 0 R · 0 D	OTHER	✓	—
OTUD6B::LRRC69	chr8:91,084,834 chr8:91,102,219 DEL	6 6 S · 0 R · 0 D	OTHER	—	—
POLR2J3::RASA4B	chr7:102,566,997 chr7:102,511,981 DEL	6 5 S · 1 R · 0 D	OTHER	✓	—
PSMD7::	chr16:74,305,571 chr16:74,332,567 DEL	6 6 S · 0 R · 0 D	OTHER	✓	—
RPS17::RPS17P2	chr15:82,538,880 chr5:116,716,504 BND	6 6 S · 0 R · 0 D	OTHER	—	—
SLC17A3::SLC17A1	chr6:25,845,380 chr6:25,830,607 DEL	6 5 S · 0 R · 1 D	OTHER	✓	—
SNORD3C::SNORD3D	chr17:19,190,156 chr17:19,112,546 DEL	6 6 S · 0 R · 0 D	OTHER	—	—
SOCS5::	chr2:46,699,449 chr2:46,855,923 DEL	6 6 S · 0 R · 0 D	OTHER	—	—
SOGA3::KIAA0408	chr6:127,473,080 chr6:127,454,087 DEL	6 4 S · 0 R · 2 D	OTHER	—	—
STYXL1::TMEM120A	chr7:75,996,445 chr7:75,992,557 DEL	6 6 S · 0 R · 0 D	OTHER	✓	—
TRAJ4::TRAC	chr14:22,542,261 chr14:22,547,506 DEL	6 6 S · 0 R · 0 D	OTHER	—	—
TRBJ2-2::	chr7:142,796,610 chr7:142,801,041 DEL	6 5 S · 1 R · 0 D	OTHER	—	—
TRIM2::MND1	chr4:153,328,670 chr4:153,350,064 DEL	6 5 S · 0 R · 1 D	OTHER	—	Mitelman Adenocarcinoma ×1 Gao et al 2018, Cell Rep — Adenocarcinoma · Breast
UQCRQ::LEAP2	chr5:132,867,708 chr5:132,873,950 DEL	6 6 S · 0 R · 0 D	OTHER	—	—
ZNF271P::	chr18:35,327,063 chr18:35,339,805 DEL	6 4 S · 1 R · 1 D	OTHER	—	—
ZNF28::ZNF28	chr19:52,857,572 chr19:52,818,031 DEL	6 6 S · 0 R · 0 D	OTHER	—	—
ZNF512::GPN1	chr2:27,621,262 chr2:27,629,859 DEL	6 5 S · 0 R · 1 D	OTHER	—	—
ZNF655::TMEM225B	chr7:99,560,695 chr7:99,600,205 DEL	6 6 S · 0 R · 0 D	OTHER	✓	—
::	chr16:48,623,603 chr16:48,741,283 DEL	5 5 S · 0 R · 0 D	OTHER	✓	—
::	chr8:66,362,111 chr8:66,432,284 DEL	5 5 S · 0 R · 0 D	OTHER	✓	—
::	chr21:8,211,414 chr21:8,255,619 DEL	5 5 S · 0 R · 0 D	OTHER	✓	—
::	chr11:88,373,327 chr11:88,423,487 DEL	5 5 S · 0 R · 0 D	OTHER	✓	—
::APOC1P1	chr19:44,927,033 chr19:44,927,795 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
::CD37	chr19:49,294,553 chr19:49,340,231 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
::CD3D	chr11:118,350,182 chr11:118,339,494 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
::CD3D	chr11:118,350,182 chr11:118,340,593 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
::CTBP2	chr4:121,656,452 chr10:124,986,282 BND	5 1 S · 4 R · 0 D	OTHER	—	—
::EMP2	chr7:130,339,797 chr16:10,531,118 BND	5 5 S · 0 R · 0 D	OTHER	—	—
::LIPA	chr10:89,414,543 chr10:89,412,922 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
::LLPH	chr12:66,130,705 chr12:66,129,113 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
::MFHAS1	chr8:8,903,496 chr8:8,892,581 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
::MNAT1	chr14:60,723,118 chr14:60,796,217 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
::NAIPP2	chr5:70,139,127 chr5:70,128,434 DEL	5 5 S · 0 R · 0 D	OTHER	✓	—
::NDUFS6	chr5:1,800,350 chr5:1,802,321 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
::RPL23AP53	chr8:232,129 chr8:213,710 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
::SFTPA2	chr10:79,594,962 chr10:79,556,881 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
::SGCG	chr13:23,160,646 chr13:23,234,611 DEL	5 5 S · 0 R · 0 D	OTHER	✓	—
::SMPD4BP	chr2:131,492,719 chr2:131,492,992 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
::UPK3BL1	chr7:102,666,077 chr7:102,640,773 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
::USP32P1	chr17:16,788,126 chr17:16,796,043 DEL	5 1 S · 0 R · 4 D	OTHER	✓	—
::ZNF596	chr8:86,580 chr8:232,129 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
::ZNF826P	chr19:20,424,786 chr19:20,409,045 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
ANKDD1A::	chr15:64,957,269 chr15:64,965,320 DEL	5 5 S · 0 R · 0 D	OTHER	✓	—
ANXA1::UBR2	chr9:73,168,880 chr6:42,640,384 BND	5 5 S · 0 R · 0 D	OTHER	—	—
CTSB::OIP5	chr8:11,843,180 chr15:41,329,546 BND	5 1 S · 4 R · 0 D	OTHER	—	—
DEFB122::DEFB119	chr20:31,428,543 chr20:31,377,439 DEL	5 3 S · 1 R · 1 D	OTHER	—	—
DELE1::	chr5:141,934,586 chr5:141,949,332 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
DGKQ::SLC26A1	chr4:986,806 chr4:979,504 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
DMKN::KRTDAP	chr19:35,498,716 chr19:35,488,840 DEL	5 4 S · 1 R · 0 D	OTHER	—	—
ELAPOR2::GRM3-AS1	chr7:86,891,724 chr7:86,803,440 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
FBXL19::ORAI3	chr16:30,948,568 chr16:30,953,185 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
FBXO46::SNRPD2	chr19:45,730,849 chr19:45,688,566 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
FKBP1A::SDCBP2	chr20:1,392,834 chr20:1,320,435 DEL	5 5 S · 0 R · 0 D	OTHER	✓	—
GLYCTK::DNAH1	chr3:52,291,111 chr3:52,316,455 DEL	5 5 S · 0 R · 0 D	OTHER	✓	—
IL33::	chr9:6,254,553 chr9:6,281,071 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
LINC02585::	chr3:48,664,960 chr3:48,678,564 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
RAB27A::PIGBOS1	chr15:55,318,931 chr15:55,317,867 DEL	5 5 S · 0 R · 0 D	OTHER	✓	—
RNASE4::ANG	chr14:20,684,696 chr14:20,693,547 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
SFTPA1::B2M	chr10:79,614,725 chr15:44,716,329 BND	5 1 S · 0 R · 4 D	OTHER	—	—
SFTPA3P::SFTPA2	chr10:79,595,553 chr10:79,557,480 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
SIRPB1::SIRPD	chr20:1,578,338 chr20:1,552,038 DEL	5 5 S · 0 R · 0 D	OTHER	—	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
SNRPEP4::SNRPEP3	chr19:5,576,695 chr16:20,239,003 BND	5 2 S · 3 R · 0 D	OTHER	—	—
SULT1A1::SULT1A2	chr16:28,609,931 chr16:28,592,443 DEL	5 5 S · 0 R · 0 D	OTHER	✓	—
SVIL-AS1::	chr10:29,415,412 chr10:29,478,474 DEL	5 5 S · 0 R · 0 D	OTHER	✓	—
TRAJ20::TRAC	chr14:22,524,381 chr14:22,547,506 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
TRAJ30::TRAC	chr14:22,512,908 chr14:22,547,506 DEL	5 4 S · 1 R · 0 D	OTHER	—	—
TRAJ45::TRAC	chr14:22,493,990 chr14:22,547,506 DEL	5 4 S · 1 R · 0 D	OTHER	✓	—
TRBJ1-3::TRBC1	chr7:142,787,679 chr7:142,791,694 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
TTC23L::	chr5:34,897,381 chr5:34,908,765 DEL	5 3 S · 1 R · 1 D	OTHER	—	—
ZNF343::SNRPB	chr20:2,492,699 chr20:2,467,758 DEL	5 5 S · 0 R · 0 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
ZNF442::ZNF563	chr19:12,347,314 chr19:12,322,711 DEL	5 1 S · 0 R · 4 D	OTHER	—	—
ZNF674-AS1::	chrX:46,545,627 chrX:46,563,259 DEL	5 5 S · 0 R · 0 D	OTHER	—	—
::	chr14:19,307,111 chr14:19,331,835 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
::	chr6:29,488,857 chr6:29,493,991 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
::	chr3:44,624,722 chr3:44,557,592 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
::	chr2:174,547,477 chr2:174,649,750 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
::	chr8:66,397,017 chr8:66,432,284 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
::	chr1:60,185,634 chr21:13,904,925 BND	4 4 S · 0 R · 0 D	OTHER	✓	—
::	chrX:145,759,451 chrX:145,863,037 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
::CA5B	chrX:15,688,858 chrX:15,721,497 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
::CNN3-DT	chr1:94,926,740 chr1:94,931,872 DEL	4 3 S · 1 R · 0 D	OTHER	—	—
::COL4A3	chr2:227,164,481 chr2:227,237,968 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
::DLG5-AS1	chr10:77,926,277 chr10:77,929,589 DEL	4 2 S · 2 R · 0 D	OTHER	—	—
::DNAJC21	chr5:34,914,961 chr5:34,929,649 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
::GMPR2	chr14:24,218,431 chr14:24,233,043 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
::HCST	chr19:35,899,452 chr19:35,902,533 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
::METTL23	chr17:76,726,287 chr17:76,729,690 DEL	4 3 S · 1 R · 0 D	OTHER	—	—
::MRM3	chr17:778,744 chr17:785,877 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
::NBEAP5	chr14:19,066,347 chr14:19,130,636 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
::PENK	chr8:56,559,453 chr8:56,446,481 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
::PPP4R1-AS1	chr18:9,613,710 chr18:9,619,195 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
::PPP5D1P	chr19:46,576,599 chr19:46,527,072 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
::RBM4	chr11:66,617,550 chr11:66,639,700 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
::RPL13A	chr8:82,653,133 chr19:49,490,475 BND	4 1 S · 3 R · 0 D	OTHER	✓	—
::RPS20P14	chr11:47,191,501 chr3:186,900,240 BND	4 4 S · 0 R · 0 D	OTHER	—	—
::SFTPA2	chr10:79,594,429 chr10:79,556,337 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
::TPM3P9	chr19:53,363,974 chr19:53,443,948 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
::TRBC1	chr7:142,801,054 chr7:142,791,708 DUP	4 4 S · 0 R · 0 D	OTHER	—	—
::TRBC1	chr7:142,801,054 chr7:142,791,708 DUP	4 4 S · 0 R · 0 D	OTHER	—	—
::TRBC2	chr7:142,796,663 chr7:142,801,041 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
::ZNF69	chr19:11,785,639 chr19:11,913,460 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
ACADL::KANSL1L	chr2:210,192,804 chr2:210,154,611 DEL	4 3 S · 1 R · 0 D	OTHER	—	Mitelman Adenocarcinoma ×3 Hu et al 2018, Nucleic Acids Res — Adenocarcinoma · Kidney Gao et al 2018, Cell Rep — Adenocarcinoma · Breast Yoshihara et al 2015, Oncogene — Adenocarcinoma · Kidney
ADH6::	chr4:99,204,357 chr4:99,159,617 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
ANKRD36C::LINC00342	chr2:95,836,937 chr2:95,814,145 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
ANKRD36C::LINC00342	chr2:95,836,937 chr2:95,814,791 DEL	4 3 S · 1 R · 0 D	OTHER	—	—
ARHGEF35-AS1::	chr7:144,252,492 chr7:144,355,338 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
ARNT::CTSK	chr1:150,812,011 chr1:150,808,325 DEL	4 2 S · 1 R · 1 D	OTHER	—	—
ARSDP1::	chrY:12,382,327 chrY:12,406,796 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
BMS1P3::AGAP11	chr10:87,000,434 chr10:87,001,636 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
CD274::	chr9:5,459,187 chr9:5,524,536 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
CEP112::AXIN2	chr17:65,635,911 chr17:65,558,736 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
CLDND2::ETFB	chr19:51,367,886 chr19:51,354,308 DEL	4 3 S · 0 R · 1 D	OTHER	—	—
CLN3::NPIPB7	chr16:28,477,464 chr16:28,466,902 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
CLUHP3::ZNF720	chr16:31,706,999 chr16:31,722,626 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
CROCCP2::CROCCP3	chr1:16,633,242 chr1:16,486,538 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
CTNNBL1::CTNNBL1P1	chr20:37,733,067 chrX:46,419,872 BND	4 4 S · 0 R · 0 D	OTHER	—	—
CYP4X1::CYP4Z1	chr1:47,049,504 chr1:47,067,575 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
DDT::	chr22:23,974,307 chr22:23,926,520 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
DNAJC25-GNG10::	chr9:111,666,946 chr9:111,763,653 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
EDDM13::	chr19:56,290,621 chr19:56,379,243 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
EOLA1-DT::IDS	chrX:149,529,367 chrX:149,501,037 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
EPS15L1::	chr19:16,413,457 chr8:97,624,323 BND	4 4 S · 0 R · 0 D	OTHER	—	—
ERI2::DCUN1D3	chr16:20,896,308 chr16:20,862,643 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
FAM228A::	chr2:24,190,553 chr2:24,214,372 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
GARS1-DT::GGCT	chr7:30,550,636 chr7:30,500,681 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
GCSH::C16orf46	chr16:81,084,463 chr16:81,054,094 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
GSTM4::GSTM2	chr1:109,659,110 chr1:109,674,747 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
HACL1::COLQ →	chr3:15,563,358 chr3:15,489,637 DEL	4 3 S · 0 R · 1 D	OTHER	✓	Mitelman Nonneoplastic hematologic disorder/lesion; Nonneoplastic epithelial disorder/lesion ×8 Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Thyroid Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Gallbladder/Biliary system Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Testis Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Bladder Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Skin Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Uterus, corpus
HP::HPR	chr16:72,058,355 chr16:72,075,145 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
KCNH8::	chr3:19,306,158 chr15:80,978,416 BND	4 1 S · 3 R · 0 D	OTHER	—	—
KRBOX1::GASK1A	chr3:42,942,071 chr3:43,032,267 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
LAMC2::	chr1:183,240,391 chr1:183,258,722 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
LINC00674::	chr17:68,114,525 chr17:68,160,990 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
LINC02898::LINC01914	chr2:41,938,417 chr2:41,933,433 DEL	4 3 S · 1 R · 0 D	OTHER	—	—
LY96::	chr8:74,026,841 chr8:74,099,419 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
MLLT6::CISD3	chr17:38,724,976 chr17:38,730,760 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
NAIPP4::OCLNP1 →	chr5:71,108,661 chr5:71,093,192 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
NIT2::	chr3:100,357,603 chr3:100,365,362 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
NPEPPSP1::TBC1D3	chr17:38,195,880 chr17:38,191,030 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
NPIPB8::NPIPB9	chr16:28,638,150 chr16:28,752,435 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
NRIP1::LINC02246	chr21:15,064,745 chr21:14,857,708 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
PAAF1::	chr11:73,877,001 chr11:73,974,852 DEL	4 3 S · 0 R · 1 D	OTHER	—	—
PAOX::MTG1 →	chr10:133,391,428 chr10:133,395,713 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
PMS2P1::	chr7:100,328,836 chr7:100,325,779 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
PNRC1::	chr6:89,081,434 chr6:89,097,539 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
PON3::PON1	chr7:95,362,362 chr7:95,318,393 DEL	4 3 S · 0 R · 1 D	OTHER	✓	—
PPP1R21::STON1	chr2:48,511,468 chr2:48,529,880 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
PRH1::PRR4	chr12:10,882,217 chr12:10,848,407 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
PRPS2::	chrX:12,824,470 chrX:12,877,411 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
PRR13::PCBP2	chr12:53,443,773 chr12:53,454,726 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
PRSS56::CHRND	chr2:232,524,844 chr2:232,526,529 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
RPS18::RPS18P9	chr6:33,272,726 chr6:149,594,187 DEL	4 1 S · 3 R · 0 D	OTHER	—	—
RPS27A::RPS27AP19	chr2:55,234,962 chr19:7,666,331 BND	4 1 S · 3 R · 0 D	OTHER	—	—
SANBR::C2orf74	chr2:61,134,276 chr2:61,162,842 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
SFTPC::COL6A1	chr8:22,163,184 chr21:46,003,906 BND	4 1 S · 1 R · 2 D	OTHER	—	—
SMURF2P1::LRRC37BP1 →	chr17:30,610,942 chr17:30,629,680 DEL	4 1 S · 0 R · 3 D	OTHER	✓	—
SNHG4::MATR3	chr5:139,279,129 chr5:139,307,239 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
SNHG4::MATR3	chr5:139,279,129 chr5:139,314,675 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
SPDYE3::	chr7:100,321,084 chr7:100,330,182 DEL	4 3 S · 0 R · 1 D	OTHER	—	—
SPDYE3::	chr7:100,321,084 chr7:100,328,836 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
SUGT1P3::TPTE2P5	chr13:40,908,159 chr13:40,826,594 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
SULT1A1::SULT1A2	chr16:28,608,708 chr16:28,595,675 DEL	4 2 S · 0 R · 2 D	OTHER	✓	—
SVIL-AS1::	chr10:29,415,412 chr10:29,458,274 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
TCEANC::RAB9A	chrX:13,680,598 chrX:13,703,814 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
TEK::	chr9:27,152,715 chr9:27,258,412 DEL	4 1 S · 0 R · 3 D	OTHER	—	—
TMEM139::CASP2	chr7:143,286,975 chr7:143,291,540 DEL	4 3 S · 0 R · 1 D	OTHER	—	—
TMEM141::CCDC183	chr9:136,792,358 chr9:136,799,102 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
TMSB4Y::	chrY:13,704,435 chrY:13,790,919 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
TOPORS::DDX58	chr9:32,550,774 chr9:32,500,939 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
TPTE2P1::	chr13:24,951,397 chr13:24,925,894 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
TRAJ18::TRAC	chr14:22,525,715 chr14:22,547,506 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
TRAJ33::TRAC	chr14:22,508,658 chr14:22,547,506 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
TRAJ37::TRAC	chr14:22,503,811 chr14:22,547,506 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
TRAJ40::TRAC	chr14:22,499,749 chr14:22,547,506 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
TRAJ42::TRAC	chr14:22,496,952 chr14:22,547,506 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
TRAJ54::TRAC	chr14:22,482,346 chr14:22,547,506 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
TRBJ2-3::	chr7:142,796,895 chr7:142,801,041 DEL	4 2 S · 2 R · 0 D	OTHER	—	—
TRDJ1::TRDC →	chr14:22,450,139 chr14:22,463,089 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
UBB::UBBP4	chr17:16,381,184 chr17:22,204,087 DEL	4 1 S · 3 R · 0 D	OTHER	—	—
VAMP8::VAMP5	chr2:85,577,649 chr2:85,591,725 DEL	4 4 S · 0 R · 0 D	OTHER	—	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
WDFY2::	chr13:51,756,632 chr13:51,771,821 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
ZBTB11-AS1::	chr3:101,678,117 chr3:101,684,895 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
ZDHHC11::ZDHHC11B	chr5:837,365 chr5:741,628 DEL	4 4 S · 0 R · 0 D	OTHER	✓	—
ZDHHC11::ZDHHC11B	chr5:825,245 chr5:745,296 DEL	4 1 S · 0 R · 3 D	OTHER	✓	—
ZNF398::	chr7:149,129,920 chr7:149,246,503 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
ZNF57::	chr19:2,915,708 chr19:2,936,524 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
ZNF71::SMIM17	chr19:56,601,591 chr19:56,645,568 DEL	4 4 S · 0 R · 0 D	OTHER	—	—
::	chr19:37,686,451 chr19:37,670,556 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
::ANKRD37	chr4:185,375,726 chr4:185,396,853 DEL	3 2 S · 0 R · 1 D	OTHER	✓	—
::CAPN3	chr15:42,354,453 chr15:42,384,483 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
::CDR2	chr16:22,426,213 chr16:22,365,014 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
::CXXC1P1	chrX:47,707,385 chrX:47,723,527 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
::CXXC1P1	chrX:47,707,385 chrX:47,724,558 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
::DNAJC21	chr5:34,918,297 chr5:34,929,649 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
::ERMARD	chr6:169,751,563 chr6:169,753,864 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
::GOLGA2P7	chr15:84,229,852 chr15:84,204,975 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
::HULC	chr6:8,307,560 chr6:8,784,191 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
::LANCL1-AS1	chr2:210,279,861 chr2:210,429,365 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
::LANCL1-AS1	chr2:210,279,861 chr2:210,427,749 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
::LINC00869	chr1:149,636,716 chr1:149,660,854 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
::NBEAP1	chr15:20,755,930 chr15:20,671,268 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
::PCTP	chr17:55,688,414 chr17:55,767,335 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
::PPP4R1-AS1	chr18:9,614,299 chr18:9,619,195 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
::PRR4	chr12:11,047,020 chr12:10,848,407 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
::RAET1E-AS1	chr6:149,864,382 chr6:149,919,187 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
::RNASEH2B	chr13:50,840,094 chr13:50,927,407 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
::S100P	chr4:6,689,226 chr4:6,696,893 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
::SEC22B4P	chr1:146,369,229 chr1:146,328,211 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
::SEC22B4P	chr1:146,369,971 chr1:146,328,211 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
::SLF1	chr5:94,618,318 chr5:94,628,811 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
::SMPD4BP	chr2:131,484,218 chr2:131,492,992 DEL	3 2 S · 1 R · 0 D	OTHER	—	—
::TM9SF5P	chrX:136,925,379 chrX:136,993,486 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
::TRAC	chr14:22,529,688 chr14:22,547,506 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
::TRBC1	chr7:142,786,039 chr7:142,791,694 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
::USP32P1	chr17:16,787,122 chr17:16,796,043 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
::USP32P1	chr17:16,783,733 chr17:16,796,043 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
::ZNF22	chr10:45,000,978 chr10:45,003,280 DEL	3 2 S · 0 R · 1 D	OTHER	—	—
::ZNRD2	chr11:65,570,510 chr11:65,570,604 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
ABCA6::ABCA9	chr17:69,078,960 chr17:69,051,139 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
AKR1E2::	chr10:4,842,504 chr10:4,873,214 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
ANKRD20A2P::FAM95B1	chr9:40,291,919 chr9:40,328,918 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
APBB3::SRA1	chr5:140,560,313 chr5:140,557,655 DEL	3 2 S · 1 R · 0 D	OTHER	—	—
APOC1::	chr19:44,916,325 chr19:44,931,000 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
ASL::CRCP	chr7:66,092,663 chr7:66,127,704 DEL	3 3 S · 0 R · 0 D	OTHER	✓	Mitelman Astrocytoma, grade III-IV/Glioblastoma ×1 Frattini et al 2013, Nat Genet — Astrocytoma, grade III-IV/Glioblastoma · Brain
BLOC1S1::RDH5	chr12:55,719,223 chr12:55,721,689 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
BTN2A3P::BTN2A1	chr6:26,422,197 chr6:26,459,481 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
CFAP221::TMEM177	chr2:119,656,483 chr2:119,685,658 DEL	3 2 S · 1 R · 0 D	OTHER	—	—
CFH::CFHR3	chr1:196,689,614 chr1:196,779,797 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
CHD4::NOP2	chr12:6,570,869 chr12:6,567,922 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
CKLF::	chr16:66,565,982 chr16:66,622,062 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
CLCF1::POLD4	chr11:67,373,524 chr11:67,353,077 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
CLECL1::	chr12:9,722,644 chr12:9,702,440 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
CTNNBIP1::CLSTN1	chr1:9,871,187 chr1:9,773,394 DEL	3 2 S · 1 R · 0 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion ×4 Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Uterus, corpus Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Skin Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Adrenal Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Oesophagus
CTSC::RAB38	chr11:88,296,133 chr11:88,149,955 DEL	3 3 S · 0 R · 0 D	OTHER	—	Mitelman Adenocarcinoma; Nonneoplastic epithelial disorder/lesion … ×7 Zheng et al 2016, Cancer Cell — Adenocarcinoma · Adrenal Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Thyroid Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung Wang et al 2015, Nat Genet — Mycosis fungoides/Sézary syndrome Frattini et al 2013, Nat Genet — Astrocytoma, grade III-IV/Glioblastoma · Brain Atak et al 2013, PLoS Genet — Acute lymphoblastic leukemia/lymphoblastic lymphoma
DCAF10::	chr9:37,860,490 chr9:37,881,518 DEL	3 2 S · 1 R · 0 D	OTHER	—	—
DCAF10::	chr9:37,848,965 chr9:37,899,829 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
DUS3L::PRR22	chr19:5,785,383 chr19:5,784,439 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
DUXAP8::NBEAP3	chr22:15,791,152 chr22:15,852,990 DEL	3 1 S · 1 R · 1 D	OTHER	—	—
ECD::P4HA1	chr10:73,134,603 chr10:73,074,915 DEL	3 2 S · 1 R · 0 D	OTHER	—	—
FAM162B::ZUP1	chr6:116,761,977 chr6:116,667,207 DEL	3 3 S · 0 R · 0 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
FAM24B::CUZD1	chr10:122,855,645 chr10:122,846,220 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
FBXL19::ORAI3	chr16:30,948,568 chr16:30,956,200 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
FBXO25::	chr8:473,742 chr8:494,494 DEL	3 2 S · 1 R · 0 D	OTHER	✓	—
FBXO25::	chr8:457,100 chr8:494,494 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
FOXA2::LINC00261	chr20:22,584,192 chr20:22,567,885 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
GARS1-DT::GGCT	chr7:30,524,312 chr7:30,500,681 DEL	3 2 S · 0 R · 1 D	OTHER	—	—
GPR155::CIR1	chr2:174,439,898 chr2:174,387,779 DEL	3 3 S · 0 R · 0 D	OTHER	✓	Mitelman Mycosis fungoides/Sézary syndrome ×1 Wang et al 2015, Nat Genet — Mycosis fungoides/Sézary syndrome
GPX6::	chr6:28,506,312 chr6:28,449,306 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
HDAC8::CITED1	chrX:72,351,733 chrX:72,302,934 DEL	3 3 S · 0 R · 0 D	OTHER	—	Mitelman Adenocarcinoma ×1 Nacu et al 2011, BMC Med Genomics — Adenocarcinoma · Prostate
HOXA3::HOXA5	chr7:27,152,288 chr7:27,142,085 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
INTS4P2::CCT6P1	chr7:65,718,322 chr7:65,755,780 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
ITCH::DYNLRB1	chr20:34,507,908 chr20:34,526,268 DEL	3 3 S · 0 R · 0 D	OTHER	✓	Mitelman Adenocarcinoma ×1 Gao et al 2018, Cell Rep — Adenocarcinoma · Ovary
KLHL23::SSB	chr2:169,741,537 chr2:169,792,573 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
LCLAT1::	chr2:30,611,989 chr2:30,730,730 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
LINC01877::	chr2:199,667,469 chr2:199,846,075 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
LINC01914::	chr2:41,933,276 chr2:41,537,794 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
LINC02435::LINC01091	chr4:123,505,381 chr4:123,652,791 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
LRRC8B::LRRC8C	chr1:89,584,789 chr1:89,686,470 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
MAG::CD22 →	chr19:35,313,429 chr19:35,329,189 DEL	3 2 S · 0 R · 1 D	OTHER	✓	—
MALRD1::PLXDC2	chr10:19,790,186 chr10:20,001,775 DEL	3 3 S · 0 R · 0 D	OTHER	—	Mitelman Astrocytoma, grade I-II ×1 Yoshihara et al 2015, Oncogene — Astrocytoma, grade I-II · Brain
MFSD14C::ZNF782	chr9:96,918,643 chr9:96,860,414 DEL	3 2 S · 0 R · 1 D	OTHER	—	—
MRPS31P4::	chr13:52,637,446 chr13:52,642,369 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
MS4A7::MS4A6E	chr11:60,392,786 chr11:60,396,562 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
MYL6::MYL6P1	chr12:56,160,320 chr21:43,855,975 BND	3 3 S · 0 R · 0 D	OTHER	—	—
NAA35::	chr9:86,014,409 chr9:86,033,282 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
NAPSA::FTH1	chr19:50,360,991 chr11:61,967,371 BND	3 1 S · 0 R · 2 D	OTHER	—	—
NIPSNAP2::MRPS17	chr7:55,951,930 chr7:55,953,179 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
NUDT14::JAG2	chr14:105,176,534 chr14:105,157,763 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
PAPLN::	chr14:73,272,908 chr14:73,282,359 DEL	3 2 S · 0 R · 1 D	OTHER	—	—
PDXDC2P::	chr16:70,010,751 chr16:69,996,468 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
PI4K2A::	chr10:97,676,217 chr10:97,679,619 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
PINLYP::	chr19:43,581,703 chr19:43,587,044 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
PIRT::TMEM238L	chr17:10,837,945 chr17:10,795,948 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
PLEKHO2::ANKDD1A	chr15:64,861,575 chr15:64,921,921 DEL	3 3 S · 0 R · 0 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
PPP2CA::SKP1	chr5:134,225,760 chr5:134,174,022 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
PSMD7::	chr16:74,305,580 chr16:74,332,567 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
PTGR2::ZNF410	chr14:73,884,127 chr14:73,892,027 DEL	3 3 S · 0 R · 0 D	OTHER	—	Mitelman Adenocarcinoma ×1 Lapuk et al 2012, J Pathol — Adenocarcinoma · Prostate
PVRIG::STAG3L5P-PVRIG2P-PILRB	chr7:100,218,641 chr7:100,345,969 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
PZP::A2M	chr12:9,158,420 chr12:9,077,420 DEL	3 2 S · 1 R · 0 D	OTHER	—	—
RAB4B-EGLN2::	chr19:40,801,415 chr19:40,826,564 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
RASA4CP::POLR2J4	chr7:44,030,781 chr7:44,016,523 DEL	3 2 S · 0 R · 1 D	OTHER	✓	—
RHBDD1::	chr2:226,980,183 chr2:227,022,048 DEL	3 2 S · 1 R · 0 D	OTHER	—	—
RNASET2::RPS6KA2	chr6:166,938,895 chr6:166,893,021 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
RPL5::RPL5P17	chr1:92,840,639 chr5:85,465,215 BND	3 1 S · 2 R · 0 D	OTHER	—	—
SCGB2B2::SCGB1B2P	chr19:34,675,630 chr19:34,577,456 DEL	3 2 S · 0 R · 1 D	OTHER	—	—
SCGB2B2::SCGB1B2P	chr19:34,675,630 chr19:34,577,732 DEL	3 2 S · 0 R · 1 D	OTHER	—	—
SCNN1A::TNFRSF1A	chr12:6,348,727 chr12:6,334,244 DEL	3 3 S · 0 R · 0 D	OTHER	—	Mitelman Nonneoplastic epithelial disorder/lesion; Adenocarcinoma … ×6 Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Bladder Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Lung Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Stomach Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung Varley et al 2014, Breast Cancer Res Treat — Adenocarcinoma · Breast Frattini et al 2013, Nat Genet — Astrocytoma, grade III-IV/Glioblastoma · Brain
SDHAF2::PPP1R32	chr11:61,438,113 chr11:61,484,688 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
SLC35A3::MFSD14A	chr1:100,017,815 chr1:100,049,909 DEL	3 3 S · 0 R · 0 D	OTHER	✓	Mitelman Acute lymphoblastic leukemia/lymphoblastic lymphoma; Nonneoplastic epithelial disorder/lesion … ×9 López-Nieva et al 2019, Sci Rep — Acute lymphoblastic leukemia/lymphoblastic lymphoma Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Oesophagus Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Testis Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Thyroid Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Large intestine Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Gallbladder/Biliary system Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Bladder Wang et al 2015, Nat Genet — Mycosis fungoides/Sézary syndrome
SMG1P2::BOLA2-SMG1P6	chr16:29,551,189 chr16:29,446,922 DEL	3 1 S · 0 R · 2 D	OTHER	✓	—
SMG5::PAQR6	chr1:156,249,569 chr1:156,246,756 DEL	3 2 S · 0 R · 1 D	OTHER	—	Mitelman Adenocarcinoma; Nonneoplastic epithelial disorder/lesion … ×3 Zhao et al 2017, Oncotarget — Adenocarcinoma · Prostate Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Skin Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion
SOCS5::	chr2:46,699,449 chr2:46,797,319 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
SRP54-AS1::	chr14:34,963,929 chr14:34,934,131 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
SUGT1P1::NOL6	chr9:33,503,827 chr9:33,472,412 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
SULT1A1::SULT1A2	chr16:28,609,931 chr16:28,593,346 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
TBC1D23::NIT2	chr3:100,320,971 chr3:100,339,087 DEL	3 2 S · 1 R · 0 D	OTHER	—	—
TRAJ10::TRAC	chr14:22,533,560 chr14:22,547,506 DEL	3 2 S · 1 R · 0 D	OTHER	—	—
TRAJ11::TRAC	chr14:22,532,561 chr14:22,547,506 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
TRAJ13::	chr14:22,531,138 chr14:22,547,506 DEL	3 2 S · 1 R · 0 D	OTHER	—	—
TRAJ17::TRAC	chr14:22,526,906 chr14:22,547,506 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
TRAJ3::TRAC	chr14:22,543,240 chr14:22,547,506 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
TRAJ31::TRAC	chr14:22,511,024 chr14:22,547,506 DEL	3 1 S · 2 R · 0 D	OTHER	—	—
TRAJ43::TRAC	chr14:22,495,966 chr14:22,547,506 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
TRAK2::FLACC1	chr2:201,381,124 chr2:201,351,451 DEL	3 2 S · 0 R · 1 D	OTHER	—	—
TRBJ1-6::	chr7:142,789,040 chr7:142,791,694 DEL	3 2 S · 1 R · 0 D	OTHER	—	—
TRMT11::CENPW	chr6:126,174,911 chr6:126,346,205 DEL	3 2 S · 1 R · 0 D	OTHER	—	—
TTLL13P::NGRN	chr15:90,264,963 chr15:90,266,288 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
TVP23C::TVP23C-CDRT4	chr17:15,516,419 chr17:15,440,285 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
TYSND1::AIFM2	chr10:70,146,533 chr10:70,124,100 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
UBA2::WTIP	chr19:34,467,014 chr19:34,490,376 DEL	3 3 S · 0 R · 0 D	OTHER	✓	Mitelman Adenocarcinoma; Acute monoblastic leukemia (FAB type M5) … ×10 Fu et al 2024, Biomark Res — Adenocarcinoma · Oesophagus Lu et al 2018, Exp Cell Res — Acute monoblastic leukemia (FAB type M5) Lu et al 2018, Exp Cell Res — Acute myeloid leukemia, NOS Lu et al 2018, Exp Cell Res — Acute myeloblastic leukemia with maturation (FAB type M2) Lu et al 2018, Exp Cell Res — Acute myelomonocytic leukemia (FAB type M4) Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Bladder Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Prostate Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Oesophagus Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Testis
VAMP8::VAMP5	chr2:85,579,167 chr2:85,591,725 DEL	3 2 S · 0 R · 1 D	OTHER	—	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
VPS45::PLEKHO1	chr1:150,110,627 chr1:150,150,912 DEL	3 3 S · 0 R · 0 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion ×3 Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Gallbladder/Biliary system Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Testis Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Thyroid
WFDC3::	chr20:45,758,392 chr20:45,708,999 DEL	3 3 S · 0 R · 0 D	OTHER	—	—
ZBTB26::ZBTB6	chr9:122,931,437 chr9:122,912,081 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
ZMYM5::PSPC1	chr13:19,824,920 chr13:19,782,791 DEL	3 3 S · 0 R · 0 D	OTHER	✓	Mitelman Acute lymphoblastic leukemia/lymphoblastic lymphoma ×1 Lilljebjörn et al 2016, Nat Commun — Acute lymphoblastic leukemia/lymphoblastic lymphoma
ZNF451::BAG2	chr6:57,161,152 chr6:57,182,032 DEL	3 3 S · 0 R · 0 D	OTHER	—	Mitelman Adenocarcinoma ×1 Yoshihara et al 2015, Oncogene — Adenocarcinoma · Breast
ZNF572::SQLE	chr8:124,978,090 chr8:125,003,176 DEL	3 2 S · 1 R · 0 D	OTHER	—	—
ZNF587B::ZNF587	chr19:57,839,149 chr19:57,856,104 DEL	3 3 S · 0 R · 0 D	OTHER	✓	—
ZNF776::ZNF586	chr19:57,756,998 chr19:57,790,274 DEL	3 2 S · 0 R · 1 D	OTHER	—	—
::	chr9:70,216,286 chr9:70,113,860 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
::CA5B	chrX:15,693,058 chrX:15,721,497 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
::FAM170A	chr5:119,626,070 chr5:119,633,960 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
::GALNT10	chr5:154,149,946 chr5:154,294,816 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
::SPTSSA	chr14:34,462,716 chr14:34,435,304 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
::ST7	chr7:116,954,679 chr7:117,099,762 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
ACAD10::ALDH2	chr12:111,755,745 chr12:111,781,918 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
AJUBA::HAUS4	chr14:22,974,047 chr14:22,955,176 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
ALG8::NDUFC2-KCTD14	chr11:78,101,093 chr11:78,073,141 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
ANKRD20A2P::FAM95B1	chr9:40,290,207 chr9:40,325,462 DEL	2 1 S · 1 R · 0 D	OTHER	—	—
ARHGEF38::	chr4:105,552,961 chr4:105,569,904 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
ARL16::OXLD1	chr17:81,683,536 chr17:81,665,584 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
ARL8B::EDEM1	chr3:5,174,414 chr3:5,195,209 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
BACH1::	chr21:29,597,694 chr21:29,748,834 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
BAZ2B::NOSTRIN	chr2:159,616,242 chr2:168,851,084 INV	2 2 S · 0 R · 0 D	OTHER	—	—
BHLHB9::LINC00630	chrX:102,721,091 chrX:102,816,992 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
BMS1P21::MBL1P	chr10:79,907,856 chr10:79,920,952 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
C6orf163::SMIM8	chr6:87,356,503 chr6:87,371,593 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
CHCHD10::VPREB3	chr22:23,767,834 chr22:23,753,198 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
CHIA::PIFO	chr1:111,319,468 chr1:111,346,910 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
CLCF1::POLD4	chr11:67,367,460 chr11:67,353,077 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
CLN6::CALML4	chr15:68,218,536 chr15:68,197,628 DEL	2 2 S · 0 R · 0 D	OTHER	✓	Mitelman Adenocarcinoma ×1 Kim et al 2014, Oncogene — Adenocarcinoma · Stomach
CLN8::ARHGEF10	chr8:1,771,597 chr8:1,843,353 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
COQ8B::NUMBL	chr19:40,692,951 chr19:40,686,995 DEL	2 2 S · 0 R · 0 D	OTHER	✓	Mitelman Squamous cell carcinoma; Astrocytoma, grade III-IV/Glioblastoma … ×3 Egashira et al 2019, J Invest Dermatol — Squamous cell carcinoma · Skin Frattini et al 2013, Nat Genet — Astrocytoma, grade III-IV/Glioblastoma · Brain Nacu et al 2011, BMC Med Genomics — Adenocarcinoma · Prostate
CORO1C::SELPLG	chr12:108,647,401 chr12:108,624,312 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
CROCCP2::CROCCP3	chr1:16,632,275 chr1:16,484,906 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
CUL5::ACAT1	chr11:108,098,529 chr11:108,131,907 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
CYP4B1::CYP4X1	chr1:46,815,264 chr1:47,029,990 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
DEFB122::DEFB119	chr20:31,428,543 chr20:31,378,391 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
DHTKD1::SEC61A2	chr10:12,120,267 chr10:12,133,241 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
DMKN::KRTDAP	chr19:35,498,598 chr19:35,488,840 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
DTD2::HEATR5A	chr14:31,453,275 chr14:31,403,049 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
EEF1AKMT2::FAM53B	chr10:124,760,318 chr10:124,706,887 DEL	2 2 S · 0 R · 0 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion; Nonneoplastic hematologic disorder/lesion ×6 Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Thyroid Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Lung Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Testis Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Oesophagus Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Adrenal Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node
EFCAB14::ATPAF1	chr1:46,683,300 chr1:46,665,364 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
EIF6::MMP24OS	chr20:35,279,566 chr20:35,272,145 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
ELAC1::SMAD4	chr18:50,974,561 chr18:51,046,920 DEL	2 2 S · 0 R · 0 D	OTHER	✓	Mitelman Adenocarcinoma ×1 Asmann et al 2012, Cancer Res — Adenocarcinoma · Breast
EXPH5::POGLUT3	chr11:108,518,235 chr11:108,491,167 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
FAM200B::BST1	chr4:15,687,148 chr4:15,705,515 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
FAM214A::ARPP19	chr15:52,584,745 chr15:52,557,222 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
FRMD1::SERPINF1	chr6:168,066,239 chr17:1,771,872 BND	2 2 S · 0 R · 0 D	OTHER	—	—
GALT::IL11RA	chr9:34,649,564 chr9:34,655,218 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
GARS1-DT::GGCT	chr7:30,524,367 chr7:30,500,681 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
GCSH::C16orf46	chr16:81,084,463 chr16:81,066,281 DEL	2 1 S · 0 R · 1 D	OTHER	✓	—
GLIDR::LERFS	chr9:39,809,486 chr9:62,869,304 DUP	2 1 S · 0 R · 1 D	OTHER	—	—
GPX7::SHISAL2A	chr1:52,606,945 chr1:52,642,863 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
GSTM2::GSTM1	chr1:109,669,371 chr1:109,689,225 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
GUK1::GJC2	chr1:228,148,456 chr1:228,157,740 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
HAUS4::PRMT5	chr14:22,947,171 chr14:22,928,615 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
HNRNPLL::ZNF532	chr2:38,602,438 chr18:58,983,972 BND	2 2 S · 0 R · 0 D	OTHER	—	—
IFNAR2::IL10RB	chr21:33,252,830 chr21:33,268,394 DEL	2 2 S · 0 R · 0 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
INTS4P2::CCT6P1	chr7:65,718,322 chr7:65,754,527 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
IRF1-AS1::RAD50	chr5:132,449,689 chr5:132,559,284 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
KBTBD11::	chr8:1,973,935 chr8:1,975,899 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
KLHL23::SSB	chr2:169,741,537 chr2:169,800,952 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
KSR1::LGALS9	chr17:27,617,428 chr17:27,638,263 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
LAMP3::MCCC1	chr3:183,135,717 chr3:183,094,605 DEL	2 2 S · 0 R · 0 D	OTHER	—	Mitelman Adenocarcinoma ×1 Gao et al 2018, Cell Rep — Adenocarcinoma · Adrenal
LBH::LINC01936	chr2:30,234,507 chr2:30,349,937 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
LILRA2::LILRB1	chr19:54,575,552 chr19:54,633,016 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
LILRB5::LILRB2	chr19:54,252,054 chr19:54,274,829 DUP	2 2 S · 0 R · 0 D	OTHER	—	—
LIMD2::STRADA	chr17:63,699,257 chr17:63,690,597 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
LINC01138::LINC01731	chr1:148,344,213 chr1:148,272,035 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
LINC02731::JAM3	chr11:134,046,945 chr11:134,139,851 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
LIPT1::MRPL30	chr2:99,156,426 chr2:99,186,177 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
MAPKAPK3::LINC02019	chr3:50,617,784 chr3:50,671,371 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
MATR3::PAIP2	chr5:139,293,805 chr5:139,363,759 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
MBD1::CFAP53	chr18:50,272,677 chr18:50,262,219 DEL	2 2 S · 0 R · 0 D	OTHER	—	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
MCEMP1::TRAPPC5	chr19:7,678,604 chr19:7,682,242 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
METTL23::MFSD11	chr17:76,733,377 chr17:76,736,190 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
MFSD14C::ZNF782	chr9:96,918,643 chr9:96,852,005 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
MMP25::IL32	chr16:3,058,669 chr16:3,065,784 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
NAIPP4::GTF2H2	chr5:71,108,661 chr5:71,062,796 DEL	2 1 S · 0 R · 1 D	OTHER	✓	—
NECAP1::CLEC4A	chr12:8,090,299 chr12:8,129,264 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
NRIP1::LINC02246	chr21:15,014,344 chr21:14,857,708 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
PLEKHO2::ANKDD1A	chr15:64,861,575 chr15:64,915,797 DEL	2 1 S · 0 R · 1 D	OTHER	✓	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
POLA2::CDC42EP2	chr11:65,295,990 chr11:65,320,544 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
PPCS::CCDC30	chr1:42,457,350 chr1:42,482,663 DEL	2 2 S · 0 R · 0 D	OTHER	—	Mitelman Acute myeloid leukemia, NOS ×1 Wen et al 2012, PLoS One — Acute myeloid leukemia, NOS
PRR4::PRH1	chr12:10,847,045 chr12:10,825,193 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
PSMA4::CHRNA5	chr15:78,546,698 chr15:78,580,811 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
PSMF1::C20orf202	chr20:1,186,495 chr20:1,206,869 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
PTCRA::CNPY3	chr6:42,924,273 chr6:42,934,475 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
PTGR2::ZNF410	chr14:73,882,438 chr14:73,892,027 DEL	2 2 S · 0 R · 0 D	OTHER	—	Mitelman Adenocarcinoma ×1 Lapuk et al 2012, J Pathol — Adenocarcinoma · Prostate
RBM25::PSEN1	chr14:73,114,333 chr14:73,147,795 DEL	2 1 S · 0 R · 1 D	OTHER	—	Mitelman Adenocarcinoma ×1 Calabrese et al 2020, Nature — Adenocarcinoma · Ovary
RHBDD2::POR	chr7:75,883,848 chr7:75,953,989 DEL	2 1 S · 0 R · 1 D	OTHER	✓	Mitelman Adenocarcinoma ×1 Hu et al 2018, Nucleic Acids Res — Adenocarcinoma · Oesophagus
RIPK3::ADCY4	chr14:24,336,885 chr14:24,332,988 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
RPL11::ELOA	chr1:23,694,791 chr1:23,749,021 DEL	2 2 S · 0 R · 0 D	OTHER	✓	Mitelman Adenocarcinoma; Mycosis fungoides/Sézary syndrome ×2 Linehan et al 2016, N Engl J Med — Adenocarcinoma · Kidney Wang et al 2015, Nat Genet — Mycosis fungoides/Sézary syndrome
RPL5::B2M	chr1:92,833,458 chr15:44,715,434 BND	2 1 S · 1 R · 0 D	OTHER	—	—
S100A4::S100A3	chr1:153,550,065 chr1:153,548,490 DEL	2 2 S · 0 R · 0 D	OTHER	—	Mitelman Adenocarcinoma ×1 Gao et al 2018, Cell Rep — Adenocarcinoma · Breast
SANBR::C2orf74	chr2:61,134,276 chr2:61,157,862 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
SCART1::CYP2E1	chr10:133,467,353 chr10:133,526,796 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
SDHD::TEX12	chr11:112,089,011 chr11:112,170,419 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
SEH1L::CEP192	chr18:12,984,190 chr18:12,999,421 DEL	2 1 S · 1 R · 0 D	OTHER	—	—
SERF1B::SMN2	chr5:70,026,515 chr5:70,063,415 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
SERF1B::SMN2	chr5:70,041,631 chr5:70,063,415 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
SHPK::TRPV1	chr17:3,621,237 chr17:3,592,383 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
SLC39A1::CRTC2	chr1:153,962,220 chr1:153,955,166 DEL	2 2 S · 0 R · 0 D	OTHER	—	Mitelman Nonneoplastic epithelial disorder/lesion; Nonneoplastic hematologic disorder/lesion ×4 Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Large intestine Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Gallbladder/Biliary system Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic hematologic disorder/lesion · Lymph node Babiceanu et al 2016, Nucleic Acids Res — Nonneoplastic epithelial disorder/lesion · Bladder
SLC43A3::PRG2	chr11:57,409,175 chr11:57,389,956 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
SMIM3::IRGM	chr5:150,778,972 chr5:150,877,980 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
STARD3::TCAP	chr17:39,662,367 chr17:39,665,716 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
SUGT1P3::TPTE2P5	chr13:40,921,619 chr13:40,855,815 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
SYNCRIP::SNX14	chr6:85,612,832 chr6:85,574,378 DEL	2 2 S · 0 R · 0 D	OTHER	—	Mitelman Squamous cell carcinoma ×1 Yoshihara et al 2015, Oncogene — Squamous cell carcinoma · Oral cavity
TAX1BP1-AS1::HIBADH	chr7:27,740,016 chr7:27,649,633 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
TNFAIP8L2::SCNM1	chr1:151,156,722 chr1:151,166,471 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
TRAJ32::TRAC	chr14:22,509,406 chr14:22,547,506 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
TRAJ34::TRAC	chr14:22,507,723 chr14:22,547,506 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
TRAJ44::TRAC	chr14:22,494,883 chr14:22,547,506 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
TRAJ48::TRAC	chr14:22,490,553 chr14:22,547,506 DEL	2 1 S · 1 R · 0 D	OTHER	—	—
TRAJ50::TRAC	chr14:22,488,652 chr14:22,547,506 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
TRAJ52::TRAC	chr14:22,486,296 chr14:22,547,506 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
TRDJ3::TRDC	chr14:22,459,156 chr14:22,462,932 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
TRGC1::TRGC2	chr7:38,262,171 chr7:38,242,475 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
TRIM52::RACK1	chr5:181,260,001 chr5:181,242,345 DEL	2 2 S · 0 R · 0 D	OTHER	✓	Mitelman Squamous cell carcinoma ×1 Pan et al 2020, Mol Cell Probes — Squamous cell carcinoma · Oral cavity
UMAD1::GLCCI1	chr7:7,801,743 chr7:8,003,908 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
WEE2-AS1::DENND11	chr7:141,723,916 chr7:141,686,658 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
WLS::DIRAS3	chr1:68,137,780 chr1:68,047,362 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
XPO7::NPM2	chr8:22,004,030 chr8:22,025,436 DEL	2 1 S · 0 R · 1 D	OTHER	✓	—
ZDHHC1::TPPP3	chr16:67,395,002 chr16:67,391,117 DEL	2 2 S · 0 R · 0 D	OTHER	—	Mitelman Nonneoplastic epithelial disorder/lesion ×1 Pintarelli et al 2016, Oncotarget — Nonneoplastic epithelial disorder/lesion · Lung
ZFP30::	chr19:37,691,521 chr19:37,670,556 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
ZNF252P::ZNF16	chr8:144,999,603 chr8:144,946,215 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
ZNF264::AURKC	chr19:57,205,492 chr19:57,231,742 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
ZNF264::ZNF805	chr19:57,205,492 chr19:57,253,073 DEL	2 2 S · 0 R · 0 D	OTHER	—	—
ZNF551::ZNF776	chr19:57,682,244 chr19:57,750,785 DEL	2 2 S · 0 R · 0 D	OTHER	✓	Mitelman Adenocarcinoma ×1 Zhao et al 2017, Oncotarget — Adenocarcinoma · Prostate
ZNF587B::ZNF587	chr19:57,820,549 chr19:57,856,104 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
ZNF587B::ZNF587	chr19:57,819,945 chr19:57,856,107 DEL	2 2 S · 0 R · 0 D	OTHER	✓	—
ZNF662::KRBOX1	chr3:42,913,302 chr3:42,938,850 DEL	2 1 S · 0 R · 1 D	OTHER	✓	—
ZNF766::ZNF480	chr19:52,283,413 chr19:52,300,394 DEL	2 1 S · 0 R · 1 D	OTHER	—	—
ZNF780A::ZNF780B	chr19:40,081,819 chr19:40,050,377 DEL	2 1 S · 0 R · 1 D	OTHER	—	—

🧬 Gene fusions

Left hand (primary)

Lung metastasis

✉️ Contact Us

Contact Us